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Abstract
Several pathogenic Gram-negative bacteria can modify the structure ofLipid A in their
outer membrane to avoid the host immune response. One of these modifications includes
addition of4-amino-4-deoxy-L-arabinose, resulting in resistance to cationic antimicrobial
peptides. Essential to this modification are both decarboxylase and formyltransferase
functions of the bifunctional enzyme ArnA. The decarboxylase and formyltransferase
domains ofArnA have been expressed and purified as discrete proteins and the crystal
structures solved to 2.3 and 1.2 A respectively. The formyltransferase structure has been
determined in complex with the substrate and cofactor analogues, UDP and N-5-formyl-
tetrahydrofolate. The decarboxylase structure represents the apo form of the enzyme and
key catalytic residues for decarboxylation were identified from the superimposition of
this structure with the related enzyme RmlB. These residues were mutated and assayed
for activity compared to the wild type protein, providing insights into ArnA
decarboxylation and hydride transfer in short chain dehydrogenases / reductases.
That ArnA catalyses two, non-sequential reactions raises the possibility that the
intermediate is channelled from ArnA to another protein, ArnB, which catalyses the
intervening step, and then back to ArnA. This possibility was explored using gel
filtration assays to determine whether a stable complex formed between ArnA and ArnB.
Sliding clamps are essential to all domains of life and their toroidal structure is
conserved, providing the basis for their non-specific encircling of duplex DNA. In
archaea and eukaryotes PCNA acts as the clamp for the replicative polymerase and is also
involved in other pathways such as DNA repair. The archaean Sulfolobus solfataricus is
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unique in that it has evolved heterotrimeric PCNA, although a heterotrimeric clamp also
exists in eukaryotes with a specialised function in the DNA damage response. The
structure ofPCNA from S. solfataricus, has been solved and progress made towards the
structural solution of this clamp in complex with an interacting domain ofXPF. This is
the first structure of a heterotrimeric sliding clamp and these preliminary results are the
basis for future studies investigating the subunit specific interactions ofS. solfataricus
PCNA. This study will provide insights into the function of eukaryotic clamps and




A - Ala - alanine
C - Cys - cysteine
D - Asp - aspartic acid
E - Glu - glutamic acid
F - Phe - phenylalanine
G- Gly- glycine
H - His - histidine
I - lie - isoleucine
K - Lys - lysine
General
L - Leu - leucine
M - Met - methionine
N -Asn - asparagines
P - Pro - praline
Q - Gin - glutamine
R - Arg - arginine
S - Ser - serine
T - Thr - threonine
V-Val-valine
W - Trp - tryptophan
Y - Tyr- tyrosine
vi
6-4PP(s) - 6-4 photoproduct(s)
9-1-1 complex - Rad9-Radl-Husl heterotrimer
A - adenine
A. aeolicus -Aquifex aeolicus
A. pernix -Aeropyrumpemix
ADH - alcohol dehydrogenase
AICAR - 5-aminoimidazole-4-carboxamide
ASADH - aspartate semialdehyde dehydrogenase
ATP - adenine triphosphate
BER - base excision repair
Bis-tris - Bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane
C - cytidine
C. elegans - Caenorhabditis elegans
CAF1 - chromatin assembly factor 1
CAMP(s) - cationic antimicrobial peptide(s)
CDK(s) - cyclin dependent kinase(s)
CDC - centres for disease control and prevention
CMP - Cytodine monophosphate
CPD(s) - cyclobutane pyrimidine dimer(s)
COFS - cerebro-oculofacio-skeletal syndrome
CS - cokayne syndrome
D. melanogaster - Drosophila melanogaster
DADH - D. melanogaster ADH
DHFR - dihydrofolate reductase
dsDNA - double stranded DNA
E. coli - Escherichia coli
vii
ESI MS - electrospray ionisation mass spectrometry
FDH - formyltetrahydrofolate dehydrogenase
FEN1 - flap endonuclase 1
FMT - 10-formyltetrahydrofolate-L-methionyl-tRNA N-formyltransferase
G - guanine
Gal - galactose
GAR(T) - glycinamide ribonucleotide (transformylase)
GGR - global genome repair
Glc- glucose
GlcNAc - N-acetyl-D-glucosamine
GlcUA - glucuronic acid
H. pylori - Helicobacterpylori
HEPES - N-(2-hydroxyethyl)piperazine-N'-(2- ethanesulfonic acid)
HhH - Helix-hairpin-helix
HIV - Human immune-deficiency vims (p2)
HNPCC - hereditary non-polyposis colorectal cancer
HPLC - high pressure liquid chromatography
HR - homologous recombination
IMPCH - inosine monophosphate cyclohydrolase
IPTG - isopropyl-li-D-thiogalactopyranoside
Kdo - 3-deoxy-D-manno-octulosonic acid
LADH - horse liver ADH
L-Ara(f)4N - (formyl) 4-amino-4-deoxy-L-arabinose
L-Ara40 - P-L-threo-pentapyranosyl-4'-ulose
LB - luria broth
LBHB - low barrier hydrogen bond
viii
LPS - Lipopolysaccharide
M. thermoautotrophicus -Methanothermobacter thermoautotrophicus
MAD -multiwavelength anomalous diffraction/dispersion
MCMT - cytosine 5-methyltransferase
MDR - medium chain dehydrogenases/reductases
MES - 2-(N-Morpholino)ethanesulfonic acid
MMR - mismatch repair
MRSA - Methacillin resistant S. aureus
N. meningitides -Neisseria meningitides
N-5-/N-10-fTHF - N-5-/N-10-formyl tetrahydrofolate
NAD(+) - nicotinamide adenine nucleotide oxidised (reduced) form
NADPO - nicotinamide adenine nucleotide phosphate oxidised (reduced) form
NER - nucleotide excision repair
P. aeruginosa - Pseudomonas aeruginosa
PBP(s) - penicillin binding protein(s)
PCNA - proliferating cell nuclear antigen
PEG - polyethylene glycol
PIP - PCNA interacting protein
Pol - DNA polymerase
R. leguminosarum - Rhizobium leguminosarum
Rad - Radiation sensitive mutant
RFC - Replication factor C
RMSD - root mean square deviation
RNAPII - RNA polymerase II
RPA - replication protein A
rRNA - ribosomal ribonucleotide
ix
S. aureus - Staphylococcus aureus
S. cerevisiae - Sacchromyces cerevisiae
S. pombe - Schizosacchromycespombe
S. typhimurium - Salmonella typhimurium
Se-Met - selenomethionine modified
SDR(s) - short chain dehydrogenases/reductases
ssDNA - single stranded DNA
SvoPCNA - S. solfataricus PCNA
Ss'oXPF - S. solfataricus XPF
T-T - Thymine-thymine
TCR - transcription coupled repair
TEAA - triethylammonium acetate
tRNA - transfer RNA
TTD - trichothiodystrophy
Udg - UDP-Glc dehydrogenase
UDP - Uracil diphosphate
UMP - uracil monophosphate
VRE - Vancomycin resistant enerococcus
VRSA - Vancomycin resistant S. aureus
WHO -World Health Organisation
XP - Xeroderma pigmentosum
XPF(HhH)2 - HhH domain ofXPF
x
Contents
Chapter 1: Introduction 1-33
1.1 Antibiotic Resistance 2-3
1.1.1 Antibiotics 4-5
1.1.2 Mechanisms ofAntibiotic Resitance 5-8
1.1.3 Multi-drug resistance 8-10
1.1.4 Future perspectives 10-11
1.2 Macromolecular assemblies 11-15
1.3 Repair ofUV damage 15-33
1.3.1 DNA damage 15-17
1.3.2 Nucleotide excision repair 18-20
1.3.3 Damage recognition 21-22
1.3.4 Damage excision 22-23
1.3.5 Re-synthesis and ligation 23-24
1.3.6 Transcription coupled repair 25-29
1.3.7 Replication bypass ofDNA lesions 30-33
Chapter 2: ArnA, a Afunctional enzyme involved in the biosynthesis of 4-
amino-4-deoxy-L-arabinose: Crystallisation, data collection and




2.1.2 Lipid A and its biosynthesis 37-40
2.1.3 The Immune Response to Lipid A 40-42
2.1.4 Cationic Antimicrobial peptides 42-44
2.1.5 Regulated modifications of lipid A 45-48
2.1.6 L-Ara4N modification of lipid A 48-51
2.1.7 Lipid A biosynthesis/modification as an antibiotic target
51-52
2.2 Materials and methods/results 53-73




2.2.4 Initial X-ray diffraction 61-62
2.2.5 Data collection and processing 62-65
2.2.6 Data collection and analysis 66-70
2.2.7 Investigation ofProtein-Protein Interactions 71-73
2.3 Discussion 74-76
2.4 Future work 76-78
Chapter 3: Structural solution of the individual formyltransferase and decarboxylase





3.1.2 Folate metabolism 83-87
3.1.3 The GART family of formyltransferases 88-90
3.1.4 Mechanism of formyl transfer 90-91
3.1.5 SDR enzymes 92-97
3.1.6 Structure of SDR enzymes 97-98
3.1.7 Coenzyme specificity 98
3.1.8 Hydride transfer 99-100
3.1.9 GalE catalysed epimerisation 101
3.1.10 RmlB dehydratase 102-103
3.1.11 ArnA 103-104
3.2 Materials and methods 105-121
3.2.1 Selenomethionine expression and purification 105-106
3.2.2 Crystallisation ofSe-Met protein 106
3.2.3 MAD data collection of formyltransferase and 107
decarboxylase SeMet crystals
3.2.4 Structural solution and refinement 107-114
3.2.5 Site directed mutagenesis 115-117
3.2.6 Kinetic assay 118-119
3.2.7 HPLC assay 119-121
xiii
3.3 Results 122-130
3.3.1 Structure of the ArnA formyltransferase domain 122-124
3.3.2 Ligand Binding 124-127
3.3.3 Structure of the ArnA decarboxylase domain 128-130
3.4 Discussion 131-139
3.4.1 Formyltransferase domain ofArnA 131-139
3.4.2 Decarboxylase 139-147
3.4.3 Apo vs complexed ArnA decarboxylase 147-149
3.5 Future work 149-150
Chapter 4 Structural studies of heterotrimeric PCNA from Sulfolobus
solfataricus'. Structural solution of a heterotrimeric sliding
clamp and initial crystallisation of this clamp in complex
with the Helix-hairpin-helix domain ofXPF 151-
Introduction 152-176
4.1.1 Sliding Clamps 152-155
4.1.2 PCNA interactions 156-160
4.1.3 PCNA control 160-161
4.1.4 DNA repair in the archaea 162-164
4.1.5 Archaeal PCNA 165-167
4.1.6 The 9-1-1 complex 168-169
4.1.7 XPF homologues 169-172
xiv
4.1.8 Structural studies ofXPF 173-176
4.2 Materials and methods 177-192




4.2.4 Data collection 190-192
4.3 Results 193-
4.3.1 Structural solution ofPCNA heterotrimer 193-196
4.3.2 Overall structure 196-197





Publication Structure and function of both domains ofArnA, a dual function








Bacteria have a typical genome size of around 4 megabases. The majority of their
genomes encode functional genes (> 90 %) with very little non-coding regions.
Bacteria have a relatively high mutation rate, its DNA polymerase makes around one
mistake in a million1 and due to the nature of their genomes any mutation occurring
has a high probability of altering a gene product. The small genome and mutation
rate, coupled to their replication rate, makes bacteria particularly adaptable2. As a
result bacteria have colonised almost all corners of the world; from the arctic and deep
sea vents, to the guts of animals. This adaptability has been harnessed by pathogenic
bacteria, which utilise an arsenal of extracellular factors to colonise their host and
promote the release of nutrients on which they survive. These pathogens are the
cause of infectious disease that has plagued higher organisms since their own
evolution.
Prior to the mid-1940's deaths from infectious bacteria were common, with
infections such as Staphylococcus aureus having a mortality rate of around 80 %3.
The discovery of the antibiotic properties of Penicillium in 1897 in Duchesne's
Doctoral thesis, its rediscovery by Alexander Fleming in 19284 and the synthesis of
Penicillin by Florey and Chain5'6, ushered in a new era for human kind, the defeat of
pathogenic bacteria. This era lasted less than 40 years; predictably bacteria have
adapted to the use of antibiotics. Unfortunately pharmaceutical interest in developing
novel antibiotics declined during the golden era of antibiotic therapy and has yet to
recover. Although the widespread use of antibiotics has contributed to an increase of
2
the average human lifespan by 8 years7, over the last 15 years hospital admissions and
mortality rates due to bacterial infections have risen steadily (figure 1.1.1). This rise
is due to the spread of antibiotic resistance in bacteria and an increase in the number
of immune suppressed individuals, largely as a result of old age, HIV and
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Figure 1.1.1: Graphs showing: (a) the decrease in deaths from infectious disease
over the last 100 years in America. The large peak around 1920 is due to the avian flu
epidemic. Inset charts the recent rise in deaths, largely due to the spread of antibiotic
resistance (WHO, CDC), (b) The decline of antibacterial drugs produced in the last 20
years8.
1.1.1 Antibiotics
There are four main cellular processes that current antibiotics target protein synthesis,
DNA replication, DNA repair and cell-wall synthesis.
Several antibiotics target protein synthesis to kill bacteria, by inhibition of one
of several steps catalysed by the ribosome during translation. These include
macrolides of the erythromycin class9, aminoglycosides10, tetracyclines 11 and a more
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recent class of antibiotics, the oxazolidinones3. Fundamental to the use of
antimicrobials that target the ribosome are the large differences that exist between this
machinery in prokaryotes and eukaryotes12. Tetracycline utilises the differences
between bacterial and eukaryotic ribosomal RNA (rRNA), an important component of
the ribosome13. The specific binding of tetracycline to bacterial rRNA prevents the
association of transfer RNA (tRNA) with the ribosome14. As a result translation
elongation and therefore protein synthesis is inhibited in prokaryotes but not
eukaryotes14.
Similarly to protein synthesis, the differences between prokaryotic and
eukaryotic DNA replication and repair can be exploited in the use of antibiotics to
specifically inhibit bacterial machinery12. The quinolone, coumarin and
cyclothialidine classes of antibiotics target DNA replication, specifically through
inhibition of the topoisomerase DNA gyrase15. DNA gyrase has the unique ability to
introduce supercoils into DNA, a process essential to prokaryotic DNA replication
due to the circular nature of their genome15. Although evolutionarily related to other
topoisomerases, close homologues of DNA gyrase do not exist in eukaryotes and
therefore these antibiotics only inhibit bacterial replication15'16.
The cell wall and outer surface of bacterial cells is different to that found in
eukaryotes and is therefore an excellent antibiotic target. In Gram-positive bacteria
the peptidoglycan layer protects the cell and provides the mechanical strength for the
cell wall to resist osmotic lysis17. It is a mesh of peptide and glycan strands.
Penicillin binding proteins (PBPs), containing both transpeptidase and glycosylase
activities17'18, link peptide chains and extend sugar chains. The substrate for the
transpeptidase is a pentapeptide, with a dipeptide D-Ala-D-Ala terminus, the
crosslinking of which gives mechanical strength to the cell17. Antibiotics such as
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penicillins, cephalosphorins and vancomycin19'20 interfere with the transglycosylation
or transpeptidation processes, weakening the bacterial cell wall, leading to lysis due to
changes in osmotic pressure.
Gram-negative bacteria have a smaller peptidoglycan layer than Gram-positive
bacteria. However, they have an outer cell membrane, the outer surface of which
contains the lipopolysaccharide (LPS) (chapter 2.1.1). This layer provides a more
effective barrier to their environment and as a result some antibiotics are less effective
against these organisms. Enzymes involved in the biosynthesis of the lipids and
sugars that make up the LPS are potential drug targets against Gram-negative
pathogens, discussed in chapter 2.
1.1.2 Mechanisms of Antibiotic Resistance
Most antibiotics are natural products that have evolved in bacteria or fungi as a
method of chemical warfare to kill competing organisms. The evolution of these
antibiotics has led to the co-evolution of resistance so that the antibiotic producer is
not killed by its own product21"23. Further, since antibiotics target fundamental
processes in bacteria that involve proteins, mutations in genes which confer resistance
are quickly selected and replicated in rapidly dividing bacterial cells. As a result



















Figure 1.1.2: Mechanisms of resistance to antibiotics. Taken from
http://www.bioteach.ubc.ca/Biomedicine/CationicPeptides.
The effect of the antibiotic can be neutralised by altering the antibiotic
molecule so that it is no longer effective. The P-lactam ring of Penicillins and
Cephalosphorins is the active part of these antibiotics. These antibiotics act as
pseudosubstrates for the transpeptidase reaction catalaysed in the formation of the
peptidoglycan layer, resulting in the acylation of the transpeptidase active site18'24.
The penicilloylated transpeptidase deacylates very slowly and so the enzyme active
site is occupied, inhibiting the normal crosslinking of peptide chains in the
peptidoglycan layer18,24. This action is prevented in some resistant bacteria by
expression of P-lactamase enzymes which hydrolyse the p-lactam ring to produce
penicillinoic acid, which does not inhibit transpeptidases24. Alternatively, instead of
breaking down the active group, the antibiotics can be covalently modified with
6
• • 25 • • •moieties that prevent its function . This is how aminoglycosides are neutralised, with
resistant bacteria expressing enzymes that can add AMP, PO32" or acyl groups to the
antibiotic, reducing its affinity for RNA and thus its effectiveness25.
The concept of pumping is similar to neutralisation; if an active form of the
antibiotic is not present at its target, it is unable to have its effect. Thus efflux pumps,
which pump out the antibiotic, have evolved as a mechanism of resistance21"23. By
pumping the antibiotic out of the cell at a faster rate than it can diffuse in, the
concentration of antibiotic is never high enough to be effective12. These pumps are
membrane proteins that are related to those normally produced21'23 and are a common
mechanism for the export of antibiotics by antibiotic producers, so that they
themselves are not affected21"23. The protein synthesis targeting antibiotics
O 1 o 1 0*7
tetracycline ' and erythromycin ' are removed by this mechanism in some
resistant bacteria.
The antibiotic target itself can be mutated or modified to prevent antibiotic
binding12. For example mono- or dimethylation of the 23 S ribosome subunit at a
specific adenosine by the methyltransferase Erm does not affect protein synthesis, but
• • •••«•• 28 •lowers the affinity for erythromycin and pristinamycin antibiotics . Alternatively
mutations to the target protein that lowers the affinity for an antibiotic can result in
resistance. For example mutation ofPBPs can render bacteria resistant to penicillin29.
The basis for methacillin resistant S. aureus (MRSA) is the acquisition of the MecA
protein, which encodes a different version of a PBP, with low affinity for almost all
P-lactam antibiotics30'31.
Vancomycin resistance works in a different, more complicated way, in which
the building blocks used for constructing the peptidoglycan layer are changed19'20.
Vancomycin acts by binding with high affinity to the terminal dipeptide D-Ala-D-Ala
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of the substrate for transpeptidases, inhibiting the crosslinking of the peptide chains in
the peptidoglycan layer19'20. In vancomycin resistant bacteria vanHAX encodes
enzymes that reduce pyruvate to D-lactate (VanH), link this to D-Ala (VanA) and
hydrolyse the normal dipeptide D-Ala-D-Ala (VanA)19'20. In these resistant bacteria
only D-Ala-D-lactate is elongated to produce a pentapeptide that can act as a substrate
for transpeptidases, with no effect on the cross-linking efficiency but with an 1000-
fold reduced affinity for vancomycin19'20.
1.1.3 Multi-drug resistance
The spread of antibiotic resistance is driven by the selective pressure placed on the
bacteria by the continued use of antibiotics and the promiscuity of gene transfer
between bacteria. As discussed above; there are many ways that bacteria can evolve
resistance to antibiotics and other antimicrobials and as a result there is an almost
inevitability that given enough time, resistance will evolve32'33. Vancomycin was
introduced in 1958 and clinical isolates of resistant bacteria were not observed until
1987, 29 years later. This is very unusual as clinically significant resistance usually
appears within months to a few years after introduction of an antibiotic34, particularly
when it only targets one gene product. The unusual time delay for vancomycin
resistance is almost certainly due to the complexity of its resistance mechanism,
requiring the action of five gene products19'20.
It is common for the genes that confer resistance to any particular antibiotic to
be collected on plasmids33 or transposons19, commonly termed mobile DNA elements.
These plasmids are independently replicated within the cell and are passed between
bacterial cells, species and sometimes genera. This is the principle mechanism
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leading to the rapid spread of resistance genes through bacterial populations33.
Transposons are able to excise themselves from one genetic locus and integrate into
another, allowing resistance genes encoded within the transposon to move
promiscuously between plasmids and the genome19. Such mobile DNA elements
allow the accumulation of more than one set of resistance genes in one organism,
resulting in the evolution of multi-drug resistant bacteria12. It is these multi-drug
resistant bacteria that are currently posing the greatest threat to human health.
There are almost weekly reports in the British press about the pandemic of
MRSA in hospitals. S. auereus causes serious infections during invasive surgery,
• • 35with a higher mortality rate associated with MRSA than susceptible infections . The
last line of defence against MRSA is the glycopeptide vancomycin, however the
emergence of strains of first enterococcr'6'37 and subsequently S. aureus38 that are
resistant to vancomycin (VRE and VRSA respectively) is extremely worrying as there
is no effective treatment for these infections. The spread of multi-drug resistant
tuberculosis39 and the Gram-negative Salmonella typhimurium DT10439 are also
particularly worrying as they are two of the leading causes of mortality and morbidity
worldwide (WHO).
Over the last 40 years more could have been done to avert this crisis we are
currently facing as, from an early time after the introduction of penicillin, the problem
of bacterial resistance became clear. It was in the 1940's that products secreted from
bacteria were identified that break down penicillin40 and Alexander Fleming, in a
New York Times article, warned of the misuse of antibiotics that could select for and
lead to the outgrowth of resistant bacteria. These warning signs were not heeded and
a combination of antibiotic misuse in both medical and agricultural sciences12 and a
general lack of investment in developing new antibiotics by pharmaceutical
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companies41'42, requires us to develop new drugs to combat infectious disease.
Pharmaceutical companies are reluctant to invest in such programs as the almost
inevitable evolution of resistance means that any new antibiotic may have limited use
in a relatively short time and any successful broad ranging drug would be limited in
its use.
1.1.4 Future perspectives
So what can be done to tackle the increasing problem of drug resistant bacteria? With
recent technological advances, coupled with the success of sequencing the genomes of
pathogenic bacteria (The Wellcome Trust Sanger Institute) and structural genomics43,
there may be many ways that this problem can be addressed. Each protein that is
essential for growth, survival, pathogenicity or antibiotic resistance of a pathogen, is a
potential drug target. As the success of genomic and proteomic projects continues,
where more genomes of pathogenic bacteria are sequenced and the function of the
encoded genes are established, more targets will be discovered. Structural genomic
projects, which are still in their infancy, will result in the structural solution of more
and more of these potential targets. In recent years the availability of high
performance computing platforms has transformed the way lead compounds are
identified and prioritised44. By molecularly docking tens or hundreds of thousands of
potential inhibitors from a virtual chemical library onto an enzyme binding site, the
mode and affinity of binding can be predicted. This allows compounds to be
prioritised for biological screening and has the potential to cut both the cost and time
needed to develop new drugs. The combination of structural genomics and virtual
screening will provide a greater base to start from for structure based drug design. In
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the future it may therefore be anticipated that academia will play a bigger role in the
initial drug discovery and improvement stages of finding new antibiotics and then, in
collaboration with industry, go on to test these drugs.
In addition, the potential of cationic antimicrobial peptides (CAMPs) may help
in the fight against resistant bacteria. CAMPs are an important part of innate
immunity in animals and in sufficient concentrations can kill a wide range of
pathogens through permeabilisation of their cell walls (chapter 2.1.4) 45,46. They
therefore have the potential of either being used as an antibiotic/anti-infective or in
combination, to increase the permeability of the cell wall of pathogens, helping in the
delivery of current and future drugs.
1.2 MACROMOLECULAR ASSEMBLIES
Over the last 10 years the success of genomic projects in sequencing the genomes of
the important model organisms Escherichia coif''', Saccharomyces cerevisiae48,
Caenorhabditis elegans49, Drosophila melanogaster50, mouse51 and the human
genome project52,53, has given us a wealth of information. These data have been
invaluable to the geneticist, biochemist, molecular biologist and structural biologist;
however it only scratches the surface in understanding how this genomic information
encodes a functional organism. The human genome project52,53 revealed that, despite
a genome size over 30 times larger, we have a similar number of genes as the
invertebrate C. elegans49, around 3000052,53. It is also apparent that the number of
human disorders actually exceeds the number of genes we possess54. These
observations suggest that the 'complexity' of humans compared to lower eukaryotes
must be in how our ensemble of expressed gene products (proteome) is utilised, as
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opposed to gene number. It is therefore not only the elucidation of function of every
gene product, but how they are combined to create an organism, that represents a
major challenge for post-genomic biology.
Macromolecular interactions and assemblies, including those between protein-
protein, protein-DNA and protein-RNA, play major roles in almost all of cellular
biology. These include mediation of cell-cell interactions5 , signal transduction56,
cell-cycle control, apoptosis57, organelle structure5 , lipid59 and amino acid
metabolism60, protein degradation61, DNA replication59, DNA repair62, transcription63,
translation64 and splicing65. Many of these pathways are present in all three domains
of life; however there exists a general trend that the more complicated an organism,
the more interactions necessary to mediate and carry out these processes. The DNA
repair pathway nucleotide excision repair (NER) is an example of one of these
processes that involves a range of protein-protein interactions and is discussed in
more detail below (1.3).
It is interesting to think of how this complexity has evolved considering the
underlying structural similarity that exists between related proteins in all domains of
life. As of January 2006 the protein data bank (PDB) contains nearly 35000
structures from the three domains of life. It is estimated that the number of distinct
structural folds contained in the proteome is approximately 100066 and those
deposited in the PDB represent around 80 % of these67. In contrast the estimation of
the number of distinct structural types of interactions that can occur is in the region of
1000068, with only 20-30 % represented in the PDB68'69. Thus it seems organisms
have evolved proteins that are made up by a relatively small number of structural
folds that can interact with other proteins in a much more complicated manner. A
feature of eukaryotic proteins over prokaryotic homologues is that, although the
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overall fold is largely conserved, extra features of the structure are present, for
example loops and N- or C-terminal extensions, which are important for protein-
protein interactions, allowing greater control and functionality of these proteins.
Protein-protein interactions are driven by thermodynamics with an equilibrium
existing between the free and complexed proteins. The extremes of this equilibrium
result in transient or very weak and very stable complex formation. An important
factor leading to the evolution of these protein-protein interactions is the conditions in
which they have evolved within the cell. In E. coli it is estimated that 20-40 % of the
cytoplasm is taken up by macromolecules, with an overall protein concentration
between 200 and 400 mg ml"1 70 and a similar concentration exists in the
compartments of eukaryotic cells71. The high levels of proteins and other
macromolecules within the cell results in an environment in which there is very little
free space available and this macromolecular crowding72 provides a non-specific force
for macromolecular compaction and association73"75. An example of the importance
of macromolecular crowding is demonstrated by the in vitro reconstitution of DNA
replication and transcription, with the presence of an in vitro crowding agent required
to obtain similar properties as observed in vivo16. There are also many other examples
of in vitro crowding agents significantly effecting both kinetic rates77,78 and
• • 7Q on . ,
macromolecular interactions ' ' . In general in vitro conditions are a poor reflection
of those in vivo as the solutions are very dilute, with protein concentrations rarely
above 10 mg ml"1. It is therefore important to consider the effect ofmacromolecular
crowding when drawing important in vivo conclusions from such assays81.
The formation of protein-protein complexes can give several advantages. The
protein complex can alter the kinetics of a process which can affect; substrate binding,
catalysis or allosteric properties82. One example is the binding of PCNA to DNA
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polymerase, which alters the processivity of this enzyme83. Protein-protein
interactions can also facilitate substrate channelling, which can result in several
advantages including an increased rate of consecutive reactions. Protein-protein
interactions also allow regulation of pathways through inactivation of proteins, such
as NFkB bound to its repressor84. They can also change the substrate specificity of
another protein as is the case for transcriptional regulation, where the interaction of
transcription factors with RNA polymerase directs the transcription of different
genes85. Another major advantage of multi-subunit complexes is the use of different
subunits to regulate or alter responses, such as differences observed in the RNA
polymerase complex during initiation of transcription, elongation63'85 and upon
stalling when a block is encountered86.
The daunting task of attempting to work out the entire 'interactome' of an
organism, i.e. how all of the protein-protein interactions occurring within (and
between) cells makes up an organism, has already begun, with S. cerevisiae%1'%8 and
D. melanogaster89 being used as model organisms. These studies have focused on the
use of yeast-two-hybrid screens to look for the interaction between bait proteins,
made from as many open reading frames as possible from an organism, and prey.
Figure 1.2.1 shows the kind of picture that is emerging from these studies and
although their accuracy is debateable, due to the number of false positives observed
and not every ORF being suitable as bait, it is clear the 'interactome' of an organism
is extremely complex and will take many years to elucidate and verify. The structural
biologists' role investigating these interactions and how they relate to cellular biology
will be one of the major features of structural biology in the 21st century.
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Figure 1.2.1: Protein interaction map (PIM) linking protein-protein interactions in D.
melanogaster, generated by the PIM Walker graphical interface, a tool developed to
display networks. The proteins in the map that bear an RA (Ras Association) or RBD
(Raf-like Ras-binding) domain (coloured in orange) define a discrete subnetwork
around Ras-like GTPases (colored in yellow). This diagram demonstrates the
complexity of protein-protein interactions within the cell Taken from Formstecher et
1.3 REPAIR OF UV-DAMAGE
1.3.1 DNA damage
DNA damage arises from many different factors including ultra-violet (UV), X-ray
and ionising radiation, mutagenic compounds and endogenous factors, for example
errors in replication by DNA polymerase and damage from reactive oxygen species
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generated during metabolism91 92. This damage can occur anywhere in the genome
and if it is not efficiently repaired it results in permanent mutation following
replication. Although it is the selection of beneficial traits arising from mutations that
drives evolution, deleterious mutations have serious consequences for the cell and are
one of the major causes of cancer91. Figure 1.3.1 shows some of the types of DNA
damage that can occur including inter-strand crosslinks by chemotherapy agents such
as cis-platin, mismatches due to errors in replication, production of cyclobutane
pyrimidine dimers (CPDs) or 6-4 photoproducts (6-4PPs) by UV exposure and single
and double strand breaks by X-rays93. The number of such mutations occurring in the
human genome (~3 x 109 bases) per day, per cell is astonishingly high, with
estimations around 2500094. Since the direct result of this damage is mutation or
blocking of replication and transcription, if this damage is not corrected the cell
quickly dies. Several mechanisms of DNA repair have evolved to deal with the
variety ofDNA damage that can occur (reviewed in62'93). These include: single repair
enzymes catalysing direct reversal of damage62, recombination repair95, both
homologous recombination95 (HR) and non-homologous end joining 96'97, mismatch
repair (MMR)98'99, base excision repair (BER)100 and nucleotide excision repair
(NER)101, the mechanism of which is discussed in detail here. The importance of
DNA repair in humans is demonstrated by a number of inherited disorders that are
defective in DNA repair. These include hereditary non-polyposis colorectal cancer
(HNPCC)102 and Xeroderma pigmentosum (XP)101, defective in MMR and NER
respectively, both ofwhich result in the early onset of cancer.
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Figure 1.3.1: Summary of DNA damaging agents and the main type of lesion they
cause along with the most common forms of repair employed to deal with this
damage. Adapted from Hoeijmakers93.
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1.3.2 Nucleotide excision repair
NER is unique in that it has evolved almost exclusively to remove exogenous DNA
damage such as the UV induced damage CPDs and 6-4PPs, as well as other bulky
lesions94'103. The common feature of these types of damage is the distortion of the
DNA helix104 and it is this distortion that is thought to be recognised by the DNA
damage recognition proteins that initiate this process104'105. The importance ofNER
in humans is highlighted by the severe genetic disorders associated with defects in
this process including XP, Cokayne syndrome (CS) trichothiodystrophy (TTD) and
cerebro-oculofacio-skeletal syndrome (COFS) 94'106'107 The phenotypes of these
disorders are detailed in table 1.3.2, with patients suffering from XP, CS, TTD and
their combination exhibiting extreme sensitivity to UV light, however only XP
patients have the early onset and high occurrence of skin lesions101. Defective DNA
repair in fibroblast cells from XP patients was first described by Cleaver in 1968108.
Since then cell lines from all of these disorders have shaped the research ofNER over
the last 40 years, with identification of the mutated genes and the variation in
phenotypes of the different disorders allowing great insights into this complex
109
process .
Observations over 20 years ago suggested that regions of DNA containing
transcribed genes were repaired at a faster rate than non-transcribed regions110'111,
with further research showing that this faster repair is specifically associated with the
transcribed strand112'113. This phenomenon has been termed transcription coupled
repair (TCR) (figure 1.3.5) and the CS, TTD, XP/CS and XP/TTD human disorders
link this process to NER94'106. As a result, TCR has been studied as a sub-pathway of
NER, specifically repairing UV-damage and bulky lesions in the transcribed gene,
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with the NER pathway required for the repair of damage in non-transcribed regions
called global genome repair (GGR) (figure 1.3.3).





UV sensitivity ++ ++a ++ ++ ++ ?
Increased Freckling ++ - - ++ ++ ?
Skin cancer ++ - - ++ + ?
Cachectic dwarfism - ++ ++ ++ + +++
Microcephaly - ++ ++ ++ ? +++
Progressive cognitive impairment - -H- ++ ++ ++ +++
Sensorineural deafness - ++ ++ ++ - +++
Eye abnormalities - ++ ++ ++ ? +++
Skeletal abnormalities - + + + ? ++
Spasticity - ++ ++ ++ ? +++
Ataxia - ++ ++ ++ - +++
Axonal neuropathy - +/- ? + ? ?
Demyelinating neuropathy - -H- ++ ++ ? ?
Myopathy - - - +/- - ?
Brain calcification - ++ ++ ++ ? +++
Hypogonadism - ++ ++ ++ ? ?
Brittle hair and nails - - ++ - + ?
Hyperkeratosis - - ++ - + ?
Progeria - -H- ++ ++ ? ?
Table 1.3.2: Summary of the clinical symptoms of the NER disorders XP, CS, TTD










Figure 1.3.3: Global genomic repair by the NER pathway. The helix distortion
resulting from DNA damage (a) is recognised by the XPC heterodimer (b), resulting
in the recruitment of other NER proteins that open up the helix around the distortion
(c). The XPG and XPF DNA-structure specific endonucleases make incisions 3' and
5' to the damage respectively, resulting in the excision of the damaged DNA (d and e).
DNA polymerase 8 or s are then loaded by the actions of the clamp loader (RFC) and
sliding clamp (PCNA), allowing gap synthesis, before DNA ligase completes the





During the GGR process of NER the protein that initially recognizes the damage
appears to be the XPC-hHR23B complex (figure 1.3.2b). This has been shown
biochemically by the decreased repair time of DNA which had been pre-incubated
with XPC-hHR23B114 and observed during the sequential assembly ofNER factors in
v/vo115. The helix distortion generated by 6-4PPs is greater than that of CPDs104 and it
has been shown that XPC-hHR23B binds to 6-4PPs with a greater affinity than
CPDs105'116. As a result the repair efficiency of 6-4PPs is 5 times greater than
CPDs104, despite UV irradiation generating more CPDs than 6-4PPs117"119. These
observations are all consistent with the notion that it is the helix distortion, not the
specific damage, which is the basis for the GGR damage recognition step. Mutations
in the genes encoding the damaged DNA binding protein heterodimer, consisting of
the 128 (pl28/DDBl) and 48 kDa (p48/DDB2) subunits, results in the XP group E
i/^A 10 1 199 1 99
disorder ' . Although this heterodimer is not essential for NER in vitro , the
XP-E phenotype demonstrates its importance in vivo94. It is thought that XPE may
play a role in assisting XPC in the recognition of damage, particularly CPDs116'124'125.
After damage recognition other factors that are crucial for NER are recruited;
to verify the damage, XPA and replication protein A (RPA)123'126 and to locally
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unwind a region of the DNA around the lesion, the TFIIH transcription factor '
XPA has the ability to bind UV-damaged DNA129. However that XPC-hHR23B
initiates NER114'115 suggests XPA acts downstream of XPC to synergistically
recognise the presence of damage130. XPA's affinity for UV lesions increases with
the extent of helical distortion131 and the observation that XPC-hH23B binding to a
lesion further increases helical distortion114 is probably how XPA is recruited to the
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site of damage. The interaction of XPA with other NER proteins including TFIIH132
and RPA133 leads to their recruitment to the complex. RPA is a heterotrimeric single
stranded DNA (ssDNA) binding protein that is involved in DNA repair,
recombination and replication134. Its function during NER is to bind the undamaged
strand, essential for the full opening of the double helix135. Along with XPA, RPA is
thought to also play a role in distinguishing the damaged and undamaged strands130.
TFIIH is a multi-subunit protein complex involved in both NER and
1 o/' -10*7 i^o i
transcription initiation , containing 9 polypeptides ' including the XPB and
XPD140 helicases, which are essential for both processes. These helicases have
opposite polarities with XPB unwinding DNA in a 3'-5' direction141 and XPD 5'-3'142
around the DNA damage. The action of the XPB and XPD helicases results in the
formation of the NER open complex (figure 1.3.1c), however the complete opening of
this region requires the presence of XPA, RPA and also X3PG, which is the
endonuclease that makes an incision 3' to the DNA damage143'144.
1.3.4 Damage excision
The function of two DNA-structure specific endonuclease enzymes, XPG145 and the
XPF-ERCC1 heterodimer146"148, results in the excision of a patch ofDNA between 24
and 32 nucleotides in length149. XPG interacts with TFIIH150 and makes an incision
on the damaged strand 3' to the damage, recognising the splayed duplex structure
formed during the initiation steps of NER151. XPG is found associated with the
proliferating cell nuclear antigen (PCNA)151, although PCNA appears to have little
role in stimulating its activity in NER151. XPG's recruitment to the NER machinery is
independent of XPA115, however it is only in the presence ofXPA, probably mediated
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by RPA148, that XPG makes the incision between 2-8 nucleotides from the damage144.
This incision is followed by the XPF-ERCC1 endonuclease activity, approximately
15-25 nucleotides 5' to the damage144'152. XPF-ERCC1 is recruited to the NER open
complex through its interactions with the XPA protein115 and the concerted action of
XPA and RPA is thought to facilitate the XPF-ERCC1 incision on the damaged
strand153.
1.3.5 Re-synthesis and ligation
si:
Figure 1.3.4: PCNA loading by the ATP-dependent clamp loader RFC. Once loaded
onto the ds/ssDNA junction PCNA can recruit the replicative polymerase Pol8 for
initiation of replication. Adapted from Bowman et al.154
After the 3' and 5' incisions are made the damaged strand is thought to dissociate
along with the NER proteins, with the exception of RPA. The excised ssDNA would
be unable to sustain the NER complex of proteins so it is likely that at this point the
complex falls apart, releasing the damaged DNA fragment and individual NER
components. The damaged stretch ofDNA would then be digested by nucleases and
the NER proteins available for recruitment to other sites of UV-damage. RPA is




double stranded (ds)/ssDNA junctions are formed after excision, with the junction 5'
to the damage having ssDNA leaving in a 3'-5' direction. This junction is recognised
by replication factor C (RFC), a component of the DNA polymerase (Pol) 8 or 8
holoenzyme126. RFC loads the PCNA sliding clamp155, which recruits DNA
polymerase 5 or s (figure 1.3.4). The damaged segment can then be re-synthesised
and the resulting nick ligated by DNA ligase I (figure 1.3.3f and g)156'157 158.
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j Recruitment of other Recruitment ofBER
NER proteins andDNArepair proteins and DNArepair
during transcription (a) results in the recruitment of a host of proteins (b) that is
thought to back-track the polymerase, uncovering the lesion (c). NER proteins are
then recruited to repair the lesion (d), as shown in figure 1.3.3c-f, before transcription
is re-initiated (e). Taken from Friedberg94.
Transcription coupled repair (TCR) (figure 1.3.5) has largely been studied as a sub-
branch ofNER, specifically involved in the removal ofUV lesions on the transcribed
strand of genes (see review159). The human disorders CS and TTD demonstrate the
importance of TCR94'106. However the lack of a suitable in vitro system for studying
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this process makes the actual mechanism of action less well understood than GGR107.
Extensive studies using cells derived from CS and XP/CS patients have given the
greatest insights into this process with certain mutations in 5 genes encoding; CSA,
CSB, XPB, XPD and XPG, resulting in TCR defects160. The current model of TCR of
UV-damage is that the proteins involved in GGR, discussed above, are conserved
with the exception of the XPC-hHR23B and XPE proteins. It has been shown that the
helix distortion introduced by CPDs and 4-6PPs, as well as other bulky lesions, act as
a hindrance to transcription, resulting in the stalling of RNA polymerase II
(RNAPII)104'161"163. It is thought that the stalled RNAPII acts as the initial DNA
damage recognition step of TCR104'112'164, resulting in the recruitment of NER
proteins94'165. CPDs are more efficiently repaired by TCR than GGR112'113 because
their recognition is more efficient by RNAPII, which will stall at every CPD, than
XPC-hHR23B, which has a relatively weak affinity for CPDs105'116.
It is also possible that the packaging ofDNA into chromatin plays a major role
in determining the rate ofNER in vivo (reviewed in166) as cell free experiments using
human cell extracts show that DNA packaging onto nucleosomes inhibits the rate of
NER167. In vitro experiments also demonstrate that the core GGR factors; XPC-
hHR23b, XPA, RPA, TFIIH, XPG and XPF-ERCC1, which are sufficient for NER on
naked DNA templates, do not repair 6-4PPs on nucleosomal DNA168. It is therefore
evident that other factors are important for NER in a chromatin context in vivo and
this is likely to involve chromatin remodelling machinery166'169, with the XPE
heterodimer implicated in this process166'170'171. Although DNA packaging into
chromatin structure would affect GGR, no such problems would be associated with
TCR as the DNA needs to be relaxed from chromatin for normal transcription. This
could be a major factor influencing the faster rate ofTCR of CPDs in vivo.
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Key to the process ofTCR is the action of the CSA and CSB proteins118'172'173,
which are essential for the restart of transcription after UV-damage174, although the
exact role of these proteins is unclear. CSA is thought to be important in facilitating
protein-protein interactions due to the presence of five WD-40 repeats, interacting
directly with RNAPII, CSB and a subunit of TFIIH175. CSB is a large, 168 kDa
protein that belongs to the DNA-dependent ATPase SWI/SNF family of proteins that
are involved in chromatin remodelling176'177. Similar to this family of proteins, CSB
exhibits DNA dependent ATPase activity178 and is able to remodel chromatin in vitro,
providing a possible link to TCR and chromatin remodelling179. DNA damage results
in the translocation of CSA to the nuclear matrix in a CSB dependent manner, co-
localising with RNAPII180, thought to be important for the initiation of TCR in vivo.
CSB may be a component of the RNAPII elongation complex178'181'182, with its
indirect interaction with RNAPII in vitro important for the elongation of transcription
on a template containing pause sites183 and may function in TCR by recruiting
TFIIH184. TFIIH is involved in transcription initiation136 and is thought to be lost
from the transcription elongation complex after approximately 50 bases185'186. The
observation that CSB deficient cells can efficiently remove CPDs from areas close to
RNA polymerase initiation start sites, but are unable to do so during transcriptional
elongation187 are consistent with its role in recruiting TFIIH to the site of stalled
RNAPII184'188.
Biochemical assays show that RNAPII stalled at a lesion actually impairs
NER104'162'189, presumably because it blocks the access of the repair proteins to the site
of DNA damage. However the requirement of both XPA and RPA for xCR101'190
suggests that upon recruitment ofTFIIH to the site of stalled RNAPII, the lesion must
be uncovered. This is hypothesised to be achieved by a backtracking of RNAPII
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rather than its dissociation104'191'192. Backtracking of the RNAPII, possibly mediated
by CSA, CSB and TFIIH proteins159, would allow XPA and RPA access to the site of
damage and NER could then proceed as discussed above for ggr104>191>192
(figure1.3.3c-f). The backtracking of RNAPII may also involve one of two recently
discovered, novel XPA binding proteins (XAB1 and 2), with XAB2 shown to interact
with CSA, CSB and RNAPII159'193
As well as being important for TCR it has been shown that mutations in genes
resulting in CS or TTD also lowers the overall levels of transcription194"196, suggesting
their importance in normal transcription. It is thought that the reason patients with CS
and TTD do not exhibit the increased susceptibility to developing cancer after UV
exposure (as seen for XP) is because any cells with significant amounts of damage
will result in RNAPII stalling which, if TCR cannot occur, will activate pathways
resulting in apoptosis196. Consistent with this idea, high levels of apoptosis are
observed in CS patients and this may contribute to the rapid aging and other
symptoms observed195'196.
Until recently TCR has only been studied as a sub-branch of NER, to repair
UV-damage and bulky lesions on transcribed strands of DNA. However cell lines
from HNPCC patients, a disorder associated with MMR defects, are also deficient in
197 • • • • 198TCR It has also been shown that TCR can repair oxidative lesions , usually
repaired by BER. These results suggest that, rather than being a branch ofNER, TCR
may be a more general repair pathway. However this idea is more contentious as the
involvement of BER proteins in TCR of oxidative lesions has yet to be shown and
although MMR proteins from E. coli have been shown to be involved in TCR197, such
a role in eukaryotes is unclear199"201. Further, cell free systems also show that RNAPII
does not stall upon encountering the 8-oxyguanine202 and thymine glycol203'204 lesions
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usually repaired by BER. Thus TCR of such lesions would presumably require a
different recognition step to classical TCR.
The description of NER above has focused on that in human cells, however
homologues ofmost of the NER proteins are conserved in eukaryotes86'103, with a few
notable exceptions (4.1.4)86'205. In prokaryotes a NER pathway exists, although the
proteins carrying out this process are not conserved. In E. coli the UvrAB complex is
important for UV induced damage recognition206 and the UvrC endonuclease makes
the incisions both 3' and then 5' to the DNA damage ' . The damaged fragment,
of between 8-12 nucleotides208, is then removed and the resulting nick ligated by the
concerted action of the UvrD helicase, Poll holoenzyme and DNA ligase 209.
The process of NER in the third kingdom of life, archaea, is less well
characterised and is discussed in Chapter 4.1.4.
Observations in a number of patients diagnosed with XP but did not have a
defective NER pathway210, XP-variants, hampered the elucidation of the NER
pathway86 It was not until 1999 that the gene responsible for the XP-V
complementation group was elucidated, revealing an alternative pathway for coping
with UV-damage within the cell.
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Figure 1.3.6: Replication bypass of a CPD by translesion synthesis. On
encountering a CPD the replication fork stalls. The cellular response to this results in
the ubiquitination of PCNA, mediated by the Rad6 family of proteins211 (a and b).
The ubiquitination of PCNA increases its affinity for Polq, leading to a polymerase
switch from Pol5 to Polr] (c). Polq then replicates the CPD and a few extra bases,
until the replication fork is free of the damage, before there is another polymerase
switch back to Pol5, resuming normal replication (d). It is thought that the damage
polymerases may be part of the normal replication machinery and the activities of
different damage polymerases (for example Poll) may be employed depending on the
damage encountered. Taken from Lehmann212.
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Post-replication repair is a term used for the observation that intact daughter strands
can be synthesised in the presence of persisting DNA damage in vzvo213'214 The
predominant mechanism for replicating this damage in E. coli involves homologous
11 < 01£ 1 o
recombination ' , however this is not the case for mammalian cells . The key to
understanding this process in eukaryotes was the identification of the gene that
resulted in the XP-V phenotype, as cells from these patients were shown to be
• • •'717990
defective in post-replication repair " . It was not until 1999 that the gene product
missing in XP-V patients was isolated and shown to be a DNA polymerase (Polt))
capable of replicating thymine-thymine (T-T) CPDs221, immediately suggesting a
mechanism of post-replication repair of this damage in mammalian cells. The Polr|
polymerase was cloned and found to be homologous to radiation sensitive mutant
999 994
(Rad) 30 in S. cerevisiae ' and has since been extensively characterised in vitro
t . • 214,225,226\(reviewed in ' '
999 999
The discovery of Polr] ' led to the subsequent identification of several
other similar polymerases including Polt from humans227, the E. coil dinB and umuC
• 990 910
gene products, PolIV and PolV respectively ' and dinB homologues in humans
(PoIk)228 and archaea229'230. These polymerases have been grouped into the Y-family
of polymerases and while they share sequence identity and similarity with one another
they are unrelated in sequence to classical polymerases214 Two other important DNA
polymerases involved in replicating damage have also been identified, Po^ and
Revl86'214. The typical error rate of the DNA-damage polymerases is approximately
10"2 on both damaged and undamaged templates, compared to 10"5 - 10"7 for the
999 99A.
replicative polymerase which is only active on undamaged DNA ' . Due to their
low fidelity they have been termed error-prone polymerases.
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Although the error-prone polymerases have been well characterised in vitro,
their in vivo function is less clear, with only Pole's role well understood212'214. An
important question is why would the cell want to use these mutagenic polymerases?
The XP-V phenotype, along with biochemical studies231'232, suggests that the in vivo
role ofPolq is for the error-free replication ofUV-induced CPDs. This is achieved as
Polri appears to have evolved a preference for adding the correct nucleotides, two
adenines, opposite the most common CPD, T-T ' . Indeed it is thought that the use
of this polymerase actually represents the predominant and most efficient way of
repairing this damage in vivo233. The mutagenesis observed in XP-V individuals is
likely to be due to the use of other damage-polymerases that replicate CPDs less
efficiently and less accurately. It has been speculated that the role of the different
damage-polymerases in the cell is to accurately replicate other DNA lesions; however
there is currently little in vivo evidence to support this212. Importantly, the use of
these polymerases must be under extremely tight control as their misuse during
normal replication would have drastic consequences for genomic stability and cell
viability.
The structural solution of the catalytic regions of S. cerevisiae Polq
homologue Rad 3 0234 and two dinB homologues from S. solfataricus229'230, one in
complex with DNA229, have provided structural insights into the mechanism of action
of the Y-family of DNA polymerases235. Despite no sequence similarity, the
structures of these polymerases reveal that they have the finger, thumb and palm
domains conserved in other DNA polymerases, as well an additional
domain ' ' ' The key difference between the error-prone and high fidelity
polymerases is that the active site of the Y-family of polymerases is slightly larger,
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forming a more open conformation that implies a mechanism for the accommodation
of altered/damaged bases within it229'230'234'235.
In vivo studies looking at the localisation of Polr) before and after UV
exposure show that upon irradiation it moves from a more disperse nuclear location to
discrete foci in the nucleus, with the foci co-localising with PCNA and replicating
/jo i
DNA ' This is consistent with the proposed mechanism of post-replication
repair by these error-prone polymerases (figure 1.3.6). It is thought that the error
prone polymerases are associated with the replication machinery212. Upon stalling of
the replication fork, due to its encounter with DNA damage, the error-prone
polymerase is utilised to synthesise the damaged DNA and just a handful of other
bases, before reverting back to the high fidelity replication polymerase101'236. Key to
this process is the interaction of these polymerases with PCNA, which increases their
polymerase activity without increasing their processivity237. It is thought that PCNA
plays a crucial role in mediating the switch between different polymerases required
during lesion bypass and that this may be controlled by ubiquitination211'214.
The elucidation of the pathways that have evolved to deal with UV-induced
DNA damage within the cell reveal a fascinating story in which the processes of
replication, transcription and NER play important roles. The emerging evidence
suggesting TCR is not unique to damage repaired by NER and the identification of
other error-prone polymerases that can replicate several types of lesions214, suggest
that this overlapping role of replication, transcription and repair in maintaining the
genome is not unique to UV-induced damage.
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Chapter 2
ArnA, a bifunctional enzyme involved in the
biosynthesis of 4-amino-4-deoxy-L-arabinose:

























Figure 2.1.1: Schematic model of the inner and outer membranes of E. coli K12
taken from Raetz and Whitfield238. The LPS makes up the outer leaflet of the outer
membrane and something similar exists in almost all Gram-negative bacteria'
239
Figure 2.1.1 shows a diagram of the membrane ofE. coli K12, which is fairly typical
for Gram-negative bacteria. It consists of inner and outer membranes separated by a
thin peptidoglycan layer, with the Lipopolysaccharide (LPS) being attached to the
outer monolayer of the asymmetric outer membrane ' The vast majority of
Gram-negative bacteria have some recognisable form of the LPS240"243 and the
function of this is important to the survival of the organism242'244. In pathogens this
role is particularly important; it provides a barrier which results in impermeability of
the outer membrane to large molecules and hydrophobic compounds, including
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antimicrobial agents245"248 and also protection against the action of phagocytic cells249.
In addition, the LPS facilitates interactions between the bacterium and its host
environment, which are often important in establishing infection250'251 and avoiding
the host's immune response251'252. The LPS consists of 3 regions: the outer segment is
called the O-antigen and is made up of repeating polysaccharide units253"255; it is this
region that first interacts with the host256'257. The composition of the repeating
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polysaccharide units varies greatly between different bacterial species ' and even
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strains " . It is this variability that results in the wide range of modes of
pathogenicity and host targets of Gram-negative bacteria256"258.
The middle section of the LPS consists of the core oligosaccharide unit263, a
short chain of sugars which, with minor variations264, are common between species
but vary from genus to genus258'264'265. The core and O-antigen are attached to the
outer membrane through the third region of LPS, the hydrophobic anchor Lipid
A ' which is an important structural component of the cell membrane The
structure of Lipid A (figure 2.1.2 and 2.1.6) is relatively well conserved between
almost all Gram-negative bacteria238'242'267. The components of the LPS are
biosynthesised by enzymes within the cytosol or the inner surface of the inner
7A7 'J/'Q
membrane ' ' and are subsequently transported out of the cell, initially to the
outer surface of the inner membrane239. This process is not well characterised but it is
hypothesised that the essential inner membrane protein MsbA270, structures of which
771 "771 7AQ 77fl 777
have recently been published ' , may transport Lipid A ' ' and the flippase
RfbX is a possible candidate for export of the O-antigen274. After assembly of the
77S 777
LPS at the inner membrane " it is transported through the periplasm and integrated
into the outer leaflet of the outer membrane by an unknown process239. In contrast,
the biosynthesis of the individual components has been relatively well characterised
36
(reviewed jn238-255'264'278'279^ particularly for Lipid A which was first described in
1984^^"^^
2.1.2 Lipid A and its Biosynthesis
The structure of Lipid A from E. coli K12 is shown in figures 2.1.2 and 2.1.6. It
consists of a P-l',6-linked disaccharide of glucosamine, phosphorylated at the 1'- and
4'-positions and acylated at the 2-, 3-, 2'- and 3'- positions with R-3-
hydroxymyristate ' ' . Glycosylation of Lipid A at the 6'-position with two 3-
deoxy-D-manno-octulosonic acid (kdo) moieties represents a minimum form of the
LPS that is required for growth of E. coli and most Gram-negative bacteria '
There are some exceptions including: the survival of Thermotoga maritimer286 and
Neisseria meningitides Type B287 mutants that are unable to biosynthesise Lipid A
• • • 288 289and the complete absence ofLipid A biosynthetic genes in some spirochetes '
The biosynthesis ofE. coli K12 Lipid A, shown in figure 2.1.2, has been well
characterised and is used as a model system as recognisable Ipx genes are present in
almost all Gram-negative bacterial genomes sequenced239.
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Figure 2.1.2: Biosynthetic pathway for the biosynthesis of Lipid A, enzymes
involved are labelled blue. Adapted from Raetz and Whitfield238.
The first step of Lipid A biosynthesis involves the acylation of UDP- (uracil
diphosphate) N-acetyl-D-glucosamine (UDP GlcNAc), catalysed by the enzyme
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LpxA, which requires acyl carrier protein thioester as a donor substrate and is
selective for (3-hydroxymyristate290'291. LpxA has an interesting structure (figure
• 292 293
2.1.3), which represents a novel fold, termed a left-handed parallel P helix ' . This
fold is formed from multiple contiguous hexad repeats in the sequence and violates
the protein folding constraints for right handed crossovers between strands of parallel
p-sheets293. The active site of this enzyme lies between coils in adjacent subunits and
the length of these coils acts as a hydrocarbon ruler294. In E.-coli there are 10 coils
stacked upon one another, which specifically incorporates 14 carbon acyl chain295,
with sequence differences in other bacteria leading to the preferential incorporation of
carbon acyl chains of different length294'296.
Figure 2.1.3: Stereo view of the LpxA structure from Helicobacterpylori in complex
• .... • 292with 1-s-octyl-P-D-thioglucoside, tartaric acid and a sulphate ion (PDB code 1J2Z)
The LpxA product, UDP-3-0-(acyl)-GlcNA, is then deacetylated by the
deacetylase LpxC, which is a zinc metalloenzyme297. The equilibrium of the LpxA
reaction strongly favours substrate290 and it is the LpxC reaction that is the committed
• • • • 290 297 298
step of Lipid A biosynthesis ' ' . LpxC bears no sequence resemblance to other
^ocOQQ
deacetylases and has been shown to be an excellent drug target '
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LpxD is the next enzyme acting in this pathway and it incorporates a second
P-hydroxymyristate moiety, forming UDP-2,3-diacylglucosamine300. The highly
selective pyrophosphatase, LpxH, then cleaves off the nucleotide and adds
pyrophosphate yielding 2,3-diacylglucosamine-l-phosphate, commonly named Lipid
X301. LpxH is one of the least well conserved Ipx genes in Gram-negative bacteria,
present in approximately 70 % of sequenced genomes and it is thought additional
isoenzymes must exist in bacteria lacking LpxH to catalyse UDP-2,3-
diacylglucosamine hydrolysis238.
The disaccharide synthase enzyme LpxB then makes the P,l'-6'- linked
• • • • •••• 280 281disaccharide by condensation of UDP-2,3-diacylglucosamine with lipid X * . The
LpxK kinase then phosphorylates the disaccharide at the 4' position, to produce Lipid
IVA302.
Lipid IVA is then transported to the inner membrane where the bifunctional
enzyme WaaA transfers the two kdo moieties303 from CMP-kdo, synthesised by KdsA
and KdsB304,305, producing Kdo2-lipid IVA.
The final stages in the biosynthesis are specific to kdo modified Lipid IVA
and involves the transfer of lauroyl and myristoyl residues, by the respective
transferases LpxL and LpxM, to the distal glucosamine unit306"308. The Kdo modified
Lipid A is also known as the endotoxin as it is this molecule that activates the host
239,242,309
immune response
2.1.3 The Immune Response to Lipid A
During infection by Gram-negative bacteria the LPS-binding protein associates with
Lipid A310 and this complex is detected at picomolar levels by CD14 receptors on
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macrophages and endothelial cells311"314. This results in a signal transduction cascade
that activates the host's innate immune response (figure 2.I.4)242'312'313. This triggers
the production of diverse mediators of inflammation including cytokines315'316,
o 1 *7 iio
chemokines and cellular adhesion molecules The overproduction of these
mediators and clotting factors can damage small blood vessels and may result in
Gram-negative sepsis319. This is accompanied by disseminated intravascular
• • 319
coagulation and in severe cases can lead to organ failure and even death . Another
important class of molecules produced by the innate immune response are cationic
antimicrobial peptides (CAMPs) ' , which can directly target bacteria through
interactions with Lipid a46'322'323.
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Figure 2.1.4: Immune response to Lipid A adapted from Raetz and Whitfield238 and
based on research using mouse and human cells '
2.1.4 Cationic Antimicrobial peptides
• • • • • • 46 322 323 • *As well as being important in innate immunity ' ' CAMPs are widespread in
nature and are produced in several human cell types including those of the digestive
tract327, skin328 and lungs329'330. They also represent a class of antibiotics that include
Polymyxin B, used in some creams and lotions331. CAMPs are small, amphiphatic,
positively charged peptides 320, which have a whole range of antimicrobial activities
that can kill a diverse range of organisms including bacteria , fungi , and
eukaryotic parasites45'334. CAMPs target cells through electrostatic interactions with
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acidic phospholipids in the outer membrane (figure 2.1.5)335 and in Gram-negative
bacteria this is specifically through affinity with phosphate groups of the Lipid A
molecule46'335,336. Upon interacting with Lipid A, the amphiphatic nature of CAMPs •
allows them to traverse the outer membrane, with several CAMPs coming together to
form a pore in the membrane, resulting in solubilisation and ultimately death of the
bacterium46'323,335,336.
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Figure 2.1.5: Mechanism of bacterial cell permealisation by the action of CAMPs,
adapted from Zasloff46. Most cationic antimicrobial peptides are amphiphatic
molecules with charged amino acids on one side (blue spheres) and hydrophobic side
chains on the other (yellow rods), allowing them to interact with the microbial
membrane (a and b). Electrostatic interactions and the transmembrane bioelectric
field result in a 'carpet' of peptides on the membrane surface, which strains the
membrane (b, shown by lightning bolts). The strain is lowered by the transition of the
peptides into another arrangement (c), forming membrane pores. If the concentration
of CAMPs is high enough this results in lysis (e). It is thought that sub-lethal levels
ofCAMPs may allow them to enter the cell without killing it, resulting in downstream
effects such as alteration of transcription.
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2.1.5 Regulated modifications of Lipid A
Figure 2.1.6: Structure of the Lipid A endotoxin with regulated modifications shown
by dashed lines, adapted from Raetz and Whitfield238. The modifications of the 4' or
-ion T-iq
6' phosphate groups with L-Ara4N or phosphatidylethanolamine " are shown as is
the addition of palmitoyl by PagP and removal of hydroxymyristate by PagL.
Modifications coloured in blue and red are under the primary control of PhoP/PhoQ
and PmrA/PmrB respectively.
The molecular structure of Lipid A can be covalently modified in response to
environmental stimuli, altering the outer surface of the bacterium. This allows
adaptation to the local environment, which can vary considerably during
iiio 0*70
infection ' . These modifications of Lipid A are under the general control of the
PhoP/PhoQ two component regulatory system338, which is required for Salmonella
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spp. virulence338'340. Environmental changes, such as the low magnesium ion
concentrations found in phagolysosomes341'342, are detected by PhoQ, a sensory
kinase, resulting in its activation and the phosphorylation of PhoP340. PhoP is a
transcription factor and when phosphorylated it regulates the expression of over 40
genes340. As part of this adaptation to the environment, the PhoP/PhoQ system
controls the resistance of S. typhimurium to CAMPs including defensin NP1343,
magainin-2344, melittin343 and those contained in crude neutrophil granule extracts345.
These modifications usually include the removal or decoration of phosphate
groups or fatty acyl chains and are carried out by additional enzymes to the nine
required for Lipid A-Kdo biosynthesis in E. coli. Alterations in the acylation pattern
of Lipid A has an impact on the fluidity of the outer membrane and is important in
adaptation to different temperatures346"348. For example, growth of E. coli at 12 °C
results in the replacement of LpxL activity with LpxP, a different acetyltransferase
that adds an acyloxyacyl linked palmitoleate to the 2' position347. An outer membrane
protein PagP, a serine hydrolase, has also been identified 342 that can transfer a
palmitoyl group to the glucosamine 2' position (fgure 2.1.5)349, resulting in hepta-
acylated Lipid A350. PagP mutants of S. typhimurium show sensitivity to certain
CAMPs of the innate immune response350 and it is thought that this modification leads
to tighter packing of the LPS and an increase in the integrity of the outer
membrane338'350.
It has been shown that the two most important features of Lipid A that result
in activation of the hosts immune response, both in vivo and in vitro, are the
phosphate groups and fatty acyl chains ' ' ' . These experiments demonstrate
that, despite the relatively well conserved structure of Lipid A, relatively small
changes in either fatty acid composition or to the phosphate groups can impact on the
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detection of LPS by the hosts defence system and it is unsurprising that evolution has
taken advantage of this. For example, Salmonella strains contain a lipase, PagL that
removes the R-3-hydroxymyristate from Lipid A (figure 2.1.5)353. It is thought that
this enzyme may also catalyse deacylation of Lipid A, resulting in Lipid A species
T7Q "JfJ
that illicit a reduced immune response by the host, thereby prolonging infection '
Further, 3-O-deacylase activities have been detected in the pathogen Pseudomonas
aeruginosa354 and may also be present in Helicobacter pylori355'356 and
Porphyromonas gingivalis241'357. There are also several examples of Lipid A that
lacks either one or both phosphate groups in their Lipid A including Rhizobium
OA/' ACO ACQ AC f AC/"
leguminosarum ' ' and H. pylori ' . Additionally phosphatases that remove
the 1' phosphate of Lipid A have been discovered in R. leguminosarum360 and H.
pylori279 and orthologues of these enzymes may exist in the pathogens Francisella
tularensis, Brucella melitenisis and Legionella pneumophila369. Removal of the
phosphate groups from Lipid A not only alters the immune response during infection,
97Q I'lO
but also results in a lower affinity for CAMPs ' . Mechanisms of resistance to
CAMPs have also evolved where, instead of removal, the 1' and/or 4' Lipid A
phosphate groups are masked with either phosphatidylethanolamine and/or 4-amino-
ion •j/'i
4-deoxy-L-arabinose (L-Ara4N) ' , neutralising their negative charges. This
modification is also under the general control of the PhoP/PhoQ system362, but is
more tightly regulated by the iron sensing two component regulatory system
PmrA/PmrB337'362'363.
PmrA is a transcription factor and its activation in S. typhimurium by
• • • 'XfPl • • •
either constitutive mutation , PhoP , extra-cytoplasmic iron levels through the iron
sensing protein PmrB364 or mildly acidic conditions365, results in elevated levels of
phosphatidylethanolamine/L-Ara4N Lipid A modifications and resistance to the
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action of certain CAMPs343'361'366. This modification is important in vivo and it has
been shown that not only do pmrA constitutive mutants of S. typhimurium survive
longer inside neutrophils367, but pmrA deficient mutants have reduced virulence368.
How PmrA regulates the addition of phosphatidylethanolamine is still unclear
although an enzyme transferring this moiety to Lipid A phosphates has recently been
detected in E. coli membranes279 and the IptA gene from N. meningitides is necessary
ozQ Q70 • • • •
for this addition ' . In contrast the PmrA regulated addition ofL-Ara4N to Lipid A
is well understood; in 1998 Gunn et al. first described 2 gene loci, pmrE and pmrF,
that are activated by PmrA, resulting in this modification363.
2.1.6 L-Ara4N modification of Lipid A
ThepmrE locus encodes the well characterised UDP-glucose dehydrogenase 363 (Ugd)
that catalyses the production of UDP-glucuronic acid (UDP-GlcUA) from UDP-
-5'71 rinr)
Glucose (UDP-Glc) ' . The pmrF locus is a multicistronic operon encoding 7
genes pmrFIFIJKLlvf'63, all ofwhich, with the exception ofpmrM, along with Ugd are
essential for L-Ara4N modification of Lipid A ' . These latent genes have also
been identified in E. coli K12 and the pathogens Yersinia pestis , Bordetella
pertussis and P. aeruginosa . The discovery of these genes allowed the
hypothesis of a biosynthetic pathway for L-Ara4N and its addition to Lipid A, based
on the similarity of the encoded proteins to other enzymes349'371 and this pathway has
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Figure 2.1.7: Currently proposed pathway for the biosynthesis of L-Ara4N from
UDP-Glc, its transport to the outer membrane and its subsequent addition to Lipid A.
Taken from Williams et a/.381.
The first unique step in the biosynthesis of L-Ara4N is carried out by the C-
terminal decarboxylase domain of ArnA377. The sequence of ArnA predicts that it
belongs to the SDR superfamily of proteins that are characterised by an initial hydride
transfer step carried out by a conserved triad of S/T, Y and K (3.1,8)382. Based on this
homology it was originally predicted that ArnA oxidises UDP-GlcUA and that there
would be a subsequent decarboxylation reaction to produce UDP-P-L-threo-
pentapyranosyl-4'-ulose (L-Ara40)377. This decarboxylation step was thought to be
catalysed by the enzyme ArnJ ' . However, Breazeale et al. showed biochemically
that ArnA alone was sufficient for the oxidative decarboxylation of UDP-GlcUA,
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suggesting that the decarboxylation step was either spontaneous or catalysed by
ArnA377
UDP-L-Ara40 acts as the substrate for ArnB, a pyridoxyl dependent
aminotransferase, which transfers an amino group from glutamate to the C4' ketone,
producing UDP-LAra4N380'384. Noland et al. have solved the structure of ArnB in
complex with PLP and PMP cofactors (figure 2.1.8)384 and its overall fold is similar to
type 1 aminotransferases such as aspartate aminotransferase385.
Figure 2.1.8: Stereo view of the ArnB structure in complex with PLP (PDB code:
• 384 385
1MDX). This enzyme belongs to the type 1 aminotransferase superfamily '
The activities of the C-terminal domain of ArnA and ArnB produce the L-
Ara4N carbohydrate attached to the nucleotide UDP it therefore remains for this
carbohydrate to be transferred from the cytosol to the outer surface of the inner
membrane where it is added to Lipid A. The next step in the pathway was originally
unclear377. ArnA has an N-terminal domain, which shares homology with
formyltransferase enzymes and is conserved between all bacteria known to modify
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their Lipid A with L-Ara4N377'381. It was shown that ArnA could transfer a formyl
group from N-10-fTHF to UDP-L-Ara4N in vitro. However until recently it was
• • • 77^ 777
unknown whether this reaction was essential in vivo ' . Breazeale et al. cloned the
ArnA C-terminal decarboxylase and N-terminal formyltansferase as two separate
proteins and showed that in ArnA defective E. coli mutants, L-Ara4N modification of
Lipid A could only be restored if both ArnA domains were reintroduced376. Further,
they have developed an enzymatic assay for the next enzyme in the pathway, ArnC
and shown it only uses UDP-L-Ara4fN and not UDP-L-Ara4N as a substrate376.
ArnC is a membrane protein and it transfers the L-Ara4fN moiety from UDP to
undecaprenyl phosphate376. This is then transferred to the outer surface of the inner
membrane by an as yet undetermined pathway and at some point it is deformylated by
the ArnD deformylase376. The final step of the pathway requires the transfer of L-
Ara4N, from the novel carrier-lipid undecaprenyl phosphate-a-L-Ara4N, to one of the
Lipid A phosphate groups386. This is catalysed by ArnT, an inner membrane
aminotransferase378.
2.1.7 Lipid A biosynthesis/modification as an antibiotic target
Enzymes involved in Lipid A biosynthesis are good antibiotic targets as, if you stop
7dA 787 788
its biosynthesis, you will stop the growth and virulence of the bacteria ' ' and
inhibition of this pathway results in increased sensitivity to other antibiotics285. The
case of LpxC really highlights the potential of these enzymes as antibiotic targets,
with inhibitors of LpxC from E. coli and related bacteria such as S. typhimurium
• 78S 78Q
having potent inhibitory effects of around 50 nM ' . Broader ranging inhibitors
that are effective against LpxC from E. coli through to the most diverse LpxC in A.
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aeolicus have also been developed, but are not yet fully optimised299. The recent
solution of the LpxC structure from A. aeolicus390>391 should help in the development
of even more potent, broad ranging inhibitors of LpxC that may be useful in future
therapies.
Although enzymes that carry out regulated modifications of Lipid A are only
conserved between a relatively small subset of Gram-negative bacteria and are not
essential for their growth, they are also good drug targets due to their importance in
avoiding the immune response. This is highlighted by the clinical isolation of P.
aeruginosa with L-Ara4N modified Lipid A, from the lungs of cystic fibrosis patients,
• • • '2Q'2
with associated increase in the inflammatory response and CAMP resistance ' . As
the overall effect of these modifications is to reduce the Lipid A affinity for CAMPs,
inhibition of the enzymes responsible would lead to greater susceptibility to these
antimicrobial agents, thus helping the host immune response and would also be useful
as a combination therapy. All of the enzymes involved in the pathway of L-Ara4N
biosynthesis and its addition to Lipid A are therefore potential drug targets, with the
accessibility of soluble proteins to X-ray crystallography singling out ArnA and ArnB
for structural studies with an eventual aim for rational drug design.
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2.2 MATERIALS AND METHODS/RESULTS
2.2.1 Over-expression ofArnA constructs and ArnB
Figure 2.2.1: Protein over-expression using the pET expression system. E. coli used
for protein expression, for example BL21 (DE3) (the designation DE3 indicates that
the host is a lysogen of A.DE3, and therefore carries a chromosomal copy of the T7
RNA polymerase gene under control of the lacUV5 promoter. The pET plasmid
includes the lacl and target genes, with the target gene been cloned immediately
downstream of the T7 promoter and lac operator. Under normal conditions
expression from the Lac and 77 promoters is repressed by the Lac repressor.
Induction by the lactose analogue IPTG inhibits the Lac repressor, allowing
expression of T7 RNA polymerase and subsequently the target gene. Adapted from
the pET handbook from Novagen.
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Table 2.2.2 details the full length ArnA, decarboxylase and formyltransferase
domains of ArnA and ArnB constructs we received from our collaborators in North
Carolina. The following procedures successfully produced soluble protein from all
constructs. E. coli BL21(DE3) cells (genotype F-, ompT, hsc/Sp(rp-mp-), dcm, gal,
(DE3) tonA) were transformed with plasmid DNA encoding the relevant protein to be
over-expressed. Single colonies were grown in 10 ml Luria broth (LB) supplemented
with 50 pgml'1 kanamycin overnight. Overnight cultures were used to inoculate 500
ml of LB in 2 1 flasks and grown to an OD6oo of 0.6-0.8 at 37 °C. The temperature
was then reduced to 18 °C and protein over-expression was achieved by overnight
induction with 0.5 mM isopropyl-B-D-thiogalactopyranoside (IPTG) (figure 2.2.1).
Cells were harvested at 10500 x g and those used to over-express histidine tagged and
native protein were re-suspended in 50 mM HEPES pH 8.0, 10 mM imidazole and
300 mM NaCl or 50 mM EIEPES ph 8.0 and 50 mM NaCl respectively. Soluble
proteins were extracted by incubation at room temperature for 1 hour with 100 pgml"1
lysozyme and 20 pgml"1 DNase (Sigma) before 4 x 30 sec sonication passes on ice
and subsequent centrifugation for 30 min at 75500 x g.
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Table 2.2.2: Constructs obtained from our collaborators in North Carolina. All genes
are from E. coli K12. N6H and C6H represents N- and C-terminal 6 x histidine
tagged constructs, respectively. pET vectors were obtained from Novagen.
2.2.2 Purification
Tagged Constructs
The same procedure was used to purify all tagged proteins. Supernatant containing
target protein was applied to a charged Histrap Nickel Sepharose, high performance
column (Amersham Biosciences), which had been equilibrated with 50 mM HEPES
pH 8.0, 300 mM NaCl and 10 mM imidazole. Unbound and weakly bound proteins
were removed by extensive washing with buffer including 10 mM and then 80 mM
imidazole. Essentially pure target protein was eluted with an imidazole gradient from
80 - 300 mM. Eluted protein was dialysed against 50 mM E1EPES pH 8.0, 300 mM
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NaCl and 2 mM dithiothreitol (DTT), before concentration and further purification by
S200 gel filtration.
Untagged Constructs
The purification protocols of all four native proteins were very similar. Supernatant
containing target protein was first applied to an HQ anion exchange affinity column
(Applied Biosystems) and bound proteins were eluted with an increasing
concentration of NaCl (0.05-1 M). ArnB, full length ArnA and the decarboxylase
domain of ArnA all bound to the anion exchange column, whereas the
formyltransferase domain of ArnA did not bind. NaCl was added to a final
concentration of 4.5 M to fractions containing the target protein and then applied to an
HP hydrophobic column (Applied Biosystems). The target protein was eluted with a
decreasing NaCl gradient, dialysed into 50 mM HEPES pH 8.0 containing 300 mM
NaCl and further purified by S200 gel filtration chromatography (Amersham
Biosciences). Each step of purification was monitored by sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE). Figure 2.2.3 shows pure ArnA
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Figure 2.2.3: Coomassie Blue stained SDS PAGE gels, (a) ArnA formyltransferase,
(b) ArnA decarboxylase, (c) His-tagged full length ArnA and (d) untagged full length





Attempts were made to crystallise the three different constructs of full length ArnA.
It was possible to concentrate the tagged and untagged ArnA protein to 10 mg ml"1
and 6 mg ml"1 respectively. After concentration ArnA protein was dialysed into 20
mM HEPES pH 7.5, 50 mM NaCl and 2 mM DTT. This protein, at a range of
concentrations between 3 and 10 mg ml"1, or protein that had been incubated at 4 °C
overnight with 5-10 mM NAD+, UDP-GlcUA and N-5-fTHF (Sigma), or some
combination of these, was used for crystallisation screening. The sitting drop vapour
diffusion technique was used with protein drops of between 2 and 6 pi and a 1:1 ratio
of protein:precipitant, set up against 100 pi of reservoir solution. Commercially
available screens from Hampton, Emerald Biosystems and Molecular Dimensions
were screened at 20 and 4 °C.
After extensive screening of both tagged and untagged full length ArnA the
most promising crystallisation conditions were at 20 °C and typically contained
between 10 and 20 % PEG 6000 - 8000, buffer at pH 6-8 and 200 mM salt. These
conditions resulted in the formation of spherulites (figure 2.2.5) which, upon addition
of izit dye (Hampton) stained blue suggesting they were protein. Resolving several
spherulites by SDS PAGE and staining with Coomassie blue confirmed them to be
full length ArnA. Extensive attempts were made to optimise these initial hits by
varying pH, precipitant and salt as well as their concentrations, stock and streak
seeding and additive screens (Hampton). No crystals suitable for X-ray diffraction
were obtained. This could be due to flexibility in the linker connecting the two
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separate domains of ArnA. Two approaches attempted to try and lock the full length
ArnA protein into a more ordered conformation, with the hope of aiding its
crystallisation. Firstly a variety of ArnA substrates, cofactors and their analogues
were used in co-crystallisation screens. It was hoped that binding of these ligands
might reduce any flexibility in the active sites of the two domains and put the ArnA
protein in a more homogeneous, ordered state that would be more likely to crystallise.
Also, as discussed below, we thought that ArnA and ArnB might interact with one
another. Therefore co-purification of these enzymes was attempted in the hope that
binding of ArnB would order the ArnA protein, allowing the crystallisation of the
complex (4.2.6). Neither attempts improved the crystallisation ofArnA and therefore
structural studies were focused on the individual domains, expressed and purified
separately.
Individual domains of ArnA
The pure decarboxylase or formyltransferase protein were concentrated to 5 mg ml"1
and 8 mg ml"1 respectively and dialysed into 25 mM HEPES pH 7.5, 50 mM NaCl
and 2 mM DTT. 5 - 10 mM NAD+ and either UDP-GlcUA, UDP-Glc, UDP
galactose (Gal) or UDP (Sigma) were added to the decarboxylase protein and 5-10
mM N-5-fTHF and UDP (Sigma) were added to the formyltransferase protein and
mixtures were incubated overnight at 4°C. Crystallisation screens were set up as for
full length ArnA at 20 °C.
Screening of decarboxylase protein was much more successful than for full
length ArnA. Initial crystals were obtained from the Hampton Index screen condition
9 (3 M NaCl and 0.1 M Bis-tris pH 5.5), using drops containing 1 pi protein and 1 pi
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mother liquor. An optimisation screen around this condition gave good quality
crystals suitable for X-ray diffraction obtained in a condition containing 3.2 M NaCl,
0.1 M Bis-tris pH 5.2, using a drop with 4 pi protein and 4 pi precipitant equilibrated
against a reservoir of 100 pi mother liquor. The improvement of the size and quality
of the crystals can be seen in figure 2.2.5, with many small crystals present before (ci)
and a large, single, well defined crystal present after the optimisation screen (cii).
After extensive screening of ArnA formyltransferase protein, good quality
crystals were obtained using a Hamilton robot in the Hampton Index screen condition
65 (17 % PEG 10000, 0.1 M Bis-tris pH 5.5 and 0.1 M ammonium acetate).
Extensive screens around this condition failed to reproduce these crystals and
therefore a drop containing 4.5 pi protein and 4.5 pi precipitant was set up against 100
pi of solution from the same well of the block that was used in the initial robot screen.














Figure 2.2.4: Figure showing protein spherulites formed by full length ArnA (a),
crystals of formyltransferase protein (b) and crystals of dehydrogenase protein before
(ci) and after (cii) optimisation.
2.2.4 Initial X-ray diffraction
An in house X-ray generator (Rigaku 007 rotating anode) was used to screen initial
decarboxylase and formyltransferase crystals to test their diffraction quality. A small
formyltransferase crystal was cryoprotected with 20 % glycerol added to the mother
liquor and 20 minute exposures with 0.5 ° oscillations produced the diffraction image
in figure 2.2.6a, with spots to 2.5 A at the edge. Because it was a small crystal that
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was tested, this result suggested that larger crystals would diffract to a high resolution
at the European Synchrotron Radiation Facility (ESRF).
Cryoprotectants were screened against the conditions giving rise to
decarboxylase crystals; 20 % glycerol, MPD and ethylene glycol mixed with mother
liquor were unsuccessful but a short soak in 4 M Na formate gave good
cryoprotection with no ice formation. A large decarboxylase crystal diffracted to 3.3
A on our in house source using a 20 min exposure with 0.5 ° oscillation (figure
2.2.6b). The relatively poor diffraction of these crystals, despite their high quality
appearance (figure 2.2.5c) suggested that a synchrotron source would be required to
obtain data above 3 A.
a b
t t
2.5 A 3.3 A
Figure 2.2.6: Initial in house x-ray diffraction obtained to 2.5 A and 3.3 A from
formyltransferase (a) and decarboxylase (b) crystals respectively.
2.2.5 Data collection and processing
Once a cryocooled crystal diffracts satisfactorily a data collection strategy needs to be
calculated to ensure that the dataset collected can be processed. The first step in this
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process is to calculate the unit cell dimensions from the diffracted spots on the
detector. The programs used to calculate this do so using autoindexing, which also
calculates the orientation of the mounted crystal394"396. Whether the unit cell
parameters are accurate can be tested by predicting spots based on the theoretical
diffraction and examining whether these approximately fit the observed spots.
Estimation of the mosaicity of the crystal allows an improvement of this prediction,
1Q<7 -JQO
which should subsequently predict almost all of the observed spots ' ' . If the
prediction looks good then a data collection strategy can be designed to give a range
of oscillation angles that gives the most complete amount of unique data with non-
overlapping lunes. Most data processing programs have functions that can calculate
this, which test the percentage of overlaps observed for different oscillation angles
and give the completeness of data over a range of angles395'396'399. Ideally, as large an
oscillation range as possible should be selected that gives zero overlaps. The larger
oscillation range not only increases the number of fully recorded reflections, but also
reduces the exposure of the crystal to the X-ray beam. The data collection strategy
will give the range of oscillation angles giving the most complete amount of unique
data. Once the data collection strategy has been calculated a complete dataset can
then be collected.
Once the data has been collected it is important to refine the cell parameters
before integrating the data, to ensure that very accurate cell parameters are defined, in
a process known as post-refinement394'395'397. This is important as the initial
autoindexing only calculates the cell from a small number of images (often one or
two) and as a result the cell parameters estimated are not as accurate as required.
Post-refinement takes segments of data, usually from different areas of the crystal
separated by around 90°, and integrates these images. Typically the differences
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between the observed and calculated spot positions (or the non-intergerness of the
indices) are minimised. The result of post-refinement is accurate cell constants to
within 0.01 A and an accurate estimate of the mosaicity395'397 In most cases of data
processing these parameters can then be fixed during integration of the data395'396'399.
The overall aim of data processing is to obtain estimates, which have been
appropriately corrected, of the intensities of the Bragg reflections contained in a set of
two-dimensional detector images395. The measurement of intensity is made by
subtracting the background level of intensity from the spot intensity. Ideally this
should be a measurement of the background behind the spot but this is impossible.
Instead the pixels within the prediction box are used for spot-profiling, with the
• • • 395 397 •
average intensity of outer pixels used as the background ' It is therefore
important to pick a box size (a range of pixels) that adequately covers the spot, since
otherwise the background calculation will include some of the diffraction intensity. It
is also important not to have too large a box as this will result in a reduction of the
signal-to-noise ratio and also increases the chance that pixels belonging to other
reflections will be included within the box for the current reflection394'395'397. During
integration of the data several other experimental parameters are also refined
including the crystal to detector distance, Y-scale and the tilt and twist of the detector.
This is important as these parameters can change slightly throughout the course of the
395-397
experiment
At the end of integration a data file is output with a measure of the intensity of
each miller index, with an estimate of the error. Despite all of the corrections made
during post-refinement and integration, further processing is necessary before the
intensity measurements can be used for structure determination or refinement4 °' .
Systematic errors that have occurred during the experiment, including changes in the
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incident beam intensity or size and absorption of the diffracted beam by the sample,
need to be corrected so that all of the measured intensities are on the same
scale398'400'4 \ The process of scaling compares the intensity estimates of symmetry
related reflections and calculates scale factors to get the best internal consistency of
these intensities400'401.
The data file from integration is a measurement of the intensity of all
reflections however, what is needed is a single estimate of the intensity of all
symmetry-related observations of a given reflection. This data-reduction is carried
out during merging and requires the correct space group to be entered into the
program so that symmetry related observations can be properly grouped and the mean
intensity and error can be calculated. If the space group is unknown the axial
reflections, listed in the output from the scaling/merging program, gives an indication
of systematic absences, which can be used to determine the correct space group (by
comparison of expected systematic absences for each space group as listed in the
international tables for crystallography402). Many crystallography applications, such
as refinement, require not the intensity but the amplitude of each unique reflection403.
The amplitudes, which are proportional to the square root of the intensities398, are
therefore calculated and output in the final data file from some merging programs.
The scaling and merging procedures are important in assessing data quality
and the standard error in the final result and result in data that can be used for
crystallagraphic applications such as phasing and refinement.
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2.2.6 Data Collection and analysis
Formyltransferase domain of ArnA
Crystals were cryocooled to 100 K using a cryoprotectant of mother liquor containing
20 % glycerol. High resolution data to 1.2 A was collected on native crystals at ESRF
beamline ID 14-2 240, 0.5 ° oscillation images were collected, using an exposure time
of 3 s and a crystal to detector distance of 91 mm. An example of the diffraction
pattern obtained is shown in figures 2.2.7 and 2.2.8. Images were indexed in
MOSFLM396, which suggested the crystal lattice belonged to the P222 Laue group
with cell dimensions of a = 67.5 A, b = 90.7 A, c = 97.6 A,a = (3=y = 90o. Data
were processed and integrated using these parameters and then scaled in SCALA and
merged in TRUNCATE (table 2.2.9)401. Observation of the systematic absences after
merging in P222 revealed that the space group is P2i2i2i. Data were reindexed in this
space group and subsequent merging gave the data statistics presented in table 2.2.9
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Figure 2.2.7: X-ray diffraction of formyltransferase crystals obtained at the ESRF




Figure 2.2.8: Formyltransferase diffraction with higher contrast than figure 2.2.7 and
white spots on a black background, showing that the diffraction goes to 1.2 A at the
edge of the detector.
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Data collection ArnA formyltransferase domain
Resolution (A) 28-1.2
Highest shell (A) 1.26-1.2
Wavelength (A) 0.934





Completeness (%) 98.3 (98.3)
Rmerge* (%) 6.2 (29.7)
I/a 7 (2.4)
Table 2.2.9: Native formyltransferase data statistics, numbers in () correspond to the
highest resolution cell. *Rmerge = Z Z^ (h)i - (/ (h)) / Z U (h)i, where 7(h)i is the
measured diffraction intensity and the summation includes all observations.
Decarboxylase Data Collection and Analysis
A large decarboxylase crystal was cryocooled to 100 K using a cryoprotectant of 4 M
sodium formate. Data to 2.3 A were collected on native crystals on beamline ID14-2
at the ESRF using an exposure time of 2 s and crystal to detector distance of 217 mm.
An example of the diffraction pattern obtained is shown in figure 2.2.10. Data were
treated similarly to the formyltransferase data, with indexing and integration in the
P23 laue group in MOSFLM396. Reindexing of the data into several possible
spacegroups with higher symmetry in SCALA401 and subsequent merging of the data
in TRUNCATE determined the space group to be either P4i32 or P4332, with cell





Figure 2.2.10: X-ray diffraction of decarboxylase crystals to 2.3 A at the ESRF
beamline ID14-EH2.
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Data collection ArnA decarboxylase domain
Resolution (A) 88-2.30








Completeness (%) 97.8 (100)
Rmerge (%) 7.0 (36.9)
I/o 7.8 (2.1)
Table 2.2.11 (above): Native decarboxylase data statistics, numbers in () correspond
to the highest resolution cell.
2.2.7 Investigation of Protein - Protein Interactions
A stable complex between ArnA and ArnB
The activities of both domains ofArnA are required for the L-Ara4N modification of
Lipid A in vivo. As shown in figure 2.1.7 the UDP-L-Ara40 intermediate, the
product of ArnA decarboxylase activity, is converted to UDP-L-Ara4N by a separate
enzyme ArnB, before going back to ArnA where the formyltransferase activity
produces UDP-L-Ara4fN. Although fusion proteins are common in biology, it is
unusual for a bifunctional enzyme to require an intervening enzymatic step. We
therefore investigated if purified full length ArnA formed a complex with ArnB, to
facilitate the process of substrate channelling between these enzymes. The purified
ArnA and ArnB proteins, at approximately 3 mg ml"1 (0.075 mM), were mixed and
incubated for 1-3 hours at room temperature in buffer containing 50 mM HEPES pH
7.5 and 250 mM NaCl. The mixture was applied to an S200 gel filtration column and
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the elution of proteins was followed by A2go. This experiment was repeated in the
presence of 5 mM UDP-GlcUA, 5 mM NAD+, 5 mM glutamic acid, 5 mM pyridoxal
5'-phosphate and 5 mM N-5-fTHF (Sigma) (figure 2.2.12). ArnA and ArnB proteins
that have been mixed elute at the same point as unmixed controls (figure 2.2.12),
demonstrating no stable complex is formed in these conditions. We conservatively
estimate that the lower level of detection from an S200 gel filtration column is about
0.06 mg ml"1 (1 (J.M), correlating to a lower limit of the Ka as 5 mM.
Figure 2.2.12: Traces from the gel filtration column investigating complex formation
between full length ArnA and ArnB. The blue trace represents the elution after
incubation of ArnA with ArnB, compared with individually eluted ArnA (red) and
ArnB (green). The slight shift in peaks is caused by use of the S200 gel filtration
column on different days and a slight difference in the volume of material loaded. X
marks the void volume of the column and it is clear no material elutes around this
area, as would be expected for any complex formation. Peak 1 is the elution of
material left on the column from a previous run.
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Our collaborators in North Carolina also performed Nickel pull down
experiments using the Penta*His antibody (Qiagen) to investigate whether N-
terminally His tagged ArnB pulled down over-expressed, untagged ArnA from cell
lysate. They also observed no complex formation between ArnA and ArnB as judged
by silver staining381.
Individual domains ofArnA
To investigate whether the individually isolated ArnA domains interact with each
other similar gel filtration experiments were performed as for full length ArnA and
ArnB, both with and without substrates, cofactors and cofactor analogues. Similarly
to ArnA and ArnB, no other peak apart from those for the individual decarboxylase
and formyltransferase proteins was observed (data not shown).
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2.3 Discussion
Genes encoded by the PmrF operon are essential for the L-Ara4N modification of
Lipid A and, in all bacteria known to carry out this modification, ArnA is encoded by
a single gene. However, although this modification has yet to be detected in
Ralstonia solanacearum and metallidurans239'376, the recent sequencing of their pmrF
operons annotates the decarboxylase and formyltransferase domains as discrete
genes404. This raises the possibility that full length ArnA may not be present in some
bacteria, which is consistent with biochemical results. Breazeale et al. showed that
the individual domains of ArnA, expressed individually, still catalyse their respective
reactions and further, they can compensate for the action of the full length enzyme in
376 377 • • •vivo ' . It was therefore attempted to structurally characterise ArnA by crysallising
full length ArnA and sub-cloned decarboxylase and formyltransferase enzymes, with
no crystallographic artefacts expected by pursuing the separated domains. Good
quality data were collected on both formyltransferase and decarboxylase proteins and
used for structural solution, detailed in Chapter 3. However no diffraction quality
crystals were obtained for any of the full length ArnA enzyme.
Although biochemical data suggest that there is no reason for the individual
domains to be present in a Afunctional enzyme ' , that full length ArnA is well
conserved suggests there is an evolutionary advantage for this. ArnA catalyses two,
non-consecutive reactions that are essential for the cytosolic biosynthesis and
"3 "7*7
subsequent transportation of L-Ara4N to the inner membrane ' The
decarboxylation and formyl transfer reactions are separated by an intermediary amino
• "3 80 "3 84
transfer reaction, catalysed by ArnB ' . This is unusual; enzymes that have two
distinct activities within a biosynthetic pathway usually catalyse consecutive
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reactions59, with substrate channelling providing the evolutionary advantage for
this405. Although unusual, bifunctional enzymes catalyzing non-consecutive reactions
are not without precedent. In E. coli a bifunctional enzyme AK-HDH I, with
aspartokinase and homoserine dehydrogenase activities, catalyses the first and third
reactions in the biosynthesis of amino acids belonging to the aspartate family406'407.
The intervening reaction is catalysed by aspartate semialdehyde dehydrogenase
(ASADH)408. Kinetic analysis of the AK-HDH I and ASADH reactions with
increasing amounts of inactive ASADH and also by the creation of inactive
bifunctional enzymes suggest that, although interactions between AK-HDH I and
ASADH have not been detected, these enzymes interact to facilitate substrate
channelling406'407. Another example of a bifunctional enzyme catalysing non-
consecutive reactions is IspDF, which is a fusion of IspD409 and IspF410 proteins that
exists in some organisms409' 11 and is involved in the non-mevalonate pathway of
isoprenoid biosynthesis412. Within this pathway the IspE kinase catalyses the
intervening reaction 413 and complex formation between IspE and both IspDF and the
mono-enzymes has been detected in vitro 41\ This complex formation has been
proposed to be the basis of substrate channelling within this pathway that could bring
together up to 18 catalytic centers411.
We therefore thought that there was a possibility that the ArnA and ArnB
enzymes may be part of a larger complex to facilitate substrate channelling. In such a
complex the L-Ara40 product of the decarboxylase reaction would be passed to the
ArnB enzyme, where an amino group would be transferred. L-Ara4N would then be
channelled back to ArnA, its formyltransferase domain, where the formyl group
would be added. If such a complex did exist it may help explain the apparent
evolutionary pressure for full length ArnA in organisms known to modify their Lipid
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A with L-Ara4N. Breazeale et al. developed an enzymatic assay for ArnB and show
that the forward reaction to produce UDP-Lara4N is thermodynamically unfavourable
with an equilibrium constant of approximately O.l380. Thus, if a complex does form
to facilitate substrate channelling, it would help to compensate for the unfavourable
ArnB reaction and act to drive all of the UDP-L-Ara40 intermediate into product.
There are other potential advantages substrate channelling could have in this pathway.
Breazeale et al. suggested investigating the use of UDP-LAra40 as an inhibitor or
alternative substrate for sugar-nucleotide utilising enzymes to ArnA377. If either
UDP-Lara40 or UDP-Lara4N intermediates could bind other enzymes in vivo,
substrate channelling in the ArnA enzyme would prevent this. Initial, but by no
means exhaustive, experiments were carried out to investigate this intriguing
possibility of a protein:protein complex forming between ArnA and ArnB. Gel
filtration experiments were performed to see whether a stable complex formed
between these enzymes, with the hope that if such a complex formed structural studies
could be undertaken. Our results suggest that ArnA and ArnB do not form a stable
complex and that any interaction that may occur between them must be transient with
the equilibrium, in vitro, strongly favouring the individual proteins. Due to advances
in other aspects of my research I did not look beyond gel filtration experiments to
investigate complex formation. However there are several experiments that could be
performed in the future to carry out a more extensive investigation into whether these
enzymes interact in vivo to facilitate substrate channelling.
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2.4 Future work
A concept overlooked in the gel filtration experiments performed above is the in vivo
phenomenon of crowding, discussed in chapter 1.2. Within the cell the high
concentrations of proteins and other macromolecules can significantly alter the
kinetics of reactions 3'75'414 and protein associations74, due to the limited volume
available. In particular the formation of specific protein-protein interactions is
enhanced due to the non-specific effect of macromolecular crowding74'414'415, as a
protein complex excludes less volume than the two individual components414.
Therefore conditions utilised in vitro, with relatively dilute buffer and protein
concentrations, are often inadequate to mimic in vivo conditions. In the future if the
possible interaction of ArnA with ArnB was to be further investigated it would be
well worth carrying out experiments in the presence of in vitro crowding agents,
reviewed in Minton, 200175 and Hall and Minton, 200381. One example of such an
experiment could be a frontal analysis gel filtration experiment similar to that
employed by Morgunov and Srere, 199880. They were able to observe complex
formation between citrate synthase and malate dehydrogenase when they applied both
proteins to a gel filtration column that had been pre-equilibrated with 0.2 mg ml"1 of
citrate synthase and 10 % polyethylene glycol (PEG)80. Since the column is pre-
equilibrated with one of the proteins there will always be the potential for an
interaction to occur, whereas in the ArnA-ArnB gel filtration experiments the
different sizes of ArnA and ArnB may result in their separation early in the column
and any transient interaction may be missed.
Several other experiments could also be performed to investigate whether
substrate channelling occurs in this pathway416, although since substrate channelling
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is dependent on at least a transient interaction between enzymes it is still important to
demonstrate such an interaction. One recent method for investigating substrate
channelling between separate enzymes is assaying the reaction in the presence of a
large excess of an inactive version of the second (or later) enzyme, which is still able
to bind substrate406'417. For ArnA such an experiment would require an inactive ArnB
mutant that can still bind substrate and have the same (presumed) ability to bind ArnA
as wild type ArnB. The excess inactive ArnB would out-compete wild-type ArnB for
the hypothetical binding sites to ArnA and would only decrease the rate of reaction if
substrate channelling was occurring between the two enzymes.
The further investigation of substrate channelling within this pathway is
intriguing and would be an interesting direction to take in the future.
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Chapter 3
Structural solution of the individual
formyltransferase and decarboxylase domains
ofArnA:
Insights into the mechanism of decarboxylation by site-




Attempts to crystallise the full length ArnA protein were unsuccessful, whereas
crystals suitable for data collection were obtained for the individual decarboxylase
and formyltransferase domains. This chapter describes the structural solution of the
decarboxylase domain to 2.3 A and the formyltransferase domain, in complex with
UMP and a cofactor analogue N-5-fTHF, to 1.2 A. Based on the superimposition of
the native decarboxylase structure with RmlB, E434 and S434 active site mutants were
designed to probe the oxidative decarboxylation mechanism. Our results suggest that
oxidative decarboxylation is enzyme catalysed and that E434 appears to be essential for
the reaction, with the second decarboxylation step driving oxidation.
3.1.1 Formyltransferases
Within the cell there are only a handful of reactions that utilise N-10-
formyltetrahydrofolate (N-10-fTHF) for formyl transfer. These include glycinamide
ribonucleotide (GART)418 and 5-aminoimidazole-4-carboxamide (AICAR)419
formyltransferases, both involved in purine biosynthesis and 10-
formyltetrahydrofolate:L-methionyl-tRNA N-formyltransferase (FMT)420, involved in
formylating the amino acid in methionyl-tRNA (figure 3.1.2). N-10-fTHF is also
hydrolysed to produce THF by the nicotinamide adening phosphate (NADP+)
dependent, bifiinctional enzyme formyltetrahydrofolate dehydrogenase (FDH), with
N-terminal hydrolase and C-terminal dehydrogenase domains421'422. The N-terminal
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domain of FDH is homologous to FMT and is capable of hydrolysing N-10-fTHF in
vitro 422. The C-terminal domain is homologous to aldolase dehydrogenase and it is
only the activity of both domains, present as a bifunctional enzyme, that is thought to
be functional in vivo422.
The N-terminal sub-domain of ArnA transfers a formyl group from N-10-
fTHF to UDP-L-Ara4N, a reaction that is essential for the L-Ara4N modification of
Lipid A (Chapter 2.1.5). ArnA shows 29 % identity to FMT, 26% identity to FDH,
25 % identity to GART (figure 3.4.1), but no significant identity to AICAR. Figure
3.1.3 shows the structures of GART418, AICAR419 and another formyltransferase
PurT423, that formylates P-GAR to produce formyl-GAR in an N-10-fTHF
independent manner. The structures of these enzymes reveal that they share no
overall structural similarity and represent three different folds that nature has evolved
to catalyse these very similar reactions. Each enzyme also employs a different
mechanism of formyltransfer423"425, demonstrating the importance of this chemistry in
biology. It is because of this importance that there have been extensive studies into
these interesting enzymes, in particular GART. As a result these enzymes have been
relatively well characterised both structurally and mechanistically, providing insights














































Figure 3.1.1: Chemical diagram of the one carbon transfer catalysed by (a) purT
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Figure 3.1.2: (a) Folate coenzymes with important functions within the cell. Only
the chemical formula of folate within the dotted box (top) is shown in the diagram,
(b) Early stages of purine biosynthesis. Enzymes are coloured in blue, with those
discussed in the text (GART, FMT and AICAR) coloured red. Adapted from the
International Union of Biochemistry and Molecular Biology website:
http ://www. chem. qmul.ac.uk/iubmb.
GART (purN), FDH, FMT and AICAR enzymes are all involved in folate metabolism
(figure 1.1.1). This is essential to cell viability as folate derivatives are required for
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the biosynthesis of the DNA and RNA nucleotide precursors, purines and
pyrimidines426, as well as some amino acids420. In many cancer cells enzymes
involved in folate metabolism are often found up- or, in the case of FDH, down-
regulated421. In turn this has created a lot of interest in these enzymes and their
427 *i • •
potential as good drug targets Dihydrofolate reductase (DHFR) is involved in
AOO AO ft
maintaining the folate cofactor in its biologically relevant, fully reduced state '
and the first inhibitors of folate metabolism, aminopterin and methotrexate429, targeted
this enzyme. These compounds, along with related drugs that inhibit species-specific
DHFR, have widespread clinical uses as anti-cancer, ant-bacterial and anti-protozoal
agents428. As a result of the success of anti-DHFR drugs other enzymes involved in
folate metabolism have also been targeted including; GART430'431, FDH422 and
AICAR432'433.
GART is a particularly well studied formyltransferase, transferring a formyl
group to its substrate (3-GAR in the first step of puridine synthesis434. In 1992 a folate
inhibitor against human GART was in clinical trials when the homologous E. coli
GART enzyme was solved418 (figure 3.1.3). Since then the human GART subdomain
has also been solved435. These structures have been important in understanding the
mechainism of formyl transfer from N-10-fTHF in this class of enzymes and have
also led to the structure based design of GART specific inhibitors that are potential
anti-cancer drugs436.
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Figure 3.1.3 (below): Three different structural folds that have evolved to transfer a
formyl group.
(a) The bifunctional AICAR-IMPCH enzyme (PDB code: 1G8M)419. The individual
AICAR and inosine monophosphate cyclohydrolase (EMPCH) enzymes are active
when separated, however although IMPCH is functional as a monomer (coloured
green and red), AICAR is only functional as a dimer (coloured orange). It is this
dimer that is required for formyl transfer from N-10-fTHF in this enzyme419. The
three shades of orange represent three distinct sub-domains in AICAR, with substrate
and N-10-fTHF binding at the dimer interface.
(b) purT GART (PDB code: 1EZ1) uses ATP and formate for formyl transfer. ATP
binds between domains A and B, coloured in lime and yellow respectively, with
substrate ((3-GAR) binding at the C-terminal end of the P-sheet in domain A, coloured
• 423blue. The ATP and formate co-complex is shown
(c) purN GART is a monomer with one functional domain (coloured violet). It is
shown with an inhibitor418 in the folate binding site (PDB code: 1CDE). Substrate










3.1.3 The GART family of formyltransferases
Of the N-10-fTHF utilising formyltransferases there are two sub-families that do not
share sequence or structural similarity. One sub-family includes AICART, which
transfers a formyl group to 5-amino-imidazole 4-caboxamide in the penultimate step
of purine biosynthesis431. The other sub-family represents the better studied class of
N-10-fTHF utilising formyltransferases that includes GART, FMT and FDH.
The GART sub-family shares relatively low sequence identity, around 15-30
%, however structurally they are quite similar (figure 3.3.2)422. All of these enzymes
share a folate binding domain. In GART this constitutes the whole enzyme418 (figures
3.1.3 and 3.3.2). In FMT the N-terminal sub-domain binds folate, with the C-terminal
sub-domain involved in substrate binding420. Similarly to FMT, the N-terminal sub-
domain of the FDH hydrolase domain binds folate; however the function of its C-
terminal sub-domain, although important for activity, is unclear (unpublished
results422).
The folate binding domain has a 7-stranded P-sheet flanked by a-helices with
6 of the 7 strands making up the characteristic Rossmann fold. There is also an extra
a-helix outside of this core, which is only ordered in GART upon N-10-fTHF binding,
but makes interactions with the C-terminal sub-domain in FMT and FDH 422. This
domain is structurally very similar between these enzymes and in particular the core
7-stranded P-sheet is largely superimposible. Chumanevich et al. found that
superimposition of just the 7-stranded P-sheet of FDH (-45 Ca's) with the
corresponding region in GART and FMT gave a rool mean square deviation (RMSD)
of just 0.8 and 1 A respectively422. In contrast the RMSD of all common Ca's (-155)
of the folate binding domain of FDH superimposed with GART and FMT, is 3.5 and
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3.7 A respectively422. This demonstrates that, in common with many enzymes, the
chemical 'core' of the enzyme is structurally well conserved.
Bicyclic ring Benzoyl Glutamate
Figure 3.1.4: The N-10-fTHF cofactor contains three regions; a bicyclic ring, a
benzoyl ring and glutamate.
There are two major structural differences between the FMT and GART
structures. In FMT there is an extra loop protruding from the active site, composed of
residues 34-49 and a C-terminal sub-domain, residues 209-314, attached to the N-
terminal sub-domain by a linker, residues 290-208437. In the apo structure ofFMT the
protruding loop is disordered420 but becomes ordered upon tRNA substrate binding437.
In the tRNA-FMT complex structure, several interactions occur between residues on
the ordered loop with the acceptor-stem of the tRNA (figure 3.4.3), correctly
orientating the adenosine base, with esterified formyl-methionyl group attached, into
the active site437. Interestingly the C-terminal sub-domain is also involved in
substrate binding; this domain is made up of 2 large and two smaller P-sheets, which
fold together to form a small P-barrel, similar to the OB-fold437. There are extensive
interactions between the tRNA substrate and the C-terminal subdomain. In particular
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the protein contacts the minor grooves of the acceptor-arm and the D-arm as well as
to the D-stem of the tRNA (figure 3.4.3). Important to the D-arm interaction is an
electropositive channel that leads towards the N-terminus of FMT, including the
residues K209, K246, K29i, R303 and R304437 The interactions between the tRNA and
protein clamp the tRNA molecule in place.
3.1.4 Mechanism of formyltransfer
Early biochemical studies of the GART mechanism showed that it did not form either
cofactor amidine (5-10-methyenyltetrahydrofolate) or enzyme-amidinium
intermediate species438. Instead the mechanism of formyl transfer was suggested to
involve direct nucleophilic attack of the P-GAR amine on the formyl carbon ofN-10-
fTHF438. Subsequent studies are consistent with this mechanism of formyl transfer
and structural solution of GART and FMT give insights into how this reaction is
catalysed by the enzyme425'434. The structures of GART418, FMT437 and FDH422 in
complex with their substrates, reveal a conserved location of the active site, with two
strictly conserved residues, Hios and Di44 (numbered as GART), ideally located to
assist in formyl transfer from N-10-f-THF. A further residue, N106, which is
conserved in GART and FMT but absent in FDH, is also positioned to assist in the
reaction425'439'440. That N106 is not conserved in FDH probably reflects the differences
in the reaction of this enzyme with other formyltransferases of this family, as the
formyl group is not transferred to a substrate.
Extensive mutational analysis has been carried out on these catalytic residues
in GART42 >439'440. These studies show that although all three residues are important
for full activity of the enzyme, none are absolutely required439'440, consistent with the
90
idea that these residues are assisting the direct attack of the 0-GAR amine on N-10-
fTHF. D144 is the most important residue in catalysis440 and is located near to the N-
10 position of the folate, however it is not close enough and sterically blocked from
the a-amine of GAR and thus cannot extract a proton425'439. Instead it is thought Hios
donates a proton to the formyl oxygen, initiating the tetrahedral intermediate
formation resulting from attack of the amino group of GAR which, due to the low-
dielectric state of the active site, is in its free base form425 (figure 3.4.2). Hiog would
need to be protonated, a situation that is facilitated by the salt bridge between Di44 and
Hio8, raising the pKa of Hios to approximately 9.8425. A proton is then transferred to
the N-10 of the folate from the p-GAR substrate through a catalytic water molecule,
the position ofwhich is mediated by Di44425. Tetrahedral intermediate breakdown and
product release follows this proton transfer. N106 is located close to the formyl group
and it is thought that this residue plays a role in stabilising the negatively charged
oxygen of the intermediate in GART and FMT mechanisms (figure 3.4.2)425.
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3.1.5 SDR enzymes
ArnADH: MRV|lL|VNf Fl|NHLTERL LREDHYEVYG L IG SDAISRFLNH
rmlb : MKiIvtIgaI FlIsAWRHI inntqdsvin v klt-yagn leslteienn
GalE : mrvIvtIgsI yiIshtcvql lqnghdviil nlcn-skrs vlpvierlgg
UDP-XS:(X83)SEKDR KRi|iT|GA| FvISHLTDKL MMDGHEVTW NFFT-GRK- -RNVEHWIGH
MLCR : MKLNFSG LRALVT|AG |I|RDTVKAL HASGAKWAV T TNS D LVSLAKECP-
DADH : MSFTLTN KNVIFVA|LG jl|LDTSKEL LKRDLKNLVI L RIEN-PAA IAELKAINPK
ArnADH:PHFHFVEGfI SIHSEWIEY- HVKKCBVVLP LVAXATPIEY TRN-|LRVFE LDFEENLRII
RmlB :ERYKFEHflll CDSVAIANIF AHHQpIaIMH LAAESHVDRS ITG-IaDFIE TNIVGTYILL
GalE :khptfvegIi rnealmteil hdhaiItvih faglkavges vqk-Ileyyd nnvngtlrli
udp-xs:enfelinh§v veplyi —ev|qiyh laspasppny myn-|iktlk tntigtlnml
MLCR :-GIEPVCVDL GDWDATEKAL GGXGPVDLLV NNAALVIMQP FLEVTKEAFD RSFSVNLRSV
DADH :VTVTFYPYDV TVPIAETTKL LKTIFAQLKT VDVLINGAGI LDD HQIE RTIAVNYTGL
ArnADH :RYCV KYRKRI IFPS^^VYG MCSDKYFDED HSN L IVGPVNKPRW
RmlB : EEARKYWLAL SEDRKGAFRF HHiHdE^B D LPHPDE VSSDTILPLF TEQTSYSPSS
GalE : SAMR AANVKN- IFSSSATVYG DQPKIPYVES FPTGTPQSPY GKSKLMVEQI
UDP-XS :GLAK RVGARL LLASjJlBVYG DPEVHPQSED Y W GHVNPIGPRA
mlcr : fqvs qmvardm inrgvpgsiv nvssmvahvt fpn li
DADH :VNTT TAILDF WDKRKGGPGG IICNIGSVTG FN AIYQVP
ArnADH:i Isvs qlld rviwaygeke glqftlfrpf nwmgIrldnl naarigssra itqlilnlve
RmlB : p isas assd hlvrawrrty glptivtncs nnyglyhfpe k L ipliilnaia
GalE :L Idlq aqpd wsiallr-yf npvgahpsgd mgedIqgipn n L mpyiaqvavg
udp-xs:c Ideg rvae tmcyaymkqe gvevrvarif ntfg|rmhmn dgr v vsnfilqalq
mlcr :t IsST gamt mltkamamel gphkirvnsv npt w ltdmgkkvsa
dadh :v(sgt aaw nftsslakla pitgvtaytv npgitrtt— L vhkfnswldv
ArnADH: G-SPIKLID- GlKQK ICFTDIRiGI EALYRIIENA GNRCDGEIIN IGNPENEASI
RmlB : G-KLLPVYG- nIeQI IdWLYVE|HA R PGH DLRYAIDASK IKQDLG W
GalE : RRDSLAIFGN DYPTEdItGV |DYIHVm1lA DGHWAMEKL ANKPGVHIYN LGAGVGNSVL
UDP-XS: G-EPLTVYG- SgSQT |AFQYVS|LV NG LVAL MNSNVSSPVN LGNPEEHTIL
MLCR : DPEFARKLK- ERHPL RKFAEVEDW NSILFLLSDR SASTSGGGIL VDAGYLAS—
DADH : EPQVAEKLL- AHPTQ PSLACAENFV KAIELNQNGA IWKLDLGTLE AIQWTKHWDS
ArnADH:EELGEMLLAS FEKHPLRHHF PPFAGFRWE SSSYYGKGYQ DVEH|KPSIR
RmlB :VPQETFETGI TKTI HWYLNNK EWWQRVMDGS
GalE : DWNAFSKAC GKPV NYHFAPRREG DLPAYWADAS





GalE :TRTLDEMAQD TWHWQSRHPQ GYPD(end)
UDP-XS :WPLEEGLNK AIHYFRKELE YQANNQ (X18)
Figure 3.1.5: Sequence alignment of ArnA decarboxylase (ArnADH) with the
similar E. coli enzymes RmlB, GalE and human UDP glucuronic decarboxylase
(UDP-XS). The classical SDR's mouse lung carbonyl reductase (MLCR) and DADH
are shown for comparison.
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Figure 3.1.5 continued: The well conserved GxxxGxG and YxxxK motifs are
highlighted in red. Residues conserved in the ArnADH, RmlB, GalE and UDP-XS
sequences are highlighted in light blue and those similar are coloured green. The
residues thought to be important in ArnA decarboxylase are highlighted dark blue,
with corresponding residues in RmlB and GalE highlighted in grey. The residues
important in NADP+ binding (MLCR) and NAD+ in the other enzymes are coloured
yellow.
Sequence analysis of the C-terminal decarboxylase domain of ArnA predicted that
this domain belongs to the SDR superfamily of enzymes (figure 3.1.5). This is one of
the largest superfamilies in nature and contains enzymes that catalyse a diverse range
of reactions, using NAD(P)+ as a cofactor. Despite this diversity, which is related in
sequence, the structures of SDR enzymes are homologous, reflecting the conserved
chemistry of hydride transfer catalysed by SDR enzymes.
NAD(P)+ dependent alcohol dehydrogenase (ADH) activity is very
widespread in nature and important in all domains of life. The independent evolution
of three main, mechanistically and structurally different, enzyme superfamilies
reflects the importance of this reaction441'442. The three superfamilies are the iron
dependent ADH's representing the smallest and least studied group443'444, the medium
chain dehydrogenases/reductases (MDR), requiring a metal ion (usually zinc) as a
cofactor445 and the short chain dehydrogenases/reductases (SDR), representing the
largest group445. The birth of the SDR superfamily as a class of enzymes was in 1981
and began with the report of an ADH from D. melanogaster (DADH)445. Although
DADH carries out the same reaction as horse liver ADH (LADH), it shares very little
sequence identity and does not require a zinc ion445. DADH is significantly shorter in
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length than horse LADH but has a conserved Rossmann fold. This fold is present in
the N-terminal region ofDADH as opposed to the C-terminal end in LADH (figure
3.1.6), suggesting DADH belonged to an unrelated family of alcohol
dehydrogenases445. Another member of this family was also identified in 1981, a
prokaryotic ribitol dehydrogenase446. Over the last 25 years the SDR superfamily has
grown to over 3000 enzymes, making it one of the largest families in nature382'447.
This is reflected by the wide substrate spectrum of these enzymes, ranging from
alcohols, through sugars and steroids to xenobiotics447'448. The main structural
difference between SDR and MDR enzymes is that SDRs have one structural domain,
sufficient for both binding cofactor and catalysis, whereas MDRs have distinct
cofactor binding and catalytic domains (figure 3.1.6). Despite catalysing homologous
reactions and having a conserved Rossmann fold, the enzyme classes have distinct
mechanisms449'450.
The SDR enzymes typically share low sequence identity of around 15-30 %
and although there are few strictly conserved residues there are several recognizable
sequence motifs382'448 (table 3.1.7). The two most important motifs are the coenzyme
binding motif GxxxGxG451 and the active site motif YxxxK (highlighted in figures
3.1.5 and 3.1.6) which, along with less well conserved S / T, makes up the catalytic
triad. The SDR superfamily can be further classified based on sequence and is split
into two main families, the classical and extended SDRs (table 3.1,7)382. The classical
SDRs include oxidoreductases such as steroid dehydrogenases and are typically
around 250 amino acids in length. Extended SDRs are usually slightly larger, around
350 amino acids, and include isomerases and lyases (dehydratases), such as galactose
epimerases and glucose dehydratases respectively, as well as some
oxidoreductases ' A more recent study of SDR enzymes by Kallberg et al.
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identified three new families, divergent, intermediate and complex SDRs and further
classifies the classical and extended SDR families into 7 and 3 sub-families
respectively448. This classification is based on more subtle differences in the
conserved motifs, designed to functionally assign the SDRs448.
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Figure 3.1.6: Stereo representation of (a) Horse liver ADH (PDB code: 1MGO)453
and (b) Drosophila ADH (PDB code: 1 SBY)454 structures (b), members of the MDR
and SDR superfamilies respectively. The Rossmann fold in each enzyme is coloured
in red. The substrate binding and catalytic domain of the MDR and the substrate
binding, functional sub-domain of the SDR enzymes are coloured blue. In DADH the
conserved GxxxGxG motif is coloured orange and the strictly conserved active site





Classical Extended Possible function
PI + al TGxxxGhG TGxxGhaG Structural role in
coenzyme binding
P3 + a3 Dhxfcp] DhxD Adenine ring
binding of
coenzyme
P4 GxhDhhhNNAGh [DEjxhhHxAA Structural role
stabilising central
p-sheet
a4 hNhxG hNhhGTxxhhc Part of active site
35 GxhhxhSSh hhhxSSxxhaG Part of active site
a5 Yx[AS][ST]K PYxx[AS]Kxxh[DE] Part of active site
P6 h[KR]h[NS]xhxPGxxxT H[KR]xxNGP Structural role
Figure 3.1.7: Table of major sequence motifs in classical and extended SDR
families448. Labelling of secondary structure is consistent with figures 3.1.6b and
3.3.5. Adapted from Kalberg et al.448.
3.1.6 Structure of SDR enzymes
The structure of a typical SDR enzyme is shown in figure 3.1.6b. It has a 7-stranded
P-sheet in the centre of the protein, flanked on either side by three a-helices. Two a-
helices are not part of the main body of the structure and these, along with the C-
terminus, are involved in substrate recognition and binding452'455'456. The 7-stranded
P-sheet makes a hydrophobic core and binds NAD(P)+. These sheets contain the
conserved GxxxGxG motif451 as well as several conserved hydrophobic residues
• • • • 4S7
important in cofactor binding ' . Six strands of the P-sheet, along with 4 of the
flanking a-helices, make up the characteristic Rossmann fold, which has two PaPaP
units with the PaP motifs having the usual right handed crossover458 (figure 3.1.6).
The seventh strand, which is separated by the two C-terminal a-helices, is linked by a
left-handed crossover452. The core Rossmann fold displays higher sequence similarity
97
between SDRs (figure 3.1.5) than the C-terminal region and in the structures solved is
superimposible. The major structural difference between members of the extended
family of SDRs (and SDRs in general) is in the C-terminus, with the two smaller oi-
helices not superimposing well, indicative of the wide substrate diversity455'456. There
are a small number of examples of monomeric SDR enzymes459, but the vast majority
exist as either a dimer or tetramer (reviewed by Tanaka et a/.452).
3.1.7 Coenzyme specificity
The PaP fold making up part of the Rossmann fold is found in enzymes that utilise
nucleotide cofactors such as NAD(P)(H) and FAD451, however side chain variations
of amino acids surrounding this motif have evolved, determining which cofactor
binds. In NAD(H)+ utilising enzymes there is usually an acidic residue, D or E, at the
C-terminal end of the second P-strand (P2), which hydrogen bonds to the 2'- and 3'-
hydroxyl groups of the adenine ribose moiety (figure 3.1.5)448. NADP utilising
SDRs lack this acidic residue as it would electrostatically repel the negative 2'-
phosphate group and instead have two positive residues, usually R or K, which
stabilise NADP+ binding448'452. These two residues are found at X on the GxxXGxG
motif and immediately following the position where the acidic residue is conserved in
NAD(H)+ utilising enzymes (figure 3.1.5). It is not surprising that the roles of these
negative and positive residues have evolved to select the use ofNAD+ or NADP+ as
the only structural difference between these cofactors is a large, negative phosphate
group at the 02 position of the adenine ring. Importantly in all SDR enzymes,
binding of the cofactor orientates the nicotinamide ring close to the active site
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Figure 3.1.8: Proton and hydride transfer catalysed by SDR enzymes.
SDRs usually catalyse oxidoreductase reactions but also include dehydratases,
epimerases and decarboxylases. Common to all of these reactions is the transfer of a
hydride and a proton between substrate and protein/NAD(P)+ (figure 3.1.8)382.
Extensive mutational and structural studies have confirmed the importance of the
catalytic triad, with mutations in Y, K or S/T leading to complete loss or reduction of
enzyme activity
460-464 This triad is located close to the nicotinamide ring of the
NAD(P)+ and the carbon of the substrate. This permits Y, which acts as a base, to
extract a proton. The conserved K plays a role in the binding and positioning of the
nicotinamide moiety of the NAD(P)+ cofactor and, along with the positive group of
NAD(P)+, lowers the acidity of the Y to a pKa ~7. This results in the tyrosine side
chain being deprotonated, allowing it to transfer a proton to and from substrate463.
Concomitant with proton transfer, hydride is transferred between NAD(P)+ and
substrate (figure 3.1.8)461'465. The precise role of the less stringently conserved S/T in
the reaction is disputed.
Early reports based on the structures of E. coli GalE, showed that the active
site Y was too far from the hydroxyl group of the galactose substrate to directly
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extract a proton460'466"468. It was proposed that the S/T residue acted to relay the
proton from the galactose hydroxyl group to Y , the so-called shuttling
mechanism463'469. However crystal structures of human GalE463, RmlB470 and
SQD1471 (an SDR that converts UDP-glucose to UDP-sulfoquinovose, important for
sulfolipid biosynthesis) have shown that Y acts directly as a base. In the dimeric
human GalE structure the catalytic Y is found 3.1 A and 4.1 A from the glucosyl C'4-
hydroxyl group in different monomers463. This suggests that the position of the
catalytic Y in the E. coli GalE structures is a crystallographic artifact and that the S/T
residue has a different role in SDR oxidation469. Further crystal structures of similar
SDR enzymes, RmlB470 and RmlD472, reveal that this residue makes close hydrogen
bonds with the substrate, leading to the proposition that it forms a low barrier
hydrogen bond (LBHB)470'471. The LBHB is thought to help stabilise any reaction
intermediates or transition states473'474. The structure ofRmlD proposed that a LBHB
is crucial but exists between the transition state of the substrate and catalytic Y472.
The role of S/T is suggested to fine tune the pKa of the transition state to facilitate
proton transfer469'472.
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3.1.9 GalE catalysed epimerisation
GalE catalyses the interconversion of UDP-galactose and UDP-glucose (figure 3.1.9).
It does this by oxidising C4', allowing the movement of the C4' hydroxyl group from
down to up positions461. The catalytic Y149 (labelling consistent with E. coli GalE)
has its pKa lowered sufficiently by the influence of K153 to allow it to either abstract
or donate a proton461'463'475'476. Upon extraction of the C4' hydroxyl proton a hydride
is transferred from C4' to NAD+; producing a 4'-ketopyranose intermediate and
NADH. Key to the whole reaction is the ability of the carbohydrate to rotate within





Figure 3.1.9: Mechanism of the E. coli GalE enzyme, which catalyses the




The committed catalytic step for the biosynthesis of most deoxy sugars is the C6'
deoxygenation catalysed by NDP-hexose 4,6-dehydratases such as RmlB, which takes
dTDP-glucose and produces dTDP-4-keto-6-deoxy-D-glucose470'477'478. The
chemistry of this reaction involves three separate steps; oxidation by NAD+ at C4',
followed by concerted elimination ofwater from C6' and C5' and finally reduction at
C6' by NADH to produce product and regenerated NAD+479. The reaction
mechanism is shown in figure 3.1.10. High resolution structural analysis along with
ab initio electronic structure calculations show that in RmlB the NADH formed is
buckled, thereby increasing this enzymes reducing potential, activating hydride
transfer480. Mutational and structural studies have shown that E135 and N134 are
essential for the second step of the reaction mechanism, elimination of water. The
formation of the keto intermediate leads to a lowering of the pKa of C3' and C5'
protons which are a to the C4' keto group. The C5' proton points towards the side
chain of E135, which is proposed to extract this proton, with the resulting negative
charge stabilised as an enolate470'480. Elimination of water requires the C6' hydroxyl
group to be protonated, with D134 supplying this proton. RmlB-like enzymes have a
conserved N that is located close to this hydroxyl group and since a negative charge
would partly remove the proton from the OH group, preventing C6-O6' cleavage, this
residue must itself be protonated470. Elimination ofwater leads to the formation of a
glucosene intermediate which is reduced by NADH. This mechanism requires
rotation of the carbohydrate within the active site to move the C6' position of the



















Figure 3.1.10: Reaction mechanism of the RmlB enzyme consisting of three distinct
steps; oxidation, elimination of water and reduction. Amino acid labelling is
consistent with RmlB from S. typhimurium. Taken from Allard et al.470.
3.1.11 ArnA
The ArnA residues T432 and Y463SVSK467 represent the conserved catalytic triad S/T
and YxxxK. This would be consistent with an initial oxidation step carried out by the
ArnA decarboxylasae domain to form a keto-sugar intermediate, which then
decomposes by decarboxylation. Breazeale et al. first demonstrated that the oxidative
decarboxylation of UDP-GlcUA to UDP-LAra40 was catalysed by ArnA377. It was
originally postulated that ArnA catalysed the oxidation of UDP-GlcUA and a second
enzyme, PmrJ, catalysed the decarboxylation step363'371. By showing that ArnA was
sufficient for both the oxidation and subsequent decarboxylation reactions they raised
the question as to whether decarboxylation occurred spontaneously or was enzyme
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catalysed? UDP-glucuronic acid decarboxylases, which are also called UDP-xylose
synthases, reutilise NADH to reduce the 4C'-keto group of the keto-intermediate,
producing UDP-xylose481. In contrast ArnA releases UDP-LAra40 and NADH as
products377. Determination of the ArnA decarboxylation structure is important for
several reasons. Firstly, as mentioned in Chapter 2, it is a potential drug target due to
its role in the L-Ara4N modification of Lipid A, a mechanism of resistance to
CAMPs. Secondly, the structure would help determine whether the decarboxylation
step is enzyme catalysed and if so, how so? Thirdly, the structure may give insights
into why NADH is not reutilised in ArnA.
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3.2 MATERIALS AND METHODS
3.2.1 Selenomethionine expression and purification
Because of the relatively low sequence identity of the decarboxylase and
formyltransferase domains to other structures in the PDB database and the failure of
initial molecular replacement attempts, selenomethionine protein was grown. 250 ml
M9 medium, supplemented with 50 pg ml"1 kanamycin in 2 1 flasks was inoculated
with an overnight culture ofE. coli BL21(DE3), transformed with either ArnA_DH or
ArnA_FT plasmids (table 2.2.2), for growth of selenomethionine modified (Se-Met)
protein. Se-Met protein was produced using a standard protocol as described by
Doublie482. Decarboxylase and formyltransferase Se-Met protein was purified to
homogeneity and prepared for crystal trials using the same procedures as for native
protein (chapter 2.2), but 7 mM DTT was added to all buffers to prevent oxidation of
the selenomethionine. A small aliquot of pure protein was sent for whole protein
mass spectrometry analysis and confirmed full selenomethionine incorporation, with
the formyltransferase results shown in figure 3.2.1.
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Figure 3.2.1: Whole protein mass spectrometry analysis of Se-Met (b) and native (a)
formyltransferase protein, with the mass difference of 234.5 corresponding to full
incorporation of 5 Se.
3.2.2 Crystallisation of Se-Met protein
Se-Met formyltransferase protein was used to screen for new crystallisation
conditions, at both 20 and 4 °C, as conditions giving rise to native crystals (2.2.4) did
not produce Se-Met crystals. Crystals suitable for X-ray diffraction formed at 4 °C in
0.22 M ammonium fluoride and 22 % PEG 3350, with drops containing 3 pi protein
and 3 pi precipitant against a well of 100 pi mother liquor. Decarboxylase Se-met
protein crystallised in 2.9 M NaCl and 0.1 M Bis-tris pH 5.6, a similar condition to
native protein.
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3.2.3 MAD data collection of formyltransferase and decarboxylase
SeMet crystals
In house screening determined that the croprotectant, space group and unit cell of the
Se-Met formyltransferase and decarboxylase crystals were essentially the same as
native crystals (2.2.3). A single Se-Met formyltransferase crystal was used to collect
multiwavelength anomalous diffraction/dispersion (MAD) data to 1.6 A at three
wavelengths. The wavelengths were chosen as peak 0.9793 A inflection 0.9796 A
and remote 0.9393 A (table 3.2.2), as measured by fluoresence scan on the ESRF
beamline ED 14-4. Similarly, a single Se-Met decarboxylase crystal was used to
collect MAD data to 3.35 A at three wavelengths (table 3.2.7) on beamline BM14 at
the ESRF. Data were indexed and integrated in MOSFLM396, scaled in SCALA401
and merged in TRUNCATE. Scaled but unmerged data were used for structure
determination. Formyltransferase and decarboxylase data collection statistics are
shown in tables 3.2.2 and 3.2.7 respectively.
3.2.4 Structural solution and refinement
Formyltransferase domain
Running SOLVE483 with data from all three wavelengths cut to 2.5 A located 8 of the
10 selenomethionines in the asymmetric unit, with sites listed in table 3.2.3
corresponding to 2 formyltransferase molecules as predicted by Matthew's coefficient.
The electron density map output from SOLVE is shown in figure 3.2.4a and there are
two separate regions within the map that are slightly darker than the background noise
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(circled) which, along with the good statistics from SOLVE (table 3.2.2 and 3.2.3),
suggested a solution. The initial phases from SOLVE were improved in RESOLVE,
which also carries out density modification including solvent flattening484. Figure
3.2.4b shows the electron density map output from RESOLVE and with the solvent
flattened the density corresponding to the two formyltransferase monomers is much
clearer. Closer inspection of electron density maps in O485 showed continuous
electron density consistent with protein secondary structure, with clear density for
side chains confirming a structural solution.
Data Collection Peak Inflection Remote
Wavelength (A) 0.9793 0.9796 0.9393
Resolution (A) 24-1.6(1.63-1.6)
Unique reflections 77800 77914 77900
Space Group P2i2]2]
Cell Dimensions a=67.5, b=90.7, c=97.6
a=p=y=90°































Refined f/f -7.8/4.9 -10.2/2.6 -3.5/3.1
Z score 21.3
Phasing power 0.64
*Rmerge = Z 27 (h)i - (I (h)) / X 27 (h)i, where /(h)i is the measured diffraction intensity and
the summation includes all observations
Table 3.2.2: Data statistics for the formyltransferase 3 wavelength MAD experiment.
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X Y Z Occupancy B- Peak Height
(°)
0.112 0.221 0.180 1.000 10.1 28.2
0.102 0.682 0.021 0.991 25.5 21.6
0.393 0.642 0.031 0.819 15.4 23.9
0.751 0.113 0.234 0.943 9.7 25.7
0.229 0.547 0.032 0.969 10.8 25.0
0.012 0.802 0.217 0.809 13.5 20.1
0.868 0.541 0.143 0.997 15.1 24.6
0.281 0.270 0.250 0.898 20.5 19.9
Table 3.2.3: 8 Se sites found by SOLVE in the formyltransferase asymmetric unit.
Figure 3.2.4: Initial electron density maps of the formyltransferase structure from
SOLVE483 (a) and from RESOLVE484 after solvent flattening (b). The darker regions
correspond to two formyltransferase monomers in the asymmetric unit (circled in a).
The 1.6 A MAD data were merged with the high resolution 1.2 A dataset, that
was previously collected on a native formyltransferase crystal (2.2.5), using the CAD
program as implemented in the CCP4 program suite486. Phases were extended to 1.2
A and further density modification carried out in the DM program487, before
automatic chain tracing was carried out in ARP/wARP488. Over 90 % of the structure
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was traced and side-chains were docked using guiSIDE489. Missing residues that had
electron density were fitted manually by hand in O485 or COOT490. During the
building process it was evident that extra density was present in the structure that
could not be accounted for by protein or water molecules and it was possible to model
N-5-fTHF and uracil monophosphate UMP into these regions (figure 3.2.6). Libraries
for these ligands were made in PRODRG491 for use in refinement using the
REFMAC5 program403. Initially rigid body refinement was carried out before TLS
groups were defined and cycles of restrained anisotropic, TLS refinement and
rebuilding were performed403. The final refined R factor and Rfree values of 13.5 and
15.8 were reached before validation by PROCHECK492 and WHATIF493 and structure
deposition into the PDB. The refinement statistics are presented in table 3.2.5. Figure
3.3.1 shows the structure of the two formyltransferase monomers in complex with N-


















Table 3.2.5: Refinement statistics for the formyltransferase structure. 1 These refer to
the Ramachandran plot and are defined by PROCHECK492. Values in parenthesis
correspond to the highest resolution shell.
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Figure 3.2.6: Stereo representation ofN-5-fTHF (a) and UMP (b) modeled into their
respective unbiased Fo-Fc electron density maps, found in the structure of the
formyltransferase domain. The molecules are shown in stick with atoms coloured;
carbon-yellow, nitrogen-blue, oxygen-red and phosphorous-purple. The map is
contoured at 3o (0.22eA~3).
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Decarboxylase domain
Data Collection Peak Inflection Remote
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Refined f/f' -9.5/5.4 -10.1/2.5 -2.6/3.7
Z score 13.8
Phasing power 0.52
*Rmerge = Z 27 (h)i - (I (h)) / Z 27 (h)b where /(h)i is the measured diffraction intensity and
the summation includes all observations
Table 3.2.7: Data statistics for the decarboxylase 3 wavelength MAD experiment.
Values in parenthesis correspond to the highest resolution shell.
Because the space group was either P4i32 or P4332 (2.2.5) SOLVE483 was run in both
hands. Good statistics were only obtained using the space group P4i32, with SOLVE
locating all 4 selenomethionines (tables 3.2.7 and 3.2.8), corresponding to one
monomer in the asymmetric unit. Observation of the raw map from SOLVE identifies
a darker region indicating that this area is above noise, suggesting that a correct
solution had been found (figure 3.2.9). RESOLVE was run to improve the phases and
carry out solvent flattening and the map from RESOLVE clearly shows the protein
region (figure 3.2.9)484.
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X Y Z Occupancy B- Peak Height
(°)
0.459 0.423 0.078 0.459 35.9 38.6
0.797 0.097 0.039 0.797 60.0 38.4
0.708 0.223 0.063 0.708 60.0 29.2
0.595 0.157 0.053 0.595 60.0 28.0
Table 3.2.8: 4 Se sites found by SOLVE in the decarboxylase asymmetric unit.
Figure 3.2.9: Initial electron density maps of the decarboxylase structure from
SOLVE483 (a) and RESOLVE484 after solvent flattening (b). The darker regions
correspond to protein.
The 3.35 A data was merged with the higher 2.3 A data using CAD from the
CCP4 suite 486, with phase extension and further density modification performed in
DM487. The 2.3 A electron density maps were viewed in O485 and interpretation of
this density confirmed that the decarboxylase domain had been solved. This data, as
well as the decarboxylase domain sequence file, was then input into ARP/wARP488,
which built over 90 % of the structure and automatically fitted side chains488. Missing
residues that had electron density were modelled by hand in O or COOT490 and water
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atoms were added using ARP/wARP488. Refinement cycles were carried out in
REFMAC5 using first rigid body and then restrained TLS refinement403 to give final
Rfactor and Rfree values of 18.6 and 22.9 % respectively, with some refinement
statistics shown in table 3.2.10. Manual inspection of electron density maps shows no
density that is not accounted for by protein or water molecules and the apo-structure is

















PDB code 2b 11
Table 3.2.10: Refinement statistics for the formyltransferase structure,
to the Ramachandran plot and are defined by PROCHECK492. Values




3.2.5 Site directed mutagenesis
Step 1 Step 2 •
Figure 3.2.11: Major steps of site directed mutagenesis. Forward and reverse
primers (blue arrows) are designed around the mutation site (red line) and used to
amplify both strands of the methylated DNA template (black line) (steps 1 and 2).
The newly synthesised, un-methylated DNA base pairs to form a nicked plasmid and
the template DNA is digested by the restriction endonuclease Dpnl (step3). This
nicked vector containing the mutant sequence is then transformed into super-
competent E. coli which ligates the nick and the new plasmid can be harvested.
Based on the superimposition of the RmlB active site with ArnA (figure 3.3.6), and
the conservation of these residues in other UDP-GlcUA decarboxylases, it was
decided to mutate the S433 and E434 residues to assess their role in the ArnA reaction.
S433 and E434 were both mutated to A and E434 was additionally mutated to the
isosteric Q, using the QuikChange® protocol, outlined in figure 3.2.11. The reaction
mixture included the ArnA-DH plasmid (table 2.2.2),P'pfu DNA polymerase, dNTP's
and the relevant oligonucleotides (table 3.2.12). The QuikChange® protocol uses a
PCR based technique to amplify the whole vector using forward and reverse primers.
These primers contain the relevant base pair changes to incorporate the mutation and
are designed around the mutation site. The PCR reaction uses the high fidelity DNA
polymerase Pfu, however it does not correct the mismatched sequence because this is
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located close to the 3' end of the primer, where the proof reading ability of the enzyme
is poor. The result of this PCR is the amplification of both strands of the vector, with
the new sequence containing the relevant mutation. Importantly, the newly
synthesised DNA is un-methylated and complimentary base pairs with one another
and the template DNA. As the template DNA is methylated (by the E. coli cells it is
extracted from) it can be specifically digested by the restriction enzyme Dpnl, which
only digests methylated and hemi-methylated duplex DNA. This leaves a mixture of
unmethylated, nicked plasmids containing the desired mutation and digested DNA
fragments, which is used to transform the super-competent E. coli TamI cells
(Novagen). The E. coli cells further digest the fragments of template DNA and the
nicked plasmid is ligated together by DNA ligase.
DNA sequencing of the vectors extracted from TamI cells after site-directed
mutagenesis confirmed the presence of the mutations, with no other mutations having
been inserted elsewhere in the gene. These new vectors were used to transform E.
coli BL21(DE3) cells for over-expression and subsequent purification of the mutant
proteins, following the same procedures as for wild-type protein (2.2.2 and 2.2.3).
Pure protein of the three mutants, along with native decarboxylase protein, was sent to
the Protein Characterisation Facility, Institute of Biomedical & Life Sciences,
University of Glasgow for Circular dichroism and fluorescence spectra analysis. The
spectra for the mutant and wild-type proteins are very similar (figure 3.2.13), strongly









Table 3.2.12: Oligonucleotides used for site-directed mutagenesis. Underlined and in
bold is the mutated codon, with the original base in ().
190 200 220 240 260 190 200 220 240 260
W.iveleiiijtli [nm] Wavelength [inn]
Figure 3.2.13: Circular dichroism-spectra of ArnA decarboxylase wild-type, E434A
(a) and E434Q (b) mutant proteins. The far-UV spectra show that the secondary
structure of the mutant proteins is the same as wild-type. The S433A spectra is
identical to (b) and its structure (PDB code 1Z73) shows correct folding. The slight
differences at low wavelength (used to determine tertiary structure) are because the
decarboxylase protein didn't exhibit a CD signal in the near UV region. This
situation usually occurs because the aromatic side chains are not particularly rigidly
held in the tertiary structure of the protein.
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3.2.6 Kinetic assay
The activity of wild-type and mutant ArnA decarboxylase enzymes to catalyse the
C4' oxidation of UDP-GlcUA was assayed by following the rate of NADH
production at A34o. The assays contained 50 mM HEPES pH 7.5, 300 mM NaCl, 2
mM DTT, 0.2 mg ml"1 bovine serum albumin, 8 mM NAD+, 4.5 mM UDP-GlcUA
and either 0.5 pM wild-type or 2.5 pM mutant protein. Reactions were carried out in
1 ml cuvettes at 30°C and the initial rate of reaction was measured over 10 minutes.
These assays allowed us to assess the Vmax for the decarboxylase enzymes as both
NAD+ and UDP-GlcUA are in a large excess. Apparent Km values were determined
by varying the amount of initial UDP-GlcUA or NAD+ from 1/5 x to 5 x Km, whilst
keeping the unvaried substrate in excess. The results of these assays are shown in
table 3.2.14. The experiments to calculate the reaction rate for native and mutant
proteins were first carried out by our collaborators in North Carolina. We then
repeated these results and calculated the Vmax and Km for the E434A mutant (table
3.2.14), while our collaborators calculated the Vmax and Km for native and S433A
proteins. It is apparent that the S433A mutant and E434A mutants do retain some
activity, approximately 40x and lOOx reduction in activity compared to wild-type,
whereas surprisingly the E434Q mutant has no detectable activity. Given that the assay
measures the rate ofNADH production it is possible that the S433A and E434A mutants
are only defective in the decarboxylation step and therefore accumulate keto-
intermediate. In order to probe this possibility the reaction was monitored by high
































No Activity N/A N/A N/A N/a 2.5
Table 3.2.14: Results of the kinetic assay, showing that although the E434Q mutant is
inactive, the activity of the S433A and E434A mutatnts are reduced around 40 and 100
times the wild-type protein respectively, without significantly perturbing UDP-GlcUA
or NAD+ binding.
3.2,7 HPLC assay
Wild-type and mutant reactions were carried out as described above and left overnight
to allow accumulation of products, a time scale in which the wild-type reaction is
approximately 50 % complete. Reaction substrates and products were separated from
the protein by spinning the reaction in a concentrator with a 30 kDa molecular weight
cut off, which retained the decarboxylase enzyme. The flow through from the
concentrator was diluted 50 times and subjected to HPLC analysis, performed using a
Varian Prostar machine. Ion-pair reversed-phase HPLC on a Varian OmniSpher C-18
column (250 x 4.6 mm) at a flow rate of 1 ml min"1, using a method based on that of
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Maki et al.494, was used to analyse the nucleotide sugars in the reaction mix. The
column was equilibrated with 20 mM triethylammonium acetate (TEAA), pH 6.0.
After isocratic elution with 20 mM TEAA (pH 6.0) for 7 min, nucleotide sugars were
eluted with a linear gradient of 0 - 1 % acetonitrile in 20 mM TEAA (pH 6.0) over 28
min, NAD+ and NADH were then eluted with a linear gradient of 1 - 25 %
acetonitrile in 20 mM TEAA (pH 6.0) over 10 min. Effluent was monitored with UV
detection at 254nm with NAD+, NADH and UDP-GlcUA being identified in the
reaction by co-elution with commercial standards (Sigma). This allowed the
determination of the elution point of UDP-LAra40 from the wild-type reaction (fig.
3.2.15a) and this peak is clearly present in the E434A mutant reaction (figure 3.2.15b),
the trace of which is identical to that of the S433A reaction. This analysis
demonstrates that the reactions carried out by the mutant enzymes are identical to the
wild-type reaction and that there is no additional build up of ketone intermediate.
The results of the HPLC assays were complemented with electrospray
ionisation mass spectrometry (ESI MS) carried out by our collaborators in North
Carolina. In this analysis wild-type, S433A and E434A reactions were left to run for 24
hours before dilution and ESI MS analysis. ESI MS identified masses corresponding
to the UDP-GlcUA and NAD' substrates and hydrated UDP-L-Ara40 and NADH



































Figure 3.2.15: HPLC traces ofwild-type (a) and E434A (b) mutant reactions, showing
that the reactions are the same and that there is no additional build up of ketone
intermediate. The small peak marked X is unidentified, however its presence is
consistent in both wild-type and mutant reactions.
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3.3 RESULTS
3.3.1 Structure of the ArnA formyltransferase domain
Figure 3.3.1: The structure of the formyltransferase domain. The protein is
represented as ribbons and the secondary structure elements are numbered as the text.
A loop (residues N35-A40) that is missing in the structure is labeled *. The two
subdomains are visible, the N-terminal subdomain is at the top of the figure and
extends to the uridine ring, the C-terminal subdomain sits below the ring. The two
monomers found in the asymmetric unit are shown. The decarboxylase domain is
attached to the C-terminus (labeled C) in full length ArnA.
The formyltransferase domain of ArnA crystallises with two monomers in the
asymmetric unit and buried surface calculations suggest that a functional dimer is not
formed. This is consistent with the structure of the apo-formyltransferase solved by
Gatzeva-Topolova et al., which crystallises with one monomer in the asymmetric
unit495. The overall ArnA formyltransferase structure consists of two sub-domains; an
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N-terminal domain (residues Mi - Kisi) and a smaller C-terminal domain (residues
F207 - N305), which are linked by a loop (residues Hig2 - S206)- This is a very similar
structure to FMT437, which also crystallises with two monomers in the asymmetric
unit, and the N-terminal hydrolase domain of FDFI422. This places ArnA
formyltransferase into the family of formyltransferases similar to GART,
characterised by a structurally conserved N-10-fTHF binding domain, rather than
AICAR (figure 3.1.3). In ArnA formyltransferase the characteristic domain is made
up of the N-terminal sub-domain and is folded into a 7-stranded P-sheet with 5
parallel P-strands (P1-5) and 2 anti-parallel strands (P6-7), flanked by a total of 6 a-
• • 418 45 8 •
helices, forming a version of the classic Rossmann fold ' . The C-terminal sub-
domain of ArnA formyltransferase is absent in GART but structurally conserved in
FMT420'437 and the hydrolase domain of FDH422. In ArnA it consists of 2 large P-
sheets (P8 and P9), 2 small P-sheets (P10 and P11) and 2 a-helices (a7 and a8). The P-
sheets fold to form a small P-barrel, which is flanked on either side by one of the
helices, with a7 located parallel to a5 of the N-terminal domain (Figure 3.3.1). A
structural alignment of the ArnA formyltransferase domain with FMT, the hydrolase
domain of FDH and GART was carried out using DALI (figure 3.3.2) with RMSD's
of 1.7, 2.2 and 2.2 A respectively.
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Figure 3.3.2: Superimposition of ArnA formyltransferase (red) with the structurally
related enzymes FMT (green), FDH (blue) and GART (salmon). N-5-fTHF and UMP
found in the ArnA active site are shown in stick and coloured as in figure 3.2.6. The
larger N-terminal folate binding domain superimposes particularly well. Overall
RMSD values are 2.2, 1.7 and 2.2 A for GART, FMT and FDH respectively.
3.3.2 Ligand Binding
During refinement of the structure clear electron density that did not correspond to
protein or water molecules was found and N-5-fTHF and UMP were modelled into
this density, shown in figure 3.2.6. Although we have been unable to get a true
substrate co-crystal, the location of these ligands in the structure and superimposition
with GART and FMT, allows us to locate the ArnA formyltransferase active site.
Relative to the protein fold, the active site ofArnA is in the same position as in FMT,
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GART and the hydrolase domain of FDH, consistent with ArnA belonging to this
class of N-10-fTHF utilising enzymes. In ArnA, UMP is bound mainly by the N-
terminal domain and is adjacent to Af-5-fTHF (Figure 3.3.1 and 3.3.3). Y42 is
hydrogen bonded to 02P and Rss to 01P of the UMP phosphate, with a further
hydrogen bond between 04 of uracil and R2oi (Figure 3.3.3). Hydrophobic
interactions occur between uracil and Nug, T2o2 and W22S. R20i and T2o2 are part of
the loop connecting the N- and C-terminal sub-domains and W228 is part of a7 of the
C-terminal subdomain (Figure 3.3.1).
N-5-fTHF binds adjacent to P4 and P5 with hydrogen bonds between the
bicyclic ring and two loops, one between P4 and a4 (residues Us and H86) and the
other between P6 and P7 (residues V136 and Di40). Hydrophobic interactions between
N-5-fTHF and residues L87 (on loop between P4 and a4), N102 (on P5), M135 and Ai39
(on loop between P6 and P7), also assist in the binding of the cofactor analogue.
Figure 3.3.3 shows these interactions in more detail.
Nils Nils
Figure 3.3.3: N-5-fTHF and UMP binding by ArnA formyltransferase. The map
coloured in blue is the unbiased Fo-Fc map contoured at 3o (0.22eA~3)., as shown in
figure 3.2.6.
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Analysis of the thermal factors of the N-5-fTHOF atoms indicates the bicyclic
ring is very well ordered, while the benzoyl ring is less ordered with the glutamate
displaying the least order. This is in agreement with the proposal of Almassy et al..
that the bicyclic ring is more tightly bound than the benzoyl or glutamate moieties in
GART 418. Figure 3.3.4 shows a space-filled model of ArnA formyltransferase and
this clearly shows why this is the case. There is a pocket into which the bicyclic ring
is bound, effectively clamping this region in place. The benzoyl ring exits this pocket
and the glutamate is more exposed to the surface. Interestingly there is a short tunnel
leading from the UMP moiety towards the folate. This gives an insight into how the
L-Ara4N moiety would be positioned towards the formyl group ofN-10-fTHF, which
has been modelled (figure 3.3.4).
Figure 3.3.4: Electrostatic space fill model of ArnA formyltransferase active site
with N-10-fTHF and UDP-Lara4N modelled in. The bicyclic ring ofN-10-fTHF is
buried in a cavity and there is a clear tunnel into which the carbohydrate of UDP-
LAra4N binds, positioning it close to the N-10 formyl group. N-10-ffTHF and L-
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Ara4N are shown in stick and coloured as in 3.2.6. Negative, positive and neutral
amino acid side chains are coloured red, blue and white respectively.
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3.3.3 Structure of the ArnA decarboxylase domain
Figure 3.3.5.: The structure of the ArnA decarboxylase domain. The protein is
represented as ribbons and the secondary structure elements are labeled as in the text.
A loop (residues V604-D615) that is missing in the structure is labeled *. The
monomeric unit is shown. The N-terminus of this domain (labeled N) is attached to
the formyltransferase domain in full length ArnA.
The overall structure of the ArnA decarboxylase domain is shown in figure 3.3.5 and
reveals that, as expected, it is a member of the SDR enzyme superfamily. It has a
modified version of the classic Rossmann fold typical for SDR enzymes, to which an
a-helix (a9) and P-strand (P9) are contributed from the C-terminal functional
carbohydrate binding domain. Gatzeva-Topolova et al. have also solved the apo-
decarboxylase domain ofArnA (PDB code 2BLL) and their structure is essentially the
same as that presented here with an RMSD of 0.2 A for all Ca's. Superimposition of
ArnA with RmlB from Streptococcus suis in complex with TDP-Glc and NAD'
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(RMSD 2.0 A) allows a conceptual model of UDP-GlcUA and NAD+ in the ArnA
decarboxyase active site to be made (figure 3.3.6). The superimposition reveals that
the ArnA residues S433 and E434 superimpose with the RmlB residues N134 and E135,
which are important in the well characterised RmlB reaction (3.1.10)462'470. In the
RmlB reaction the catalytic tyrosine directly extracts a proton, forming the keto
intermediate, before the glutamic acid deprotonates the C'5 position462'470. The initial
oxidation step in the ArnA reaction is expected to be the same as in RmlB as the
catalytic triad is conserved. Mutations remote from the catalytic triad and NAD+
binding would not be expected to perturb hydride transfer. We therefore expected
that mutating S433 and E434 would not significantly impact hydride transfer but, if
these residues were important in the decarboxylation reaction, would effectively cause
the reaction to stall here and release NADH and the keto-intermediate. However we
observed that these mutants significantly reduced the ability of this enzyme to transfer
hydride, without significantly affecting NAD+ or UDP-GlcUA binding (table 3.2.14).
Furthermore, the S433A and E434A mutants still produce the decarboxylated L-Ara40
product and do not accumulate the keto-UDP-GlcUA intermediate (figure 3.2.15).
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Figure 3.3.6: The active site of the decarboxylase enzyme. We have modeled in the
UDP-GlcUA substrate to generate a conceptual model. The model is based on a
superposition of the RmlB substrate complex470. The catalytic triad residues are
shown as are the residues we predict to be important in the decarboxylation step (S433
and E434). These residues superimpose with N134 and E135 of RmlB, which are
responsible for catalysis of the dehydration step in RmlB transformation462'470. The
molecules are shown in stick atoms for NAD+ and UDP-GlcUA are coloured as figure
3.3.6 and residues are coloured; carbon grey, nitrogen blue and oxygen red.
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3.4 DISCUSSION
3.4.1 Formyltransferase domain ofArnA
ArnA is a bifuntional enzyme with two distinct activities, both of which are essential
for L-Ara4N modification of Lipid A and polymyxin resistance in Gram-negative
bacteria (Chapter 2.1) ' . The interest in this field is high and in September of
2004 a group from Colorado published the structure of the apo-decarboxylase
enzyme496. Further, whilst our results were in press381, the same group published two
papers; one on the apo-formyltransferase domain with active site mutational
analysis495 and the other with the full length ArnA enzyme, with the decarboxylase
domain in complex with UDP-GlcUA and ATP. This study also included mutational
analysis of the decarboxylase active site497, suggesting a different mechanism of
decarboxylation. The discussion compares these results with those obtained here.
Figure 3.4.1 shows the sequence alignment between the formyltransferase
domain of ArnA, GART and FMT. Highlighted are N102, H104 and Di40 (in ArnA),
the three conserved residues thought to be involved in catalysis. Their sequence and
structural conservation suggests a similar mechanism of formyl transfer as described
for GART by Shim et a/.425'434, with the major differences between the proteins being
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Figure 3.4.2: Sequence alignment of ArnA formyltransferase domain, FMT and
GART, numbering corresponds to full length ArnA. The key conserved catalytic
residues are highlighted in red and marked * as in Figure 3.3.3. Conserved residues
between all three enzymes are highlighted blue and further residues conserved
between ArnA and FMT are highlighted in green. ArnA residues that recognize N-5-
fTHF and UMP are marked with J and # respectively.
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In ArnA N102, H104 and Di40 are thought to assist in formyl transfer. In this
mechanism an important salt bridge formed between Hum and D140 raises the pKa of
Hum to around 9.8 so that the imidazole group is protonated. This allows hydrogen
bonding of the formyl group of N-10-fTHF to H104 as well as to N102, resulting in
activation of the carbonyl carbon, allowing direct nucleophilic attack by the primary
amine of UDP-L-Ara4N. A tetrahedral intermediate is formed, with hydrogen
bonding to H104 and N102 stabilising the oxyanion. Di40 then plays a further important
role by mediating, along with a water molecule, the transfer of a proton from UDP-L-
Ara4N to the N-10 position of the folate. This is followed by the breakdown of the
intermediate and release of products. Mutational analysis carried out by Gatzeva-




Figure 3.4.1: Plausible mechanism for formyltransfer in ArnA as proposed by
Gatzeva-Topolova et al.495. Ri is the benzoyl ring and glutamate regions and R2 the
bicyclic ring ofN-10-fTHF (figure 3.1.4). R3 is the carbohydrate and UDP region of
UDP-L-Ara4N.
It is interesting that the C-terminal sub-domain is conserved in ArnA, FMT
and the hydrolase domain of FDH yet absent in GART (figure 3.3.2). In FMT the
role of this small |3-barrel domain has been well characterised. It extensively binds to
the tRNA molecule, stabilising the interaction between the enzyme and this large
substrate and allows the correct positioning of adenosine (3.1.3)437. This C-terminal
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sub-domain seems to play a similar role in ArnA formyltransferase, interacting with a
nucleotide, UMP, presumably to correctly orientate the L-Ara4N moiety in the active
site, allowing formyl transfer. These interactions are made by two residues on a loop
linking the N- and C-terminus and one residue on the C-terminus proper.
Further comparison of ligand binding in FMT and ArnA also suggests a lesser
role for the ArnA C-terminal sub-domain in substrate binding. Figure 3.4.3 shows the
superimposition of apo-FMT and tRNA-complexed FMT structures420'437 and apo-
and complexed ArnA formyltransferase structures381'495. There is an obvious shift of
the C-terminal sub-domain in FMT upon substrate binding, caused by a hinge like
motion of the loop connecting the two sub-domains, with an RMSD between these
structures of 1.8 A. This, along with the ordering of a loop in the active site,
effectively clamps the tRNA substrate between C- and N-terminal sub-domains437.
Upon binding of UMP and N-5-fTHF to ArnA there are no such conformational
changes, with the apo495 and complexed381 structures being largely superimposible,
with a RMSD of 0.7 A (figure 3.4.3). It is possible that binding of the true substrate,
UDP-L-Ara4N, may cause the ordering of the active site loop and this might trigger
the C-terminal shift, but such a conformational change would seem unnecessary as the
binding of UMP and the modeling of UDP-L-Ara4N in the active site shows no
reason why such a shift would be necessary (figure 3.3.4). It is interesting that GART
only requires the folate binding domain to both bind its substrate, p-GAR, which is
much closer in size to UDP-L-Ara4N than tRNA, and catalyse formyl transfer. It
might be envisaged that removal of the C-terminal sub-domain in ArnA may not
greatly hinder formyl transfer to UDP-L-Ara4N. However unpublished results by
Gatzeva Topolova et al. show that such a mutant does lack activity495. Therefore it is
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clear that the small number of interactions between the C-terminal sub-domain of
ArnA and substrate are important for either substrate recognition or formyl transfer.
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D-stem ' / D-stem
b
Figure 3.4.3: C-terminal sub-domain shift and ordering of active site loop occurring
upon binding of tRNA substrate (orange) to FMT (a) but not upon UMP and N-5-
fTHF binding to ArnA formyltransferase (b). Apo- and complexed structures are
shown in blue and red respectively. The tRNA D-stem and acceptor stem that are part
of the D- and acceptor-arms respectively, referred to in the text, are labelled.
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FDH is another bifimctional enzyme with N-terminal hydrolase and C-
terminal dehydrogenase domains homologous to the formyltransferase domain of
ArnA and aldolase dehydrogenase respectively422. Importantly the C-terminal sub-
domain of the hydrolase domain matches that in ArnA formyltransferase and FMT.
This is an interesting case as it catalyses the NADP+ dependent removal of formyl
from N-10-fTHF to produce THF422. In this reaction it is thought that hydrolysis of
N-10-fTHF is carried out by the N-terminal hydrolase domain (figure 3.3.2) and that
NADP+ is utilized to oxidise the formyl to CO2, allowing product release422. The
FDH hydrolase domain therefore only utilises N-10-fTHF as a substrate but, despite
this, it appears the C-terminal sub-domain is essential for activity (unpublished
data)422. The crystal structure of the hydrolase domain gives no insight into why this
domain is important, but it may have some role in the communication of the hydrolase
and dehydrogenase domains as both of these are necessary for function in vivo422.
These results suggest that even when not directly involved in substrate binding this C-
terminal sub-domain may have important functions. This may therefore be the case in
ArnA too. The C-terminal sub-domain is present in the middle of the full length
ArnA enzyme and could play a critical role in spatially separating the
formyltransferase and decarboxylase domains, allowing them to be active as a
bifunctional enzyme. The conservation of the full length protein suggests that despite
the formyltransferase and decarboxylase domains being active as discrete enzymes,
evolution seems to preferentially select the full length enzyme. There must be a
reason for this and we hypothesised that some extent of substrate channelling may
occur from the decarboxylase domain of ArnA to ArnB and back to the ArnA
formyltransferase domain. Although gel filtration experiments (2.2.4) failed to detect
the necessary complex formation between ArnA and ArnB, the limitations of this
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technique do not rule out the possibility of substrate channelling (2.3). The full length
structure of ArnA (figure 3.4.7) is very interesting as it forms a large hexameric
structure. This structure provides few insights into why full length ArnA is conserved
as no substantial interactions are provided by the formyltransferase domain in the
oligomerisation of the enzyme497. It is tempting to speculate that, if substrate
channelling provided the selection pressure for full length ArnA (2.4), the unusual
structure of ArnA may form a platform for a larger multi-enzyme complex, which
would include ArnB.
3.4.2 Decarboxylase domain ofArnA
The biochemical data presented in 3.2 and 3.3 allows us to draw important
conclusions about the ArnA decarboxylation reaction. First, decarboxylation of 4-
keto-UDP-GlcUA would appear not to occur spontaneously, but is indeed enzyme
catalysed. If the reaction was spontaneous then one would not expect mutations that
do not perturb either NAD+ or UDP-GlcUA binding, are not conserved in SDR
enzymes, or implicated in hydride transfer, to alter the reaction rate. Secondly, if
these mutants are perturbing decarboxylation one would perhaps expect accumulation
of the keto-intermediate. That this is not observed (figure 4.2.15) provides new
insights into the thermodynamics of hydride transfer.
The inactivity of E434Q and reduced activity of S433A and E434A mutants (40x
and lOOx reduction from wild-type activity respectively) (table 4.2.14), suggests that
the NAD+ dependent oxidation of UDP-GlcUA has not been decoupled from
decarboxylation leading to UDP-L-Ara40 product. It was postulated by Gaetzeva-
Topolova et al. that the E434 residue acted as a steric hindrance to prevent rotation of
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the substrate and keto-intermediate in the active site, in a mechanism similar to
GalE496. Implicit in this mechanism is that the rates of oxidation and decarboxylation
are significantly slower than rotation of the carbohydrate in the active site. The
reduced activity of the E434A mutant would, at least in part, be explicable by such a
mechanism. However the isosteric E434Q mutant would be able to block rotation of
the carbohydrate in the active site just as effectively as the wild-type enzyme. That
this mutant is inactive suggests that E434 plays a different role in the deacrboxylation
step than merely blocking rotation of the glucuronic moiety. It is possible that E434
could act as a base, ensuring deprotonation of the carboxylic acid, thus promoting
decarboxylation on formation of the 4'-keto intermediate. The residual activity of the
E434A mutant may be accounted for by water molecules filling the created void to
provide a bridge between the carboxylate of UDP-GlcUA and a second unidentified
base in ArnA. In E434Q there would be no room for a water molecule, therefore there
would be no bridge to a second base, thus decarboxylation could be inhibited. We
suggest that S433, by hydrogen bonding to the carboxylate group of the GlcUA, may






Figure 3.4.4: Potential mechanisms of the ArnA decarboxylation reaction using E345
as a base, proposed from our kinetic study'.381
Gatzeva-Topolova et al. originally implicated the ArnA residues S433 and R4519
in the decarboxylation reaction based on their superimposition of the ArnA
decarboxylase domain with E. coli GalE and because R^i9 is conserved in other UDP-
GlcUA decarboxylases (UDP-xylose synthases)496. In their more recent paper
detailing the full length ArnA structure they test their hypothesis by making several
mutations of these residues497. Encouragingly the results they obtain for the S433A
mutant are very similar to ours in that there is a 40-fold reduction in activity.
Interestingly they find that mutation of the R^ig residue also has a significant impact
on catalysis, reducing the overall activity around 400 fold compared to wild-type,
strongly implicating this residue in the ArnA decarboxylase reaction497. However,
although they use a large excess of substrate (6 mM), they do not calculate Km values
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for NAD+ or UDP-GlcUA binding497. These results led to their proposed
decarboxylase mechanism presented in figure 3.4.5, involving the deprotonation of
R<5i9. Although the pKa of the enolate would be higher than that of R^i9 (pKa -12),
deprotonation of arginine in enzyme mechanisms is rare.
Figure 3.4.5: Alternative mechanism of ArnA decarboxylation using R<si9 as an acid.
Proposed by Gatzeva-Topolova et al.497.
Along with their mutational analysis Gatzeva-Topolova et al. presented the
full length structure ofArnA, with the decarboxylase domain in complex with adenine
triphosphate (ATP) and the UDP-GlcUA substrate. This provides insights into the
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decarboxylase active site, which further confuses the mechanistic picture. In the
structure R619 is around 3.5 A from C5' (figure 3.4.6), putting it in a position where it
may play a direct role in the decarboxylation reaction. However E434 is 6.5 A from
the carboxylic acid (figure 3.4.6), suggesting a more indirect role for this residue,
which is not consistent with our E434Q mutant. In their full length structure of ArnA
the active site Y is 4.8 A from the C4' hydroxyl group. Therefore Gaetzeva-Topolova
et al. hypothesise the proton shuttle mechanism of hydride extraction468 through
T432497. However, structural studies ofHuman GalE463, SQD1471 and RmlB462'470 have
shown direct hydride extraction by the catalytic Y, consistent with mutagenesis
studies (3.1.8)460'464. It is now generally accepted that earlier crystallographic results
suggesting C4' deprotonation may occur through a shuttle mechanism466'467 were an
artifact and are inconsistent with mutagenesis460. The positioning of Y in the ArnA
active site is therefore likely to be an artifact and thus the picture of the decarboxylase
active site presented by Gatzeva-Topolova et al.A97 may not accurately represent the
true positioning of catalytic residues during the reaction. It is therefore possible that
hat although E434 is over 6 A from the carboxylic acid in the full length ArnA crystal
structure, this may not reflect its position during the decarboxylase reaction. One
reason why these distances are observed may be because ATP, a relatively poor
analogue ofNAD+ (figure 3.4.7) is bound in the crystal structure. It is possible that
the binding of the nicotinamide moiety ofNAD+ in the active site may rearrange the
positioning of these residues and such a co-complex would be desirable to get a more






Figure 3.4.6: Important active site residues of the decarboxylase domain of ArnA,
adapted from the full length structure of ArnA with the decarboxylase domain in
complex with UDP-GlcUA and ATP497. Residues are labelled with nitrogen blue,
oxygen red and carbon either yellow, light blue or grey for the UDP-GlcUA moiety,
the conserved catalytic triad or residues proposed to be important for the
decarboxylation respectively. Distances shown by dotted line are in A.
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Figure 3.4.7: Chemical structures ofATP (a) and NAD+ (b).
The second conclusion from our results, which is consistent with the data
published by Gatzeva-Topolova et al., is more subtle. If S433 and E434 are involved in
decarboxylation it would be expected that the reactions catalysed by these mutants
should transfer a hydride in the initial oxidation step. This would result in the build
up ofNADH as the 4-keto-UDP-GlcUA intermediate was produced. The same would
be true for the IC19 mutant of Gatzeva-Topolova497. Like us the assay utilised by
Gatzeva-Topolova et al. monitors NADH production, not product formation. Thus all
of the R4519, E434 and S433 mutants, which are presumed only to affect the second step
of the reaction, all affect the initial oxidation. We show that there is no accumulation
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of keto-intermediate for any of the mutants we made, suggesting a very tight coupling
of the oxidation and decarboxylation reactions. The question is why, in the stepwise
reaction of oxidative decarboxylation, does decarboxylation affect the preceding step
of hydride transfer? The answer must be that, since NADH production does not
occur, the initial hydride transfer has an unfavourable free energy. It seems that the
equilibrium for the oxidative step lies far to the substrate UDP-GlcUA than the
intermediate UDP-4-keto-GlcUA. It must therefore be the decarboxylation step,
which is effectively irreversible, that drives the reaction and serves to pull substrate to
product. When this irreversible step is abolished or significantly slowed, the hydride
remains principally on the substrate, consistent with a slower rate of NADH
production. Examining mechanisms of other carbohydrate utilising SDR's suggests
that this may be a common theme. In RmlB an irreversible step, the elimination of
water, occurs after hydride transfer from substrate470. Prior to this elimination the
reaction is reversible, with both substrate and keto sugar intermediate shown to
exist498'499. GalE oxidses and reduces its substrates without ever releasing the keto-
sugar intermediate4 6' . Thus in all three cases the equilibrium between oxidised
substrate and NAD+ is finely balanced. High resolution structure analysis and
electronic structure calculations have shown that SDR enzymes fine tune the redox
potential of NAD(P)H by distortion of the nicotinamide ring480. ArnA, RmlB and
GalE all operate on quite similar carbohydrates, GlcUA, glucose and galactose
respectively, and all three have similar active site volumes. Thus, by poising the
equilibrium of hydride transfer towards substrate such that only a second irreversible
step will create flux through the pathway, a subtle substrate specificity can be created
by the second irreversible step. The structure of ArnA does not reveal any reason
why UDP-Glc should not bind; it is slightly smaller than UDP-GlcUA. The presence
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of E434 and S433 in ArnA would prevent catalysis of the dehydration of UDP-Glc,
since the proton source required for water elimination is absent. By ensuring in
ArnA, that the equilibrium for the first oxidation reaction favours substrate,
accumulation of reactive and undesired 4'-keto sugars closely related in structure to
the true substrate are prevented. This may well be a general feature of these very
similar SDR enzymes.
3.4.3 Apo vs complexed ArnA decarboxylase
Figure 3.4.7: Overall structure of the full length ArnA hexamer. One monomer is
labeled with red a-helices and purple P-sheets, another has the decarboxylase domain
coloured in slate and formyltransferase domain coloured in raspberry. Cyan, orange,
yellow and green are used to individually colour the both the decarboxylase and
formyltransferase domains of the other 4 monomers. Adapted from Gaetzeva-
Topolova et al491.
As the full length ArnA structure published by Gatzeva et al. is a co-complex with




Full length ArnA crystallises as a hexamer and this multimeric form of ArnA
is confirmed by gel filtration and multiangle light scattering analysis497. The structure
is effectively a dimer of trimers and the hexamer adopts the shape of a three-blade
propeller with dimensions of 162 x 87 A. The core of the structure is made up of the
C-terminal decarboxylase domains, with the N-terminal formyltransferase domains
sticking out on the periphery. The majority of the interactions between the individual
components are contributed by the decarboxylase domain which, from observation of
B-factors, is more rigid than the formyltransferase domains497. The major contacts
between the subunits of each trimer are mediated by hydrogen bonding and
electrostatic interactions; these include salt bridging between K381 and K382 with D368
and E366 in adjacent protomers and hydrogen bonding between E374 with S373 and E374.
The dimerisation of each trimer occurs across a hydrophobic surface made up by
residues 448-456 of adjacent trimers and results in the formation of a two stranded
antiparallel P-sheet. A 4-helix bundle also forms between neighbouring protomers,
formed by residues 401-423 and 460-480. A few interactions are also contributed by
the formyltransferase domain, but these are relatively minimal497.
Comparison of the apo and complexed ArnA decarboxylase structures reveals
several key differences. Most strikingly a loop, residues 500-509, that appears to
block the NAD' binding pocket in the apo structure, has undergone a large
conformational change, with I505, in the middle of the loop, being displaced by 17.5
A. Interestingly in the complexed form of the enzyme this loop takes on the form of a
short a-helix positioned over UDP-GlcUA, trapping the substrate in its binding
pocket. This suggests an ordered sequential mechanism of substrate binding, with
UDP-GlcUA binding first and NAD+ subsequently binding. That the ArnA reaction
does not reutilise the NADH formed in a subsequent reduction step is unusual for
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such SDR enzymes. Gatzeva-Topolova et al. suggest that after the initial hydride
transfer NADH may dissociate, with the helix trapping UDP-GlcUA keeping it bound
to the enzyme, explaining why NADH is not utilised to reduce the ketone product.
However such a mechanism would perhaps suggest the decoupling of the oxidation
and decarboxylation steps, inconsistent with the biochemical data. In RmlB462'470 and
GalE467 the further reduction by NADH relies on the rotation of the substrate
carbohydrate moiety in the active site. It may be that in ArnA such a rotation cannot
occur and this may be the reason why NADH is not further utilised.
Additional conformational changes also contribute to substrate binding. A
loop, residues 605-616, becomes ordered upon UDP-GlcUA and ATP binding,
making several contacts to the uracil group of UDP-GlcUA497. There is also a small
hinge-like motion of the overall enzyme between the substrate and NAD+ binding
functional sub-domains of the decarboxylase enzyme. This causes the enzyme to
close in slightly around both UDP-GlcUA and ATP497.
3.5 Future work
This study has provided insights into the decarboxylase reaction catalysed by ArnA,
however the results of Gatzeva-Topolova et al. leave unanswered questions. Further
structural and mutational studies are required to determine whether the mechanism of
decarboxylation catalysed by ArnA involves E434 or IU19. The catalytic tyrosine is ~5
A from the C4' position and therefore unable to directly extract a proton. This
suggests that the active site presented by Gatzeva-Topolova et al. is different to that
formed during the oxidative decarboxylation reaction of ArnA. It is therefore
important to get a co-complex of ArnA decarboxylase with both UDP-L-Ara4N and
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NADr bound, to give a more accurate representation of the active site. Mutational
analysis of the catalytic triad, particularly the tyrosine and threonine, will also be
important to confirm that the ArnA reaction proceeds via direct proton extraction by
tyrosine.
As the functions of both the decarboxylase and formyltransferase domains are
essential for the resistance of several pathogens to cationic antimicrobial peptides,
their structural solution provides two templates for structure-based drug design. The
robust assays that exist for both the decarboxylase (presented here) and formyltransfer
reactions376'495, will be important for validation of any potential inhibitors.
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Chapter 4
Structural studies of heterotrimeric PCNA from
Sulfolobus solfataricus:
Structural solution of a heterotrimeric sliding clamp and






Figure 4.1.1: Initiation of DNA replication, (a) The clamp loader recognises the
ds/ssDNA junction and (b) uses ATP to load the sliding clamp, (c) The sliding clamp
recruits the replicative DNA polymerase and processive replication can occur. Taken
from Bruck and O'Donnell500
The replicative DNA polymerase III (PolIII) holoenzyme from E. coli is capable of
non-disociative replication of long stretches of DNA at an astonishing rate of over
750 bases per second501"504. A similar processivity is found for the archaeal and
eukaryotic replicative polymerase holoenzymes, PolB504 and Pol8 or s (Pol5 or s)505
respectively. This processivity is achieved due to the activity of two associated
proteins that are part of the holoenzyme, the sliding clamp and clamp loader506"508.
The clamp loader utilises ATP to load the sliding clamp onto a primed section of
DNA508 and the clamp interacts with the core DNA polymerase tethering it to DNA,
resulting in processive replication504 that continues after the removal of the clamp
loader (figure 4.1.1)509. In prokaryotes the (3-subunit of the PolIII holoenzyme acts as
the sliding clamp506'507'509 and it is the proliferating cell nuclear antigen (PCNA)510 in
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archaea505 and eukarya83'511"513. PCNA was discovered over 25 years ago510'514 and its
name derives from its essential role in cellular proliferation510.
In E. coli the P-subunit clamp is also essential for lagging strand synthesis,
where PolIII is passed from one P-subunit to the next at newly primed Okazaki
fragments506'515. Biochemical studies show that both the P-subunit509 and PCNA516
can be cross-linked to circular duplex DNA in vitro but, upon linearisation, this
association is not seen509'516. The reconstitution of DNA replication in vitro also
shows that PCNA can initiate processive replication without the aid of a clamp loader
on a linearised template516. These studies suggested a mechanism for the sliding
clamp in which it non-specifically encircles DNA and can freely slide in either
direction along the duplex509. The structure of the P-subunit was solved in 1992517
and, consistent with the biochemical data509'516, it forms a 'donut' or toroidal
structure, with a central hole big enough to accommodate the B and A forms of
DNA517 that are found during replication518. The P-subunit forms a head to tail dimer
with each monomer consisting of three globular domains. These domains are
structurally almost identical, despite low sequence identity of less than 15 %517. Each
domain consists of two anti-parallel a-helices flanked by two, four stranded P-sheets,
with the 12 a-helices and 12 P-sheets in the dimer lining the inner and outer surface of
the toroidal structure respectively517. The p-subunit has an overall negative charge.
However, more locally, the surface that lines the central cavity is electrostatically
positive suggesting, consistent with biochemical studies509'516'517, that DNA passes
through the centre of the sliding clamp. Further structural features also suggest this
method of DNA binding517 and it is thought that the P-subunit only interacts with
DNA through non-specific interactions, mediated mainly by water molecules517.
Several electrostatic, as well as hydrophobic and hydrogen bond, interactions
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contribute to the dimer interface and results in the formation of a very stable (3-
subunit517. It is this stability of the dimer that results in the requirement of an ATP
dependent accessory protein, the five subunit y-complex to load the P-subunit onto
DNA519. Structural studies suggest that the y-complex acts as a molecular wrench,
forcing the dimer apart at one of the interfaces, allowing P-clamp loading to DNA519.
Eukarya and archaea have evolved the use of a trimeric sliding clamp in
replication506'520, with each PCNA monomer approximately two thirds of the
molecular weight of the p-subunit monomers (-28 as opposed to -40 kDa)509. These
observations led to the prediction that the PCNA trimer also consists of 6 structural
domains that, despite the lack of sequence conservation, are structurally similar to
those of the P-subunit517. The structural solution of the PCNA sliding clamp in S.
SOI soo so^
cerevisiaea , humans and archaea as well as the bacteriophage T4 sliding
clamp gene45 protein524 showed this to be the case, with a remarkable conservation of
topology between sliding clamps conserved right the way through evolution. This
structural conservation is depicted in the superimposition of the P-subunit and S.
cerivisiae PCNA (figure 4.1.2). The structural features suggesting non-specific
encircling ofDNA for the P-subunit are conserved in PCNA. The major differences
between the structures of these two sliding clamps are the subunit interfaces, with
PCNA utilising more hydrophobic, rather than electrostatic, interactions and extra
loop regions that are present in PCNA. It is these loop regions that have been shown
both biochemically (see table 4.1.2) and structurally522'525 to be important in
mediating protein-protein interactions. Indeed eukaryotic PCNA is found to have
many more interactions with other cellular proteins than the P-subunit sliding clamp,
which is exclusively involved in replication. This suggests PCNA has diverse cellular
roles, with some of the known partners shown in table 4.1.2..
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Figure 4.1.2: Structural superimposition (c) of the dimeric j3-subunit517 from E. coli
(PDB code: 2POL)517 (a) and trimeric PCNA from S. cerivisiaea (PDB code:
521 •
1PLQ) (b). Monomers are coloured differently. Despite the lack of sequence
conservation and different oligomeric states the two structures superimpose
remarkably well. Superimpositions were carried out in COOT490.
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4.1.2 PCNA interactions:




















RPA IDL N-ter 530
Lagging strand synthesis
DNA ligase I Stimulation of ligase IDL N-ter 531,532




Promotes chromatin assembly IDL N-ter 534,535
DNA cytosine-
methyltransferase (MeCTr)









DNA repair and recombination
Apurinic/apyrimidinic
endonuclease 1 and 2
(APN1, APN2)
Stimulates APE1 and 2





Poip, X, q, K, t





Growth arrest and DNA
damage (Gadd45)





Role in mismatch repair IDL NK
547
MutS homologue 2, 3 and
6 (MSH2, 3 and 6)
Role in MMR IDL N-ter 548,549
Radiation sensitive mutant











Role in BER N-ter 550
Xeroderma pigmentosum
G (XPG)
Essential for NER IDL C-ter 151
Regulatory proteins
P21 Cell cycle control: inhibition
of PCNA dependent DNA
replication
IDL N-ter 522,551
P300 Facilitation ofPCNA function
in DNA repair
C-ter NK 552
Cyclin D Cell cycle control: inhibits cell
growth
N- and C-ter NK 553,554
Cyclin dependent kinases
(CDK))




IDL* represents the interdomain linker region of PCNA
156
Table 4.1.3 (above): Some of the diverse range of proteins that have been shown to
interact with PCNA from eukaryotes, adapted from Vivona and Kelman556 and Maga
557and Hiibscher
The range of proteins shown to interact with PCNA in eukaryotes link PCNA into
• *ii* • • 83 512 513 526almost all forms of DNA maintenance including; replication ' ' ' ,
repair151'211'542, the DNA damage response522'551, chromatin remodelling534"537, as well
as apoptosis546'558 and cell cycle progression551'554'559.
PCNA is essential for leading and lagging strand synthesis560 and the addition
of antisense PCNA oligonucleotides stops both DNA synthesis and cellular
progression561'562. In addition to its role in tethering the replicative polymerase to
DNA, PCNA is a central coordinator for the processing of Okazaki fragments on the
lagging strand563'564. In this process PCNA coordinates the sequential actions ofPolS,
flap endonuclease 1 (FEN1) and DNA ligase I (figure 4.1.4)563"565.
Figure 4.1.4: PCNA's role in coordinating the sequential actions of PolS, FEN1 and
DNA ligase I during Okazaki fragment maturation in eukaryotes. In the rotary
handoff mechanism PCNA coordinates the switch from (a) PolS to (b) FEN1 and
finally (c) DNA ligase I. Adapted from Chapados et al.566.
During replication DNA needs to be relaxed and then re-compacted
following passage of the replication fork, a process carried out by the chromatin
remodelling machinery (reviewed in567). PCNA is implicated in the re-compaction
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step due to its interactions with several proteins involved in chromatin remodelling
and inheritance including DNA cytosine 5-methyltransferase (MCMT)536 and
chromatin assembly factor 1 (CAF1)534'5 . MCMT specifically recognises
hemimethylated DNA and is essential for the inheritance of the methylation pattern of
DNA568'569. CAF1 is a molecular chaperone that loads H3 and H4 histones onto
newly synthesised DNA, marking the new strand for chromatin assembly535. Some
PCNA molecules are left behind on newly synthesised DNA and it is thought that
these act as a topological marker, allowing methylation inheritance and chromatin
co *7 cOA
assembly (figure 4.1.5) ' In addition to its role in mediating chromatin
remodelling following DNA replication, PCNA is also thought to remodel chromatin
during DNA repair, allowing access of the repair machinery to the site of damage. In
this role the interaction of PCNA with p300, part of chromatin remodelling
• 552 557
machinery, is thought to be important ' .
PCNA is an important accessory protein for many DNA repair enzymes and is
involved in almost all forms of repair (reviewed in Maga and Hubscher557). Its major
role is in mediating the DNA resynthesis that is required for BER542, NER123,
MMR548,549,570,571^ double strand break repair572 and replication repair involving lesion
bypass237'543'544 (1.3). In addition to mediating resynthesis, PCNA is also thought to
be involved in early events of DNA repair. For example in NER PCNA has been
shown to co-localise on DNA with XPA in vivo, implicating PCNA in early NER
events573'574. PCNA also forms a complex with the XPG endonuclease enzyme151, an
interaction that is unlikely to result in resynthesis but may important for NER
efficiency151'575. Also during MMR PCNA has been shown to interact with and
increase the mismatch binding specificity of the MSH2, MSH3 and MSH6
proteins548'571. Further, a PCNA-MSH2-MSH6 complex is found to be stable on
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newly synthesised DNA, with the MSH2-MSH6 complex actively transferred to
mismatched bases570. This further suggests PCNA can act as a topological marker for
DNA, as thought to be important for MCMT and CAF1 interactions, allowing newly
synthesised DNA to be scanned for mismatches (figure 4.1.5).
PCNA is also involved in cell-cycle control through interactions with
p2i522,551^ cyclic553'554 ancj CyCiin dependent kinases (CDKs)576. The PCNA CDK2-
cyclinA complex bridges to other proteins which can then be phosphorylated576. This
may be an essential mechanism for the control of the replication fork.
Figure 4.1.5: Stereo view of the human PCNA-FEN1 complex, adapted from Sakuri
et al. (PDB code: 1UL1)525. PCNA is coloured in red with the FEN1 subunits
coloured magenta, green and orange. The C-terminal of each FEN1 subunit is
coloured in blue and this is the PIP motif that superimposes well with the p21 PIP
peptide solved in complex with human PCNA522, which previously provided the basis











Figure 4.1.5: Schematic of PCNA's role in post-replication events, mediating
chromatin remodelling and mismatch repair. For simplicity only lagging strand
synthesis is shown (dotted line represents the lagging strand), (a) PCNA is left on
DNA following replication (new, unmethylated strand coloured red), (b) This PCNA
recruits mismatch repair proteins and proteins involved in chromatin inheritance, (c)
mis-matches are repaired and DNA packaged back into its chromatin state.
4.1.3 PCNA control
An important question is how are the vast numbers of interactions that can occur with
PCNA controlled within the cell? p21 is a key cell cycle control protein and plays a
major role. Under normal cellular conditions p21 is expressed at low levels during S-
phase of the cell cycle, a time where PCNA levels are high and localise with
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replication foci522. Upon initiation of the DNA damage response the cellular levels of
577 578 557 57Q
p21 increases in both p53 dependent" ' and independent ' pathways. This
upregulation results in the co-localisation of p21 with PCNA, inhibiting DNA
replication580. Importantly, although an inhibition to replication, p21 levels do not
inhibit PCNA's function in DNA repair580'581. Thus initiation of DNA damage
checkpoints resulting in p21 upregulation directs PCNA away from its role in
replication, prolonging S-phase, giving the cell more time to complete DNA repair
before replication proceeds522.
p21 contains the same PCNA interaction motif as the replicative polymerase,
FEN1 and DNA ligase I and is thought to inhibit replication by out-competing these
enzymes for the same PCNA binding site582. The structural solution of the C-terminal
peptide of p21 in complex with PCNA522, shows this site to be the interdomain linker
region of PCNA (figure 4.1.5). This region is responsible for the majority of
interactions made by PCNA (table 4.1.3), however the N- and C-terminal regions are
also known to bind other proteins such as cyclin D553 and GADD45546 respectively.
That p21 does not inhibit PCNA's role in DNA repair suggests that its recruitment to
repair pathways relies on interaction away from the IDL of PCNA. However the
situation within the cell cannot be as simple as that since a major part of PCNA's
function in DNA repair is the resynthesis step, involving the replicative polymerase.
Presumably at some point during the repair process p21 must dissociate or be
removed to allow this resynthesis step to occur.
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4.1.4 DNA repair in the archaea
Bacteria Archaea Eukarya
Crenarchaea Euryarchaea
* Last universal common ancestor
Figure 4.1.6: The tree of life, showing that the last common ancestor between
archaea and eukaryotes was more recent than either to bacteria, adapted from
White583.
The separation of cellular life into three domains; bacteria; archaea and eukarya, was
i • 584
first proposed by Woese in 1977, based on rRNA sequence divergences . tRNA
sequence differences585 and biochemical studies585'586 further validated this three-
domains of life theory. Since then a large amount of phylogenetic research587 has
provided evidence that archaea and eukarya share a more recent common ancestor
than either does to bacteria588'589, as depicted in figure 4.1.6. Archaea can further be
divided into euryarchaea and crenarchaea587. Euryarchaea includes methanogens,
sulphate-reducing species and extreme halophiles. Crenarchaea includes acidophiles,
extreme thermophiles and sulphate dependent archaea, originally classified due to
their entirely thermophilic niches587. As many archaea can survive at high
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temperatures it may suggest that the common ancestor between eury- and crenarchaea
was thermophilic in nature.
The close phylogenetic relationship between archaea and eukarya is
particularly striking for the nucleic acid metabolism pathways of translation " ,
transcription591"593 and replication594'595. Similarities between DNA repair pathways
were thought to be less. However evidence is emerging that these processes may be
more closely related583.
HR double strand break repair is conserved throughout the three domains of
life, driven by the homologous recombinases RecA596, RadA597 and Rad51598 in
bacteria, archaea and eukarya respectively. Closer similarity of RadA to Rad51599,
along with archaeal homologues of the eukaryotic Rad50/Mrell proteins600, suggests
that HR-double strand break repair is more similar to the eukaryotic equivalent601.
The enzymes involved in BER are conserved throughout all three domains of life,
centred around DNA glycosylases that have specialised to remove specific DNA
lesions602. The MMR process is more puzzling as, although homologues of the
proteins involved are conserved between bacteria and eukaryotes, they are not present
in archaea583, suggesting that novel mechanisms may have evolved in archaea to deal
with this type of damage. NER in archaea has been subject to the greatest debate in
this field, with both prokaryotic and eukaryotic NER protein homologues found in
i 583,603
some archaea
The ability of archaea to carry out NER was first demonstrated in
Methanothermobacter thermoautotrophicus604 and shown to have a similar excision
fragment to prokaryotes. Genomic analysis ofM. thermoautotrophicum603, reveals
that they have a set of bacterial Uvr enzymes (1.3.6), as do a select group of other
archaea including mesophilic methagens and halophiles583. However the majority of
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archaea, including all crenarchaea, lack Uvr enzymes but instead have orthologues of
the eukaryotic NER enzymes XPF, XPG, XPD and XPB (1.3), which are also present
in some archaea that have Uvr enzymes583. It is now widely thought that the Uvr
enzymes have been obtained from bacteria by horizontal gene transfer and that the
original NER pathway in archaea was eukaryal in nature583. It is interesting to note
the absence of any obvious homologues of the eukaryal NER DNA damage
recognition proteins XPA, XPC and XPE602 The published genome of the primitive
eukaryote Plasmodium falciparum605 also lacks such homologues and S. cerevisiae
lacks XPE, with the heterodimer Rad7-Radl6, along with the XPC homologue Rad4,
providing the DNA damage recognition step103. This suggests that these DNA
damage recognition proteins may have evolved in eukaryotes583 and that other DNA
damage sensing proteins may exist in archaea.
No patch repair, characteristic of prokaryotic and eukaryotic NER, has been
detected in archaea lacking Uvr homologues. However the ability of the model
archaean S. solfataricus (lacking Uvr enzymes) to repair the UV induced lesions
CPDs and 6-4 PPs in the dark has been shown in vivo606, suggesting a form ofNER
exists. Analysis of the S. solfolobus transcriptional response to UV damage, reveals
that XPF, XPB and XPG are upregulated606. XPF and XPG are also upregulated after
exposure to actinomycin D, an inter-collating agent that also inhibits transcription,
although the XPB level is unaffected606. This implicates these enzymes in the damage
response. However the varying degrees of upregulation suggests diverse roles of
these proteins, for example XPB in transcription, XPG in Okazaki fragment
maturation and XPF in recombination606.
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4.1.5 Archaeal PCNA
PCNA but not P-subunit homologues exist in archaea, sharing approximately 20-30 %
sequence identity with eukaryotic PCNA607. The sequenced genomes of euryarchaea
all contain one copy of PCNA, shown to form a homotrimer523. In the crenarchaea
the situation is more complicated with two homologues existing in Pyrobaculum
/AO /Aq fOA
aerophilium and three homologues in Aeropyrum pernix S. tokodaii , and S.
solfataricus601. While it has been shown that in A. pernix PCNA can exist as both
homo- and heterotrimers609, S. solfataricus only forms a PCNA1, PCNA2 and
PCNA3 heterotrimer 607.
Protein Effects of interaction
with PCNA
Interaction detection method References
DNA replication
Elongation
DNA polymerase B Stimulation of
polymerase activity
Co-IP, in vitro functional assays,
yeast-2-hybrid, GST pulldown
607,610,611
DNA polymerase D Stimulation of
polymerase activity
Co-IP, in vitro functional assays 610,611
RFC Loading of PCNA onto
DNA




DNA ligase Ligase stimulation GST-pulldown
607
FEN1/XPG FEN-1 stimulation GST-pulldown, yeast-2-hybrid, in
vitro functional assay
607,613,614
RNase HII RNase HII stimulation Yeast-2-hybrid
610
DNA repair and recombination








FEN1/XPG Stimulation ofFEN 1
endouclease
in vitro functional assays
607,613,614
XPF XPF stimulation in vitro functional assays, GST-
pulldown
601
Table 4.1.7: Known PCNA interaction proteins in archaea, adapted from Vivona and
Kelman 2003 556.
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The formation of the S. solfataricus PCNA heterotrimer (SsoPCNA) first
requires the heterodimerisation ofPCNA1 and PCNA2, which form a stable complex
with a Kd of 1.2 X 10"11 M607. This heterodimer, but not the PCNA1 or PCNA2
monomers, can then interact with PCNA3 forming a complex with a Kd of 2.7 X 10"7
cryi
M° . No homotrimer formation is observed for any individual PCNA subunit
This heterotrimer is functional in DNA replication607 and repair607'616 and has been
shown to make important interactions with some of the proteins shown in table
4.1.7601.
The heterotrimeric nature of SsoPCNA suggests that the 3 individual subunits
will be able to make subunit specific interactions and this hypothesis was tested by
Bell and co-workers in the original paper describing the heterotrimer607. They found
strong interactions between PCNA1 and FEN1, PCNA2 and PolB and PCNA3 with
DNA ligase, they also showed that the PCNA heterotrimer could simultaneously bind
these enzymes607. These results suggest that in some archaea the machinery involved
in Okazaki fragment maturation563'564 may assemble with heterotrimeric PCNA
forming a functional machine. The observation that XsoPCNA can bind uracil DNA
glycosylase (UDGl) through PCNA3 suggests that a similar machine may also form
during processive replication to scan newly synthesised DNA for uracil
incorporation616. It is unlikely that such an interaction is important for a global form
of BER by UDGl in vivo as, in the presence of archaeal chromatin-like binding
proteins, the PCNA-UDG1 activity is strongly repressed616.
The archaeal clamp loader (RFC) consists of one large subunit (RFC-1) and a
homotetrameric small subunit (RFC-s)612'617. The interactions formed between
XsoPCNA and RFC are also subunit specific, with PCNA3 interacting with RFC-1 and
only the PCNA1-PCNA2 heterodimer interacting with RFC-s607. This suggests a
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mechanism of loading where either RFC-1 pulls PCNA3 away from the PCNA1-
PCNA2 heterodimer or the RFC-1 and RFC-s subunits bind their partners and keep the




Figure 4.1.8: Cartoon representation of the possible mechanism for the loading of
XsoPCNA onto DNA. (a and b) RFC pulls or keeps PCNA3 apart from the PCNA1-
PCNA2 heterodimer and recognises the ds/ssDNA junction, (c) The heterotrimeric
clamp is loaded onto DNA in an ATP dependent reaction, (d) PCNA can then recruit
interacting proteins to DNA.
SsoPCNA also interacts with S. solfataricus XPF (Xs'oXPF)601, which was
unexpected as this interaction is not conserved in euryarchaea or eukaryotes, unlike
the XPG-PCNA interaction151' . This interaction is dependent on the extreme C-
terminus of XsoXPF and is essential for the endonuclease activities observed for
XsoXPF601'618'619. GST-fusion pull-down experiments show that XsoXPF specifically
interacts with XsoPCNA through the PCNA1 and PCNA3 subunits601.
A heterotrimeric sliding clamp also exists in eukarya, although this clamp does
not function in replication but is specialised to the DNA damage response
(4 1 6)62°,621
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4.1.6 The 9-1-1 complex
The 9-1-1 heterotrimeric complex consists of the eukaryotic proteins that are
homologous to the Schizosaccharomycespombe proteins Rad9, Radl and Husl620'621.
Structural modelling techniques predicted that, despite limited sequence conservation,
all three proteins had a PCNA-like fold, suggesting that this heterotrimer formed a
sliding clamp called the 9-1-1 complex62 '621. This is supported by biochemical
evidence622 and transmission electron microscopy show that the 9-1-1 complex forms
a ring-like structure which is indistinguishable from that ofPCNA623.
In response to DNA damage the damage checkpoint is activated, resulting in
the arrest of the cell cycle and activation ofDNA repair pathways624'625 as well as a
variety of other DNA metabolic functions626 and apoptosis (figure 4.1.9)627'628. This
checkpoint coordinates the repair process and gives the cell time to repair its genome.
The proteins that sense the DNA damage have yet to be identified although the 9-1-1
• 626
complex, along with Radl7, are all implicated in these early events . Radl7 shares
homology with the 5 subunits of RFC and can interact with the 4 RFC-s subunits629.
Radl7 can bind to chromatin, an association that is greatly up-regulated in response to
DNA damage626'630. It can also interact with the 9-1-1 complex, which is essential for
the recruitment of this complex to chromatin62 , suggesting that it functions as a
clamp loader for the 9-1-1 complex631'632
Sensing of DNA damage results in the activation of the ATM and ATR
kinases, which phosphorylate a variety of substrates involved in the damage
cyi'i P.'Xr)
response ' including, in a 9-1-1 complex dependent manner, Radl7 and the
Chkl and Chk2 kinases629. This has led to the hypothesis that the 9-1-1 complex acts
as a central mediator of these early events632, bridging interactions between the ATR
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and ATM kinases and their substrates, reminiscent of PCNA's role in cell cycle
control (4.1.2).
Cell cycle ► Apoptosis -4 Transcription ► DNA repair
arrest
Figure 4.1.9: Initial DNA damage response events mediated by the Rad9-Radl-Husl
sliding clamp. Adapted from Zhou134.
4.1.7 XPF homologues
Figure 4.1.10 shows the domain architecture and oligomeric nature of XPF
orthologues from crenarchaea, euryarchaea and eukarya. Crenarchaeal XPF has an N-
terminal nuclease domain and two consecutive C-terminal helix-hairpin-helix (HhH)
domains (XPF(HhH)2), separated by an 11 amino acid linker601'634. Each of the HhH
domains contains two consecutive HhH motifs601'634. The crenarchaeal XPF has a
PCNA interaction motif at its C-terminus and its interaction with S. solfataricus
169
heterotrimeric PCNA is essential for its nuclease activity, but not its DNA
binding601'634
Euryarchaea have an extra N-terminal domain that shows sequence similarity
to DNA helicases and indeed possesses DNA dependent ATPase activity635. The C-
terminal nuclease and XPF(HhH)2 domain is conserved between cren- and
euryarchaea601. However euryarchaea lack the C-terminal PCNA interaction motif,
suggesting that the fusion of a helicase with XPF nuclease during evolution dispensed
with the PCNA dependence of the XPF nuclease activity601.
Eukaryotic PCNA is similar in domain architecture to euryarchaea, however
the sequence of the N-terminal DNA helicase domain has diverged such that it is no
longer active636. Unlike archaeal XPF, which forms a functional homodimer,
eukaryotic XPF forms a heterodimer with the ERCC1 protein148, which acts as a
bridge in the NER pathway by interacting with RPA135'637. ERCC1 is distantly related
to XPF, containing the nuclease and HhH2 domains, although the nuclease activity has
been lost638. The conservation of these domains suggests that during the evolution of
eukaryotes the nuclease and HhH2 domains of XPF have duplicated and the product
diverged to evolve the ERCC1 protein583. A similar process has also occurred to
evolve another eukaryotic XPF homologue, Mus81, which forms a functional
heterodimer with either Emel/Mms4639 or cdsl640'641. A major difference between the
domain architecture of Mus81 and other XPF nuclease domains is that instead of
having the two HhH motifs at its C-terminus, Mus81 is flanked by single HhH motifs
(figure 4.1.1 Od)634.
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Figure 4.1.10:Functional XPF from crenarchaea (a), euryarchaea (b) eukaryotes (c)
and the XPF homologue Mus81-Emel (d). Domains are coloured as labelled for
cren- or euryarchaea and non-functional domains are coloured a shade darker. PCNA
is shown bound to XPF in crenarchaea as it is essential for it activity601. Adapted
from Roberts el a/.601 and Newman el al 634.
XPF homologues have been the subject of extensive biochemical studies
including the XPF-ERCC1148, Mus81639'640 and S. solfataricus XPF enzymes601'618'619.
XPF-ERCC1 endonuclease activity relies on both the structure and sequence of its
DNA substrate. It cleaves 3' to a pyrimidine nucleotide14 , upstream of a ds/ssDNA
junction where the ssDNA leaves in a 5'-3' direction, such as the DNA structure
formed 5' to DNA damage during NER148'642. Mus81 shows no sequence specificity
for its DNA substrate and is most active on 3' flaps with both upstream and
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downstream duplex present and DNA junctions, which are formed from the
processing of stalled replication forks639"641. There appears to be no overlap in the
substrate specificity of XPF-ERCC1 and Mus81, with each enzyme evolved to
specifically process different DNA junctions that occur within the cell.
S. solfataricus XPF (Xs'oXPF) shows similar sequence specificity for its DNA
substrate as XPF-ERCC1 and it can also cleave a splayed duplex (figure 4.1.11), the
XPF-ERCC1 DNA substrate601. Further kinetic analysis of the substrate specificity of
AsoXPF demonstrates that it is more active on Mus81-like substrates, particularly 3'
flaps, nicked duplexes, 3- and 4-way junctions619. These results suggest that
crenarchaeal XPF is an ancient form of both XPF-ERCC1 and Mus81, sharing
features of both enzymes. The recent structural solution ofXPF from the crenarchaea
A. pernix, which is closely related to S. solfataricus634, both in complex and in the
absence of DNA provides insights into how crenarchaeal XPF recognises its DNA
substrates and the evolution of the XPF family of endonucleases.
a b
Figure 4.1.11: Substrates cleaved most efficiently by the eukaryotic XPF
homologues XPF-ERCC1 (a) and Mus81 (b). XsoXPF can cleave both junctions;




Figure 4.1.12: Stereo views of (a) the superimposition of apo-XPF from A. pernix
(green) with the ERCC1 nuclease domain (yellow) and XPF (red) - ERCC1 (blue)
HhH2 domains, (b) DNA-complexed XPF from A. pernix. One monomer is coloured
in red and the other in blue, the picture is orientated with the XPF(HhH)2 and nuclease
domains at the top and bottom of the picture respectively. The compaction of the






Attempts to structurally characterise eukaryotic XPF homologues have been
hampered due to instability of the enzyme, although structures of both the ERCC1
nuclease domain and HhH2 domains of the XPF-ERCC1 heterodimer643 have recently
been reported. Archaeal XPF has therefore been a useful model for structural studies
(figure 4.1.12, 4.1.13). The structures of the nuclease domain of XPF from
Pyrococcus furiosus 44 and both apo- and DNA complexed, essentially full length
XPF from the crenarchaean Aeropyru. pernix634 (figure 4.1.12) have been published.
These structures, particularly of A. pernix XPF, provide insights into the DNA-
structure specificity of these enzymes634.
The A. pernix XPF-DNA complex is with a duplex of DNA which is not a
substrate. Upon DNA binding one of the protomers folds up, with the XPF(HhH)2
domains moving 30 A (figure 4.1.12), interacting with DNA and the nuclease
domain634. The authors commented on a two-fold axis between the XPF(HhH)2
domains of the dimer, suggesting that there is the potential for a DNA duplex to bind
to the XPF(FIhH)2 domain of the extended protomer634. Modelling of this second
DNA duplex positions the 5' end into the nuclease active site of the extended
protomer, with an angle of approximately 90° between the modelled and complexed
duplexes (figure 4.1.13). The authors hypothesise that the duplex DNA bound in the
structure represents the downstream duplex of an XPF substrate. There is a
hydrophobic cleft adjacent to this duplex DNA which is thought to bind the short
region of ssDNA produced by XPF cleavage634.
The separate structures of the nuclease and HhH2 domains of human ERCC1
show that the fold is the same as archaeal XPF (figure 4.1.12)643. Based on these
structures and biochemical observations the authors propose a model for XPF-ERCC1
binding to a splayed duplex in which the ssDNA arm leaving in a 3'-5' direction is
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bound by both the nuclease and HhFk domain of ERCC1, with the other arm bound
by the XPF(HhH)2 domain (figure 4.1.13)643. In this model the nuclease domain of
XPF binds the ds/ssDNA junction where the ssDNA leaves in a 5'-3' direction, where
it makes its incision643. This model is in contrast with that proposed by Newman et
al. who drew analogies from their XPF structures from A. pernix. In this model they
suggest that the extended protomer represents ERCC1, with the HhH2 domain
proposed to bind the upstream dsDNA, with XPF(HhH)2 binding the downstream
ssDNA634.
Although these models of archaeal XPF and XPF-ERCC1 substrate
recognition are attractive they are not conclusive. Further characterisation of XPF
from crenarchaea, both in complexes with DNA and with PCNA, is therefore



















Figure 4.1.13: Models of substrate binding by XPF homologues. (a) XPF from the
crenarchaean A. pernix, taken from Newman et al.634. (b) Human XPF-ERCC1, taken
from Tsodikov et al643.
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4.2 MATERIALS AND METHODS
4.2.1 Over-expression of PCNA1, PCNA2, PCNA3 and XPF(HhH)2
IPTG induction (for tagged and untagged constructs)
Table 4.2.1 details the PCNA and XPF constructs we received from our collaborators
in St Andrews. Soluble protein was over-expressed from all constructs using the
same conditions. E. coli Rosetta (DE3) cells, a BL21 (DE3) derivative which
contains a plasmid (pRARE) containing the 6 rare codons tRNAs for the codons
AGG, AGA, AUA, CUA, CCC, and GGA, were transformed with plasmid DNA
encoding the relevant protein to be over-expressed. The Rosetta (DE3) cell line
enhances the the expression of genes in E. coli that contain codons not commonly
found in E. coli. Single colonies were grown in 10 ml LB overnight, supplemented
with 50 pgml"1 kanamycin or 100 pgmf1 ampicillin for tagged and untagged
constructs respectively. Overnight cultures were used to inoculate 500 ml ofLB in 2 1
flasks and grown to an ODeoo of 0.8-1.0 at 37 °C. The temperature was then reduced
to 25 °C and protein over-expression was achieved by overnight induction with 0.2
mM IPTG.
Auto-induction (for tagged constructs)
1 ml of a 10 ml overnight, grown as above, was used to inoculate 50 ml of LB and
cells were harvested, after overnight incubation at 37 °C, at 2000 g and re-suspended
in 20 ml PBS. This was then used to inoculate auto-induction medium for over-
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expression of protein, as detailed by Studier645. Briefly, 400 ml of auto-induction
growth medium in a 2 1 baffled flask, supplemented with 100 pgml"1 kanamycin, was
inoculated with 5 ml re-suspended cells and grown at 37 °C, with shaking at 300
r.p.m, for 6 hours to start bacterial growth. The temperature was then lowered to 20
°C and left for 72 hours, allowing bacterial growth to reach saturation and the
subsequent self-induction of protein expression645.















Ncol / BamHI Kanamycin M] - L249
PCNA2
(SSO1047)





Ncol / BamHI Kanamycin MI - D246
PCNA3
(SS00405)
















Kanamycin Ml 50 - L233
Table 4.2.1: Constructs of the PCNA and XPF(HhH)2 genes obtained from out
collaborators Jana Rudolph and Professor Malcolm White in St Andrews. In brackets
are the gene annotations from the S. solfataricus genome.
Cells grown by either technique were harvested at 10500 g and were re-
suspended in 50 mM HEPES pH 7.5, 10 mM imidazole and 300 mM NaCl (His-
tagged) or 50 mM MES pH 5.7 and 50 mM NaCl (untagged). Soluble proteins were
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extracted by incubation at room temperature for 1 hour with 100 pgml"1 lysozyme and
20 pgml"1 DNase (Sigma) before lysis, either by 4 x 30 sec sonication passes on ice or
two passes through a Constant cell disrupter (Constant systems). The soluble and




The same procedure was used to purify all tagged proteins as detailed for tagged
ArnA in chapter 2.2.2 (figure 4.2.2).
Lysate containing target untagged protein was applied to a 5 ml Heparin HP
column (Amersham Biosciences), pre-equilibrated with 50 mM MES pH 5.7 and 50
mM NaCl. Extensive washing with 50 mM MES pH 5.7 and 1 M NaCl removed
almost all contaminating proteins and essentially pure PCNA1, 2 or 3 was eluted from
the column with an increasing salt concentration up to 2 M. After concentration of
relevant fractions and dialysis into 50 mM MES pH 5.7, 300 mM NaCl and 2 mM
DTT, the individual proteins were purified to homogeneity by S200 gel filtration
(Amersham Biosciences).
The XPF(HhH)2 construct contains a thrombin cleavage site between the
histidine tag and the start of the XPF(HhH)2 gene. Untagged XPF(HhH)2 was
obtained by overnight incubation of histidine tagged protein, eluted from the HisTrap
column and dialysed into 50 mM Tris pH 8.2 and 250 mM NaCl, with 1 unit of
thrombin. Untagged XPF(HhH)2 was separated from any uncleaved protein, the
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cleaved tag and thrombin by passing it back through the HisTrap column, before
further purification by S200 gel filtration.
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Figure 4.2.2: Coomssie blue stained SDS PAGE gel showing the purified tagged
individual PCNA proteins, XPF(HhH)2 (HhH), the tagged PCNA heterotrimer and
tagged PCNA-XPF(HhH)2 heterotetramer.
As it took so long to purify large amounts of the three PCNA components and
their complex (in excess of 15 gel filtration columns), this purification protocol was
optimised and the throughput significantly improved without impacting on final
purity, as judged by Coomassie blue stained SDS-PAGE. In the optimised protocol
the PCNA1, 2 and 3 soluble lysates, containing a slight excess of PCNA3, were
mixed for one hour before heat treatment for 30 min at 65 °C. Precipitated protein
was removed by centrifugation at 75500 g for 20 min and the PCNA heterotrimer was
purified as for an individual PCNA subunit.
The pure heterotrimer was mixed with an excess of purified XPF(HhH)2,
either tagged or untagged, for 1 hour at room temperature, before the PCNA
heterotetramer was purified by S200 gel filtration. In solution XPF(HhH)2 exists as a
homodimer of -20 kDa and the PCNA heterotetramer is -105 kDa, therefore
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XPF(HhH)2 was mixed in excess as it is easier to resolve species of -105 and -20
kDa than -105 and -75 kDa by gel filtration (figure 4.2.3).
&oPCNA-XPF(HhH)2 (red). The overlapping traces of the heterotetramer and
heterotrimer show the importance ofusing an excess of XPF-(HhH)2.
4.2.3 Crystallisation
Purified heterotrimer and heterotetramer were concentrated to 20 mg ml"1 as judged
by Bradford assay (Sigma) and dialysed into 20 mM HEPES pH 7.5, 20 mM NaCl
and 2 mM DTT prior to screening for crystallisation conditions. The sitting drop
method was employed for crystal screening, using a drop size of 2 pi, containing 1 pi
protein and 1 pi precipitant, against 100 pi of mother liquor. Crystal screens 1 and 2,
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Index, Peg/Ion, Natrix (Hampton), Wizard 1 and 2 (Emarald Biosciences) and
protein-protein complex (Sigma) sparse matrix screens were employed for initial
crystal screening.
PCNA Hetereotrimer
Tagged PCNA heterotrimer formed small clusters of crystals in several initial
conditions, which all contained between 10 and 25 % PEG (between PEG 1000 and
PEG 4000), 100-300 mM salt and a pH between 6 and 8. The clusters were
cryoprotected in 10 - 20 % (2R,3R)-(-)2,3-butanediol (Sigma) and subjected to X-ray
diffraction on our in-house source (Rigaku 007 rotating anode) using an RAxis IV
detector. A 20 min exposure revealed that these crystals were protein, diffracting to
~8 A, figure 4.2.3a. Extensive optimisation of these conditions was employed
including variation of precipitant, salt and buffer, along with changing the
concentrations of these and the pH of the buffer. Different batches of purified PCNA
heterotrimer was also used during optimisation trials at concentrations varying from 3
to 20 mg ml'1. Eventually this optimisation, using a protein concentration between 10
and 20 mg ml"1 from a batch of protein over-expressed using the auto-inducing
medium, gave rise to large, single crystals that had well defined edges (figure 4.2.3b).
This condition was 11 % PEG 3350, 0.18 M ammonium acetate, 0.01 M calcium
chloride and 100 mM Bis-tris pH 6.5. A single crystal was looped out and
cryoproteced as above to test for diffraction quality in house and at the ESRF.
Despite their excellent appearance, these crystals only diffracted to between 4.5 and 5
A (figure 4.2.3b). Further optimisation using streak and stock seeding as well the
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Figure 4.2.3: Initial crystals of the PCNA heterotrimer and the resulting diffraction
on our in house source (a) and after optimisation at the ESRF (b). Labels on the
diagrams are in A.
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The Sigma protein-protein complex screen was designed based on the
structures of macromolecular complexes in the PDB as of 2001646. Their finding was
that, in general, protein-protein complexes are more likely to crystallise with a lower
precipitant concentration than normal soluble proteins, with a preference for PEG as a
precipitant and a smaller pH range between 4 and 9646. Observation of the conditions
that gave rise to PCNA heterotrimer crystals in the initial screening process was
consistent with this, revealing a preference for PEG at a lower concentration than
present in most commercial screens. The Nextal PEG screen contains the 48 20 %
PEG 3350 conditions that are present in the Hampton Peg/Ion screen as well as a
further 48 conditions, screening different PEGs against buffers. Further crystal trials
were focussed around the Nextal PEG screen with the 96 conditions undiluted, diluted
by 30 % or diluted by 50 % with water, screened against PCNA heterotrimer at 7, 10
and 15 mg ml"1. The screens using 50 % diluted Nextal PEG solutions gave rise to
crystals that looked good quality within 1 week, however these crystals diffracted
poorly (figure 4.2.3b). Two other conditions in the 50 % diluted screen also gave rise
to crystals, 0.05 M sodium acetate pH 4.6 and either 10 % PEG 10000 or 7.5 % PEG
20000. Their quality appears poor, forming very thin sheets that clustered together.
However careful manipulation allowed removal of a single crystal, which was
cryoprotected with 20 % (2R,3R)-(-)2,3-butanediol prior to X-ray diffraction. A 30
min exposure on an in-house source resulted in diffraction to 3.3 A (figure 4.2.9a).
Optimisation of these crystals resulted in larger, slightly thicker plates and although
they were always found as a cluster, good single crystals could be removed and used
for data collection (figure 4.2.9) (4.2.4).
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PCNA-XPF(HhH)2 complex
Initial crystals were obtained for the tagged PCNA-XPF(HhH)2 complex in 25 % PEG
3350, 0.2 M ammonium acetate and Bis-tris pH 5.5. These small crystals were
cryoprotected in 20 % glycerol and a 20 min exposure to X-rays from our in-house
source showed them to be protein, with some spots diffracting to —11 A (figure
4.2.6a). Optimisation of this initial condition gave rise to single crystals of an
approximate size of 0.2 by 0.2 by 0.1 mm, that took between 3 and 5 weeks to grow.
These crystals were cryoprotected with 20 % glycerol and frozen at 100 K. X-ray
diffraction was obtained on our in-house source to ~6 A, with a 20 min exposure.
Increasing the exposure time to 40 min resulted in the diffraction at 0° to 3.7 A (figure
4.2.6b). However, because the crystal was damaged, the 90° diffraction was only to
~5 A and was therefore not suitable for data collection.
It was hoped that taking the crystals to a synchrotron X-ray source would
improve their diffraction. These crystals grow on the bottom or side of the sitting
drop plate and are very fragile and attempts to tease the crystals off the plate usually
resulted in cracked crystals, which diffracted poorly (around 5 A). One small crystal
was successfully removed from a drop without cracking, and in some directions this
crystal diffracted to 3 A. This diffraction was very anisotropic and the data collected
was of poor quality and unsuitable for structural solution. The fragility of the crystals
at the ESRF was not observed when mounting the crystals in house and it is likely that
the transportation of these crystals to the ESRF resulted in their deterioration.
Hanging drop plates were also utilised in the optimisation of these crystals to prevent
their growth on the surface of the crystal plates. Although relatively large single
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crystals could be obtained and looped from the drop without damage, they degraded
upon cryoprotection at the ESRF, diffracting to only 5 A.
Figure 4.2.6: Initial diffraction from PCNA-XPF(HhH)2 crystals (a), then after
optimisation to 3.7 A (b).
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Attempts to repeat this crystal condition have failed. Many other conditions
have yielded crystals that look of excellent quality however, similarly to the
heterotrimeric PCNA these only diffract, at best, to 4.5- 5 A at the synchrotron, shown
in figure 4.2.7.
Very recently untagged PCNA-XPF(HhH)2, at a concentration of 8 mg ml"1,
formed a small cluster of crystals (figure 4.2.8) in 12.5 % PEG 3350, 0.1 M
ammonium sulphate and 0.05 M HEPES pH 7.5. This cluster of crystals was
cryoprotected in 20 % (2R,3R)-(-)2,3-butanediol and initial diffraction to 3.0 A was
observed (figure 4.2.8), although due to the presence ofmultiple lattices this crystal is
not suitable for data collection. Optimisation trials for improving these promising




Figure 4.2.7: Anisotropic diffraction of PCNA-XPF(HhH)2 crystals at the ESRF (a)
and new crystals that, despite their excellent appearance, only diffract to ~5 A (b).
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Figure 4.2.8: Recent diffraction of a cluster of crystals formed by the untagged
PCNA-XPF(HhH)2 heterotetramer. These crystals diffract in-house to approximately
3 A at 0° and 90° apart.
4.2.4 Data collection
A large SsoPCNA crystal, from an optimised condition containing 0.07 M sodium
acetate pH 4.9, was used to collect data to 2.8 A (fig 4.2.9b) on beamline BM14 at
Daresbury light source. MOSFLM396 identified the space group as belonging to the
P222 Laue group, with the unit cell a = 45.1 b = 79.3 c = 235.0, a = P = y = 90.0°.
360 images were collected with an oscillation angle of 0.5 0 on a CCD image plate
using an exposure time of 50 sec. Data were integrated with MOSFLM396, scaled




Figure 4.2.9: Good quality diffraction was obtained to 3.3 A for initial PCNA
heterotrimer crystals obtained in 0.05 M sodium acetate and 5 % PEG 2000 (a).
Optimised crystals were used to collect data at Daresbury to 2.8 A at the edge of the
plate (b).
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Data collection PCNA Heterotrimer
Resolution (A) 79.4-2.8
Highest shell (A) 2.85-2.8
Wavelength (A) 0.979
Unit cell
a = 45.1 b = 79.3 c = 235.0




Completeness (%) 77.8 (77.8)
Rmerge (%) 9.5 (33.5)
I/a 6.5 (2.3)
Table 4.2.10: Data statistics for the heterotrimeric PCNA crystal, collected at
Daresbury light source, beam station BM14.
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4.3 RESULTS
4.3.1 Structural solution of PCNA heterotrimer
Figure 4.3.1 shows the sequence alignment of PCNA from S. cerivisiae with human
PCNA and AroPCNA. PCNA1, 2 and 3 do no not share high sequence identity with
one another. PCNA1 is 24 % and 22 % identical to PCNA2 and 3 respectively with
PCNA2 sharing 23 % identity to PCNA3. BLAST searches of all three sequences
against structures in the PDB reveal several potential search models. The closest
homologue found was from S. tokodaii (PDB code 1UD9), sharing 63 % identity with
PCNA3, 27 % with PCNA2 and 22 % with PCNA1. Although the identity is not very
high for PCNA1 or 2 it was hoped that during molecular replacement, if the PCNA3
orientation was found then this would help the determination of the PCNA1 and 2
positions. Default search parameters in PHASER647 were employed with the
following modifications. The resolution for the molecular replacement search was cut
to 3 A and the number of clashes allowed within the packing of the structural
solutions was increased from 0 to 25 due to the low similarity between PCNA1 and
PCNA2 with the search model. The poly-alanine trace of 1UD9 was used as a search
model. The statistics output from PHASER looked very promising (table 4.3.2), with












pcna3 : -mkwyddvr vlkdiiqala
51
yeast: eigveafqey rc-dhpvtlg mdltslskb:
human: tlrsegfdty rc-drnlamg vnltsmskb.
pcna1: ripkdvlsey si-dsptsvk ldvssvkkb;
pcna2: flpssyfegf evsqekeiig fkledvndb
pcna3: nlpremfkey dvn-defkfg fntqylmkj
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yeast: illfedtkkd riaeyslklm didadflkie
human: alvfeapnqe kvsdyemklm dldveqlgip
pcna1: kiiirdeksg akstiyikae kgqveqltep
pcna2: tltfdgeft rsfelpli qvestqppsv































dlsqlsdsin imitketikf vadgdigsgs viikpfvdme hpetsiklem
dlshigdaw iscakdgvkf sasgelgngn iklsqtsnvd keeeavtiem
dvtlvgeemr isteedkiki ea-geegkry vaf lm kdkplkelsi
elsdlgevln ihskenklyf evigdlstak velst dngtlleas-
evstvtdnw veghedrili kaeges-eve vefsk dtgglqdlef
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yeast: dqpvdltfga kylldiikg- sslldrvgir lsseapalfq fdlksggflq
human: nepvqltfal rylnfftka- tpl|stvtls msadvplwe ykiadmghlk
pcna1: dtsasssysa emfkdavkgl rgf!aptmvs fgenlpmkid veavsgghmi
pcna2: gadvsssygm eyvanttkm- rraIdsmely fgsqiplklr fklpqegygd
pcna3 : skesknsysa eylddvlsl- tkl|dyvkis fgnqkplqlf fnmegggkvt
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yeast : ffl.■kfnde e
human : yyl■kiede egs
pcna1 : fwi Irl
pcna2 : fy i. ■rad
pcna3 : yll |kv
Figure 4.3.1: Sequence alignment of S. cerevisiae (yeast) PCNA with human PCNA,
PCNA1, PCNA2 and PCNA3. Residues conserved in three out of five and all
sequences are highlighted in yellow and blue respectively. Numbers correspond to








Fast rotation 4.69 31.01 -
function
Fast translation 9.05 76.63 78.2
function
PCNA2 search
Fast rotation 3.67 89.67 -
function
Fast translation 10.42 147.26 163.09
function
PCNA1 search
Fast rotation 3.53 172.76 -
function
Fast translation 8.10 208.40 265.31
function
Table 4.3.2: Output from PHASER. The different sequence identities between the
PCNA monomers and search model allowed each subunit to be searched for
separately. As judged by manual inspection of the solution PHASER found the
positions of PCNA3, followed by PCNA2 and finally PCNA1. The Z-scores
(highlighted in bold) for the rotation function demonstrate that PCNA3 is more easily
located than PCNA 2 and both are more easily located than PCNA1. The refined log
likelihood gain (highlighted in bold and italic) is accumulative.
PHASER output one solution that contains one dimer and one monomer in the
asymmetric unit (figure 4.3.3). Generation of the symmetry related molecules in
COOT490 creates a heterotrimer that immediately suggested a correct solution was
found (figure 4.3.5). Observation of the electron density maps confirmed this solution
as side chains could be identified corresponding to each PCNA monomer.
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Figure 4.3.4: PCNA subunits found by PHASER in the asymmetric unit with
PCNA1, 2 and 3 coloured blue, red and green respectively. Generation of the
symmetry related objects generates the heterotrimer, shown in figure 4.3.4.
4.3.2 Overall structure
Figure 4.3.3: Superimposition ofPCNA1 (yellow), PCNA2 (blue) and PCNA3 (red)
shows that their overall structure is very similar.
The electron density map has been initially traced by hand in COOT490 and O485 and
side chains for PCNA1-3 fitted. Initial rigid body and restrained refinement has been
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carried out in REFMAC5403 to an Rfactor of 35 % and Rfree of 40 %, however further
refinement of the model is needed before detailed analysis of the structure can be
performed. The overall fold of the PCNA1-3 monomers are essentially the same as
each other (figure 4.3.4). The two domains within each monomer fold to form the
typical PaPP fold found in all sliding clamps. PCNA3 superimposes with a RMSD of
1.7 and 1.3 A between PCNA1 and PCNA2 respectively, with PCNA1 and PCNA2
superimposing with a RMSD of 1.7 A. The structure formed by heterotrimeric PCNA
is very similar to that of other sliding clamps, superimposing well with S. cerevisiae
PCNA and E. coli P-subunit (figure 4.3.5) with RMSD of 2.5 and 3.2 A respectively.
Figure 4.3.4: Superimposition of AsoPCNA (red) with S. cerevisiaea PCNA (blue)
and the P-subunit (yellow). The superimposition shows that, despite the
heterotrimeric nature of AsoPCNA, the overall toroidal structure formed is essentially
the same as other clamps.
Tracing the electron density reveals some areas that have poorly defined
electron density. These areas map to the interdomain linker of each PCNA monomer,
suggesting, along with several other PCNA structures that also lack density for these
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loops (PDB code 1UD9), the flexibility of this region. It is possible that as the
refinement progresses these areas may become traceable.
4.3.3 Sequence alignments with the 9-1-1 complex
Venclovas and Thelen carried out structure-based predictions of the Radl, Rad9 and
Husl proteins and found they were likely to contain a PCNA-like fold621. They
performed a complex sequence alignment of these proteins with PCNA from a
number of eukaryotes621. Based on this alignment and that for PCNA1-3 with S.
cerevisiae PCNA (figure 4.3.1) allows PCNA1-3 to be tentatively aligned with Radl
(figure 4.3.3a), Husl (figure 4.3.3b) and Rad9 (figure 4.3.3c) to see if there is any
significant sequence similarity between these proteins.
These sequence alignments reveal that Radl, Husl and Rad9 protein
sequences only share around 8-12/10-15 % identity/similarity to &oPCNA. PCNA1
is 8.8/13.3, 9.2/13.3 and 11.2/14.9 % identical to Radl, Husl and Rad9 respectively.
PCNA2 is 11.4/13.8, 12.2/12.2 and 7.7/13.4 % identical to Radl, Husl and Rad9
respectively. PCNA3 is 10.4/13.1, 10.0/11.6 and 11.6/10.0 % identical to Radl, Husl
and Rad9 respectively. This tentatively suggests that PCNA2 is most closely related
to Husl and Radl, PCNA1 to Rad9 and PCNA3 shares similar identity / similarity to
all three proteins.
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RAD1:-KFSASTVHLEHITTAL CLT PCNA1:MFKIVYPNAKDFFSFINSIT PCNA2:MMKAKVIDAVSFSYILRTVG PCNA3:-MKWYDDVRVLKDIIQAA
PFGSKDDVLIFIDADGLSFVREN-NHVIKI NVTD—SIILFTEDGIFSRHL KVLMA DFLS—EANFIVTKEGIRVSGIDPSRWFL RLVD—EAVLKFKQSV LALDRAISL
RAD1:QLLLSRELFMSYSYRNETE- PCNA1:IMRIPKDVLSEYSID PCNA2:DIFLPSSYFEG EVSQ PCNA3:SVNMKED RAD1:DIVECTLSYDGHGSPFVLIF PCNA1:SKKA-TIELTETDSGLKIII PCNA2:KDDTLIL-SS-NESKLTLTF PCNA3:RKEAIEI-ASESPDSVIINI RAD1:ERISFEAIIKGE LHS LKD PCNA1:—L VNFTTDESVL VIAAD Pcna2:—FPFKAQLLTITFADIIDE Pcna3:—FDISTSDG KISE
DHMKLCVKINHILDSVS MRN D SPTSVKLDVSVKKILSK—A EKEIIGFKLEDVNDILKR—L EFFGFNTQYLMKILK—A ED—SFISERVEYSTYLIKDF TNGLELD RDEKSGAKSTIYIKAEKGQVEQ-LTEP VN DGEFTRSFELPLIQVESTQ- P VNLK TGSTNREFNVRNLEVSEQE-IP I LQ LKEIGCKECYVYAKTEANDENVFALISKSQ VTLVG-EEMRIST EDKIKIEA-GE LSDLG-EVLNIHSKENKLYFEVIGD VSTVT-DNWEGHEDRILIKAEGE
RAD1 PCNA1 PCNA2 PCNA3
LGFSKIKLPSNRSY—LEKLQV DGDSTTVIDGFAVIGFFDFT F KIRK EGKRYVAF—LMKDKPLKELSIDTSAS SYSA M KDAVK LSTAKVELSTDNGTLE S-GADVSSSYGMEYVANTTK S-EVEVEFSKDTGGL FK SKNSYA YLL
RAD1:S-TKIASKVLFRMDVHGVLSVNILSQTDDVI(20)PK YPG-IVIEVCM PCNA1:GLRGFS PTMVSF ENL MKIDVEAVSGGHMIFWIA PCNA2:M-RRASDSMELYFGSQIPLKFKLPQEGYG FYIA PCNA3:L-SDYKISFGNQKPQL F MEGGKVTYLLA RAD1:EKESID(83)— PCNA1:RL PCNA2:RAD PCNA3:V Figure4.3.3a
HUSl PCNA1 PCNA2 PCNA3
MKLKLIVNGC -MFKIVYP— -MMKAKVI— —MWYD
EAPDDYKLLR -NAKDFFSFI -DAVSFSYIL -DVRVLDII
TTINTVASLR NSITNVTD— RTVGDFLS— QALARLVD—
KTAILRFNSE -SIILNFTED -EANFIVTKE -EVKQD
RLTIISTPK(13 GIFSRHLTE GIRVSGIDP SVELVALDR
HUSl:GDTGQLWCTIPHD-VFRLYTVISARELNTMECNCDSLLSVFKRY(7)S PCNA1:DKVLM IMRIDV-LSEYSISPTVK DVSSVKKILSKA—S PCNA2:SRWFLDIFLSSY-FEGFEVSQEKIIGF DVNDIL RV—LK PCNA3:AHISLISVNLREM-KEDNEFFGTQYLVA—KR HUSl:SSNMIIKLQSM(25)PICALGITFEEIVH(32)NKVIMHSFKVP KL FRA PCNA1:KKA-TIELTETDSGLIIIRDSG KSIYIKAEKGQ PCNA2:DDTLIL-SS-NE KLTLTFDGEFTRSF LPLIQVE PCNA3:KEAIE- SESDSVINITG TNREFNV HUSl:QDTRIQEPMI PCNA1:VEQLTEPKVN Pcna2:STQPPSVNLK Pcna3:EQEIPEINLQ HUSl:ELKIIVNKLD PCNA1:KIEA-GEEGK PCNA2:YFEVIGDLST PCNA3:LIAEGES-ENYIQLMMY(12)FHGFIRRVE -LAVNFTTDESVLN IAA -FPFKAQLLTITFADIID -FDISATISDKSA WHGEICWNGPLDSVIQRQEG RYVAFLMKDKPL AKVELSTDNGTL VEVFSKDTGGLRYSNVNHIHLMGVKK(8)DV DVTLVG-EEMRISTE-EDKI ELSDLG-EVLNIHSK-ENK EVTVT-DNVWEGH-EDRI LTDNPSQN(86)STHEVIIRC KELSIDTSASSSYSA LEASGADVSSSYGM QDLEFKESKNSYSA HUSl:KDWKVCSKLYAAFEEWLA PCNA1:EMFKDAVKGLRG SAPTMVS PCNA2:EYVANTTKM-RR SDSMELY PCNA3:EYLDDVLS-TKLSDYKIISHDESCVFHC LDRGSL(8)PRER-GQIIY FGENLPMKIDV AVSGGHMI FGSQIPLKLRKLPQEGYGDF FGNQKPLQLFMEGKVT HUSl:YIARSKGL PCNA1:W PCNA2:Y PCNA3:L Figure4.3.3b
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RAD9 : MSFKATITES GKQNIWFRAI YVLSTIQDDI KITVTTNELI AWSMNETDTT
PCNA1: MFKIVYP N-AKDFFSFI NSITNVTDSI ILNFTEDGIF SRHLTEDKVL
PCNA2: MMKAKVI D-AVSFSYIL RTVGDFLSEA NFIVTKEGIR VSGIDPSRW
PCNA3: MKWYD D-VRVLKDI QA ARLV EA VLKFKQDSVE LVALDRAHIS
RAD9 : LCQVRFQKSF FEEYEFKPHE (15)GNSHKL YSFRVNGRHL TTISRKPDGD
PCNA1: MAIMRIPKDV LSEYSID SP TSVKLDVSSV KKILSKASS-
PCNA2: FLDIFLPSSY FEGFEVSQ— EK EIIGFKLEDV NDILKRVLK-
PCNA3: IS NLPREM K DVN DE FK GF TQY MK LKVAKR-
RAD9 : GIKSFTIAVN NTSTCPESLA NRLIWIEMD SLIV(12)DP IIINLKY-KR
PCNA1: KKA-T IELTET-DSG LKIIIRDEKS
PCNA2 : DDTLI L-SS—NESK LTLTFDGEFT
PCNA3: KEAIE I-ASES-P S V ITGSTN
S(23)TSALF NEE(16)INY ICCNSTLLKN FLDNCNVNVT
EKGQVEQLTE PKVN—LAVN FTTDESVLNV IAADVTL-VG
IQVESTQPPS VNLK—FPFK AQLLTITFAD IIDELSD-LG
LEVSEQEIPE INLQ—FDIS ATIS DGFKS AISEVST-
RLSITAFTKA VYGKNNDLLR NALSMSNTIS T LDLE
KIKIEA-GE- E GKRYVAF —LMKDKPLK
KLYFEVIGD- L STAKVELST- DNGTLL
IL K EGES -EVEVEFSK- DTGG Q
IFKLKDFKNF ITI-GP(9)D NISLWFCHPG DPILMQMQKP
SYSAEMFKDA VKGLRGF-SA PTMVSFGE-N LPMKIDVEAV
SYGMEYVANT TKM-RRA-SD SMELYFGS-Q IPLKLRFKLP
SYSAEYLDDV LSL-TKL-S YVKIS GN-Q K LQLFFNME




Figure 4.3.5: Sequence alignment ofRadl (a), Husl (b) and Rad9 (c) with PCNA1-3
Residues that are identical to Radl, Husl or Rad9 in PCNA1, 2 and 3 are coloured








PCNA3 : N W GHED
RAD9 : HYCL(22)SI
PCNA1: ELSIDTSASS





Sliding clamps have been the focus of intense structural interest due to their
involvement in processive DNA replication and unique ability to non-specifically
encircle duplex DNA and freely slide in either direction along it. The structures of
clamps involved in replication, including the P-subunit from Gram-negative517 and
Gram-positive bacteria648, gene45 from bacteriophage524 and PCNA from archaea523
and eukaryotes522, all form a ring-shaped structure with a central cavity that is thought
to encircle DNA. The majority of these clamps are homodimeric (bacteria) or
homotrimeric (bacteriophage, archaea and eukaryotes), however nature has also
evolved heterotrimeric sliding clamps. More than one homologue ofPCNA exists in
some crenarchaea, which have been shown to form a heterotrimer that acts as the
sliding clamp for their replicative polymerase607. A heterotrimeric sliding clamp with
a similar overall structure to PCNA is also thought to exist in eukaryotes621, made up
of the Radl, Husl and Rad9 proteins and called the 9-1-1 complex (4.1.6). This
sliding clamp is unique in that it is not an accessory protein for DNA replication,
instead it is involved in initial DNA damage response events626. Presented here is the
partially refined 2.8 A structure of the first heterotrimeric sliding clamp, the PCNA
heterotrimer from S. solfataricus. This structure superimposes well with other sliding
clamps (figure 4.3.5), suggesting that the topological nature of encircling DNA is the
essential feature of all clamps.
The As'oPCNA structure provides the initial basis of an interesting structural
biology study. It demonstrates that this heterotrimer is amenable to crystallographic
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studies and the fully refined structure will give further insights into this sliding clamp
family of proteins. It is also highly desirable to optimise the &0PCNA crystals
further to collect data at a higher resolution, as this structure will act as a model for
future structural studies. As the 2.8 A structure presented here is not fully refined, a
detailed structural analysis of AsoPCNA is not carried out. Instead this discussion
focuses on the directions this project may take.
The two most interesting features of the heterotrimeric clamp are the
interactions between individual PCNA protomers at the three dimer interfaces and the
subunit specific interactions that are important for its cellular function. The binding
affinities of the individual PCNA monomers as well as their specific interaction with
RFC suggest that PCNA3 is pulled apart from the PCNA1-PCNA2 heterodimer
during clamp loading (figure 4.1.5). This is likely to be reflected in the structure, with
the PCNA3-PCNA2 and PCNA3-PCNA1 interfaces presumably weaker than the
PCNA1-PCNA2 interface. The fully refined &0PCNA structure will allow this to be
assessed in detail and will provide insight into the clamp loading of this sliding clamp.
This may have further implications for the heterotrimeric sliding clamp in eukaryotes.
It would be interesting to calculate the affinities of the binding of each component
within the 9-1-1 complex as, although some groups observe dimerisation of each
component with the other two622, this is not always seen. It has been reported that
Husl and Radl from S. pombe do not interact with one another in the absence of
Rad9649'650. This suggests that the components of the 9-1-1 complex interact with one
another with different affinities, which is likely to have an effect on the clamp loading
of this complex, reminiscent ofAsoPCNA.
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4.1.2 AsoPCNA-XPF
The progress made towards the structural solution of the XsoPCNA-XPF(HhH)2
complex suggests that the interactions of this sliding clamp with cellular partners are
also accessible to X-ray crystallography. Such subunit-specific interactions are also
essential to the 9-1-1 complex626 and PCNA's function in at least some of its cellular
roles (4.1.2), for example the bridging of the CDK2-cyclinA complex with its
substrate577. The Xs<9PCNA-XPF(HhH)2 structure would provide the first insights into
subunit-specific interactions made by a sliding clamp and would provide a useful
model for understanding these interactions in eukaryotes, particularly for the 9-1-1
complex.
There are also several other co-complexes that would be desirable to help
characterise the subunit specific interactions made by XsoPCNA. Firstly, peptides
could be designed based on the PCNA interacting motifs of PolB, FEN-1 and DNA
ligase from S. solfataricus that will specifically bind PCNA2, PCNA1 and PCNA3
respectively. The structural solution of these peptides in complex with XsoPCNA
would provide insights into the Okazaki fragment maturation machine thought to
form during replication of S. solfataricus616. A more ambitious aim would be the
elucidation of this okazakaki fragment maturation machine in its entirety. That
XsoPCNA forms a hexameric complex with PolB, FEN1 and DNA ligase616 suggests
that this may be a possibility.
Although structures of archaeal XPF in complex with DNA634 and the
ERCCl(FfhH)2-XPF(HhH)2643 (4.1.9) have provided insights into the substrate
recognition of the XPF family of endonucleases, they are not conclusive. The
solution of the SsoPCNA-XPF(HhH)2 structure will allow accurate modelling of
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XsoPCNA' s interaction with both apo- and DNA complexed XPF. This will either
add confidence to the model of substrate recognition hypothesised by Newmann et
al.634 or suggest an alternative mechanism. As SsoXPF is active against both XPF-
ERCC1601 and Mus81619 like DNA substrates the SsoPCNA-XPF(HhH)2 structure
will act as an excellent model, providing insights into substrate recognition by this
family of enzymes. Further structural work of the AsoPCNA-XPF interaction would
also be interesting. Most importantly would be the solution of XsoPCNA with full
length XPF and this complex with a variety of DNA substrates. These structures
would further characterise the substrate specificities of this class of enzymes.
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